Imidazopyrazine syk inhibitors

ABSTRACT

Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

This application claims the benefit of provisional U.S. PatentApplication 61/120,587, filed Dec. 8, 2008, provisional U.S. PatentApplication No. 61/140,514, filed Dec. 23, 2008, and provisional U.S.Patent Application No. 61/240,979, filed Sep. 9, 2009, each of which ishereby incorporated by reference.

Provided herein are certain imidazopyrazines, compositions, and methodsof their manufacture and use.

Protein kinases, the largest family of human enzymes, encompass wellover 500 proteins. Spleen Tyrosine Kinase (Syk) is a member of the Sykfamily of tyrosine kinases, and is a regulator of early B-celldevelopment as well as mature B-cell activation, signaling, andsurvival.

Syk is a non-receptor tyrosine kinase that plays critical roles inimmunoreceptor- and integrin-mediated signaling in a variety of celltypes, including B cells, macrophages, monocytes, mast cells,eosinophils, basophils, neutrophils, dendritic cells, T cells, naturalkiller cells, platelets, and osteoclasts. Immunoreceptors as describedhere include classical immunoreceptors and immunoreceptor-likemolecules. Classical immunoreceptors include B-cell and T-cell antigenreceptors as well as various immunoglobulin receptors (Fc receptors).Immunoreceptor-like molecules are either structurally related toimmunoreceptors or participate in similar signal transduction pathwaysand are primarily involved in non-adaptive immune functions, includingneutrophil activation, natural killer cell recognition, and osteoclastactivity. Integrins are cell surface receptors that play key roles inthe control of leukocyte adhesion and activation in both innate andadaptive immunity.

Ligand binding leads to activation of both immunoreceptors andintegrins, which results in Src family kinases being activated, andphosphorylation of immunoreceptor tyrosine-based activation motifs(ITAMs) in the cytoplasmic face of receptor-associated transmembraneadaptors. Syk binds to the phosphorylated ITAM motifs of the adaptors,leading to activation of Syk and subsequent phosphorylation andactivation of downstream signaling pathways.

Syk is essential for B-cell activation through B-cell receptor (BCR)signaling. SYK becomes activated upon binding to phosphoryated BCR andthus initiates the early signaling events following BCR activation.B-cell signaling through BCR can lead to a wide range of biologicaloutputs, which in turn depend on the developmental stage of the B-cell.The magnitude and duration of BCR signals must be precisely regulated.Aberrant BCR-mediated signaling can cause disregulated B-cell activationand/or the formation of pathogenic auto-antibodies leading to multipleautoimmune and/or inflammatory diseases. Mice lacking Syk show impairedmaturation of B-cells, diminished immunoglobulin production, compromisedT-cell-independent immune responses and marked attenuation of thesustained calcium sign upon BCR stimulation.

A large body of evidence supports the role of B-cells and the humoralimmune system in the pathogenesis of autoimmune and/or inflammatorydiseases. Protein-based therapeutics (such as Rituxan) developed todeplete B-cells represent an approach to the treatment of a number ofautoimmune and inflammatory diseases. Auto-antibodies and theirresulting immune complexes are known to play pathogenic roles inautoimmune disease and/or inflammatory disease. The pathogenic responseto these antibodies is dependent on signaling through Fc Receptors,which is, in turn, dependent upon Syk. Because of Syk's role in B-cellactivation, as well as FcR dependent signaling, inhibitors of Syk can beuseful as inhibitors of B-cell mediated pathogenic activity, includingautoantibody production. Therefore, inhibition of Syk enzymatic activityin cells is proposed as a treatment for autoimmune disease through itseffects on autoantibody production.

Syk also plays a key role in FCεRI mediated mast cell degranulation andeosinophil activation. Thus, Syk is implicated in allergic disordersincluding asthma. Syk binds to the phosphorylated gamma chain of FCεRIvia its SH2 domains and is essential for downstream signaling. Sykdeficient mast cells demonstrate defective degranulation, arachidonicacid and cytokine secretion. This also has been shown for pharmacologicagents that inhibit Syk activity in mast cells. Treatment with Sykantisense oligonucleotides inhibits antigen-induced infiltration ofeosinophils and neutrophils in an animal model of asthma. Syk deficienteosinophils also show impaired activation in response to FCεRIstimulation. Therefore, small molecule inhibitors of Syk will be usefulfor treatment of allergy-induced inflammatory diseases including asthma.

Syk is also expressed in mast cells and monocytes and has been shown tobe important for the function of these cells. For example, Sykdeficiency in mice is associated with impaired IgE-mediated mast cellactivation, which is marked diminution of TNF-alpha and otherinflammatory cytokine release. Syk kinase inhibitors have also beenshown to inhibit mast cell degranulation in cell based assays.Additionally, a Syk inhibitors have been shown to inhibitantigen-induced passive cutaneous anaphylaxsis, bronchoconstriction andbronchial edema in rats.

Thus, the inhibition of Syk activity can be useful for the treatment ofallergic disorders, autoimmune diseases and inflammatory diseases suchas: SLE, rheumatoid arthritis, multiple vasculitides, idiopathicthrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis,chronic obstructive pulmonary disease (COPD), adult respiratory distresssyndrome (ARDs) and asthma. In addition, Syk has been reported to playan important role in ligand-independent tonic signaling through theB-cell receptor, known to be an important survival signal in B-cells.Thus, inhibition of Syk activity may be useful in treating certain typesof cancer, including B-cell lymphoma and leukemia.

Provided is at least one chemical entity chosen from compounds ofFormula I:

and pharmaceutically acceptable salts thereof, wherein

-   R₁ is phenyl substituted with one or two groups chosen from    -   halo,    -   hydroxy,    -   carboxy,    -   cyano,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   cycloalkyloxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from acyl, halo, optionally substituted amino, hydroxy,        lower alkoxy, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with lower alkoxy, lower alkyl        substituted with one, two, or three halo groups, optionally        substituted amino, optionally substituted heterocycloalkyl, and        oxo,    -   heterocycloalkyloxy optionally substituted with one or two        groups chosen from halo, optionally substituted amino, hydroxy,        lower alkoxy, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with lower alkoxy, lower alkyl        substituted with one, two, or three halo groups, optionally        substituted amino, optionally substituted heterocycloalkyl, and        oxo,    -   heteroaryl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with halo, lower alkyl        substituted with hydroxy, and lower alkyl substituted with lower        alkoxy,    -   —C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy, provided that at least one of R₆ and        R₇ is not hydrogen,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, optionally substituted        aminocarbonyl, optionally substituted amino, carboxy,        aminocarbonyl, and heterocycloalkyl,    -   heteroaryloxy, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, optionally        substituted amino, and heterocycloalkyl optionally substituted        with lower alkyl; or-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted;

-   R₂ is chosen from optionally substituted aryl and optionally    substituted heteroaryl;-   R₃ is chosen from hydrogen, lower alkyl, and halo;-   R₄ is chosen from hydrogen and lower alkyl; and-   R₅ is hydrogen,-   provided that-   if R₃ and R₄ are hydrogen and R₁ is    3-methoxy-4-(morpholin-4-ylcarbonyl)phenyl,    4-(morpholin-4-yl)phenyl, 3,4-diethoxyphenyl,    3-fluoro-4-methoxyphenyl, 4-(4-ethylpiperazin-1-yl)phenyl,    4-(3-oxopiperazin-1-yl)phenyl, 4-(morpholin-4-yl)phenyl,    3-methoxy-4-(morpholin-4-yl)phenyl, 3-methoxy-4-methylphenyl,    4-methoxy-3-methylphenyl, 2-(dimethylamino)ethoxy-3-methoxyphenyl,    3-ethoxy-4-methoxyphenyl, or 4-ethoxy-3-methoxyphenyl, then R₂ is    not phenyl substituted with —(CO)NHR₆ where R₆ is optionally    substituted aryl;-   if R₃ and R₄ are hydrogen and R₁ is 3,4-dimethoxyphenyl, then R₂ is    not phenyl substituted with    -   —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionally        substituted heterocycloalkyl or optionally substituted        heteroaryl or where R₈ is hydrogen, methyl or ethyl and R₉ is        hydrogen, optionally substituted aryl, optionally substituted        cycloalkyl, optionally substituted heterocycloalkyl, optionally        substituted alkyl, or optionally substituted heteroaryl wherein        said phenyl is further optionally substituted with a group        chosen from methyl, methoxy, and halo, or    -   —(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl;-   if R₃ and R₄ are hydrogen and R₁ is 4-(morpholin-4-yl)phenyl, then    R₂ is not pyridinyl, 2-fluorophenyl, benzo[d][1,3]dioxolyl,    2-methoxyphenyl, 2,6-dimethoxyphenyl, 3-acetamidophenyl,    3-carboxyphenyl, 2-(hydroxymethyl)phenyl, furanyl, or    3-(hydroxyethylcarbamoyl)phenyl;-   if R₃ and R₄ are hydrogen and R₁ is chlorophenyl, then R₂ is not    phenyl substituted with piperidin-1-yl-carbonyl or NH(CO)NHR₁₂ where    R₁₂ is phenyl substituted with trifluoromethyl or one or more    halogens;-   if R₃ and R₄ are hydrogen and R₁ is phenyl substituted with    optionally substituted piperazinyl then R₂ is not 3-aminophenyl;-   if R₃ and R₄ are hydrogen and R₁ is 4-chlorophenyl, then R₂ is not    4-carboxyphenyl, 3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or    4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and-   if R₃ and R₄ are hydrogen and R₁ is 4-(2-hydroxy-ethyl)phenyl or    4-(hydroxyethyl)phenyl, then R₂ is not 2-methoxyphenyl or    2-fluorophenyl;-   if R₃ and R₄ are hydrogen and R₁ is    4[(4-ethylpiperazin-1-yl)methyl]phenyl or    4-(2-hydroxypropan-2-yl)phenyl, then R₂ is not phenyl substituted    with —(CO)NR₈R₉ where R₈ is hydrogen and R₉ is hydrogen, methyl or    optionally substituted aryl wherein said phenyl is optionally    further substituted with a group chosen from methyl;-   if R₃ and R₄ are hydrogen and R₂ is 4-carbamoylphenyl, then R₁ is    not 4-(hydroxymethyl)phenyl, 3-(1-hydroxyethyl)phenyl,    4-(1H-imidazol-2-yl)-3-methylphenyl,    3-methoxy-4-(piperidin-4-yloxy)phenyl,    3-methoxy-4-(2-methoxyethoxy)phenyl,    4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl,    4-(2-hydroxyethoxy)-3-methoxyphenyl,    3-methoxy-4-(propan-2-yloxy)phenyl, 3-methoxy-4-propoxyphenyl,    4-(propylcarbamoyl)phenyl, 4-ethoxy-3-methoxyphenyl,    4-(1H-imidazol-2-yl)phenyl, 3-methoxy-4-(1H-pyrazol-5-yl)phenyl,-   if R₃ and R₄ are hydrogen and R₂ is pyridin-3-yl substituted with    carbamoyl, then R₁ is not 3,4-dimethoxyphenyl,-   if R₃ and R₄ are hydrogen and R₁ is 4-ethoxy-3-methoxyphenyl, then    R₂ is not phenyl substituted with methyl and further substituted    with —(CO)NR₈R₉ where R₈ is hydrogen and R₉ is    4-(methylcarbamoyl)phenyl, and-   further provided that R₂ is not phenyl substituted with —NHC(O)R₁₁    where R₁₁ is optionally substituted aryl.

Also provided is at least one chemical entity chosen from compounds ofFormula I:

and pharmaceutically acceptable salts thereof, wherein

-   R₁ is phenyl substituted with one or two groups chosen from    -   halo,    -   hydroxy,    -   carboxy,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, lower alkyl, lower alkyl        substituted with hydroxy, optionally substituted amino, and oxo,    -   heteroaryl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with halo, lower alkyl        substituted with hydroxy, and lower alkyl substituted with lower        alkoxy,    -   —C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy, provided that at least one of R₆ and        R₇ is not hydrogen,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, optionally substituted amino,        carboxy, aminocarbonyl, and    -   heterocycloalkyl,    -   heteroaryloxy, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, optionally        substituted amino, and heterocycloalkyl optionally substituted        with lower alkyl; or-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted;

-   R₂ is chosen from optionally substituted aryl and optionally    substituted heteroaryl;-   R₃ is hydrogen;-   R₄ is hydrogen; and-   R₅ is hydrogen,    provided that-   if R₁ is 3-methoxy-4-methylphenyl, 4-methoxy-3-methylphenyl,    2-(dimethylamino)ethoxy-3-methoxyphenyl, 3-ethoxy-4-methoxyphenyl,    or 4-ethoxy-3-methoxyphenyl, then R₂ is not phenyl substituted with    —(CO)NHR₆ where R₆ is optionally substituted aryl;-   if R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenyl substituted with    -   —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionally        substituted heterocycloalkyl or optionally substituted        heteroaryl or where R₈ is hydrogen and R₉ is optionally        substituted aryl, optionally substituted cycloalkyl, optionally        substituted heterocycloalkyl, optionally substituted alkyl, or        optionally substituted heteroaryl, or    -   —(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl;-   if R₁ is 4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl,    2-fluorophenyl, benzo[d][1,3]dioxolyl, 2-methoxyphenyl,    2,6-dimethoxyphenyl, 3-acetamidophenyl, 3-carboxyphenyl,    2-(hydroxymethyl)phenyl, furanyl, or 3-(hyroxyethylcarbamoyl)phenyl;-   if R₁ is chlorophenyl, then R₂ is not phenyl substituted with    piperidin-1-yl-carbonyl or NH(CO)NR₁₂ where R₁₂ is phenyl    substituted with trifluoromethyl or one or more halogens;-   if R₁ is optionally substituted piperazinyl then R₂ is not    3-aminophenyl;-   if R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,    3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or    4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and-   if R₁ is 4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then    R₂ is not 2-methoxyphenyl or 2-fluorophenyl; and-   further provided that R₂ is not phenyl substituted with —NHC(O)R₁₁    where R₁₁ is optionally substituted aryl.

Also provided is at least one chemical entity chosen from compounds ofFormula I:

and pharmaceutically acceptable salts thereof, wherein

-   R₁ is phenyl substituted with one or two groups chosen from    -   halo,    -   hydroxy,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl,    -   lower alkyl substituted with halo, lower alkyl substituted with        hydroxy, and lower alkyl substituted with lower alkoxy,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and optionally substituted        amino, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, and        optionally substituted amino; or-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted;

-   R₂ is chosen from optionally substituted aryl and optionally    substituted heteroaryl;-   R₃ is hydrogen;-   R₄ is hydrogen; and-   R₅ is hydrogen,    provided that-   if R₁ is 3-methoxy-4-methylphenyl, 4-methoxy-3-methylphenyl,    2-(dimethylamino)ethoxy-3-methoxyphenyl, 3-ethoxy-4-methoxyphenyl,    or 4-ethoxy-3-methoxyphenyl, then R₂ is not phenyl substituted with    —(CO)NHR₆ where R₆ is optionally substituted aryl;-   if R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenyl substituted with    -   —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionally        substituted heterocycloalkyl or optionally substituted        heteroaryl or where R₈ is hydrogen and R₉ is optionally        substituted aryl, optionally substituted cycloalkyl, optionally        substituted heterocycloalkyl, optionally substituted alkyl, or        optionally substituted heteroaryl, or    -   —(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl;-   if R₁ is 4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl,    2-fluorophenyl, benzo[d][1,3]dioxolyl, 2-methoxyphenyl,    2,6-dimethoxyphenyl, 3-acetamidophenyl, 3-carboxyphenyl,    2-(hydroxymethyl)phenyl, furanyl, or    3-(hydroxyethylcarbamoyl)phenyl;-   if R₁ is chlorophenyl, then R₂ is not phenyl substituted with    piperidin-1-yl-carbonyl or NH(CO)NR₁₂ where R₁₂ is phenyl    substituted with trifluoromethyl or one or more halogens;-   if R₁ is optionally substituted piperazinyl then R₂ is not    3-aminophenyl;-   if R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,    3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or    4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and-   if R₁ is 4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then    R₂ is not 2-methoxyphenyl or 2-fluorophenyl; and-   further provided that R₂ is not phenyl substituted with —NHC(O)R₁₁    where R₁₁ is optionally substituted aryl.

Also provided is a pharmaceutical composition, comprising at least onechemical entity described herein, together with at least onepharmaceutically acceptable vehicle chosen from carriers, adjuvants, andexcipients.

Also provided is a method for treating a patient having a diseaseresponsive to inhibition of Syk activity, comprising administering tothe patient an effective amount of at least one chemical entitydescribed herein.

Also provided is a method for treating a patient having a disease chosenfrom cancer, autoimmune diseases, inflammatory diseases, acuteinflammatory reactions, and allergic disorders comprising administeringto the patient an effective amount of at least one chemical entitydescribed herein. Also provided is a method for treating a patienthaving polycystic kidney disease comprising administering to the patientan effective amount of at least one chemical entity described herein.

Also provided is a method for increasing sensitivity of cancer cells tochemotherapy, comprising administering to a patient undergoingchemotherapy with a chemotherapeutic agent an amount of at least onechemical entity described herein, sufficient to increase the sensitivityof cancer cells to the chemotherapeutic agent.

Also provided is a method for inhibiting ATP hydrolysis, the methodcomprising contacting cells expressing Syk with at least one chemicalentity described herein in an amount sufficient to detectably decreasethe level of ATP hydrolysis in vitro.

Also provided is a method for determining the presence of Syk in asample, comprising contacting the sample with at least one chemicalentity described herein under conditions that permit detection of Sykactivity, detecting a level of Syk activity in the sample, and therefromdetermining the presence or absence of Syk in the sample.

Also provided is a method for inhibiting B-cell activity comprisingcontacting cells expressing Syk with at least one chemical entitydescribed herein in an amount sufficient to detectably decrease B-cellactivity in vitro.

As used herein, when any variable occurs more than one time in achemical formula, its definition on each occurrence is independent ofits definition at every other occurrence. In accordance with the usualmeaning of “a” and “the” in patents, reference, for example, to “a”kinase or “the” kinase is inclusive of one or more kinases.

As used in the present specification, the following words, phrases andsymbols are generally intended to have the meanings as set forth below,except to the extent that the context in which they are used indicatesotherwise. The following abbreviations and terms have the indicatedmeanings throughout:

A dash (“-”) that is not between two letters or symbols is used toindicate a point of attachment for a substituent. For example, —CONH₂ isattached through the carbon atom.

By “optional” or “optionally” is meant that the subsequently describedevent or circumstance may or may not occur, and that the descriptionincludes instances where the event or circumstance occurs and instancesin which it does not. For example, “optionally substituted alkyl”encompasses both “alkyl” and “substituted alkyl” as defined below. Itwill be understood by those skilled in the art, with respect to anygroup containing one or more substituents, that such groups are notintended to introduce any substitution or substitution patterns that aresterically impractical, synthetically non-feasible and/or inherentlyunstable.

“Alkyl” encompasses straight chain and branched chain having theindicated number of carbon atoms, usually from 1 to 20 carbon atoms, forexample 1 to 8 carbon atoms, such as 1 to 6 carbon atoms. For exampleC₁-C₆ alkyl encompasses both straight and branched chain alkyl of from 1to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl,propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl,isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and thelike. Alkylene is another subset of alkyl, referring to the sameresidues as alkyl, but having two points of attachment. Alkylene groupswill usually have from 2 to 20 carbon atoms, for example 2 to 8 carbonatoms, such as from 2 to 6 carbon atoms. For example, C₀ alkyleneindicates a covalent bond and C₁ alkylene is a methylene group. When analkyl residue having a specific number of carbons is named, allgeometric isomers having that number of carbons are intended to beencompassed; thus, for example, “butyl” is meant to include n-butyl,sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl andisopropyl. “Lower alkyl” refers to alkyl groups having 1 to 4 carbons.

“Alkenyl” indicates an unsaturated branched or straight-chain alkylgroup having at least one carbon-carbon double bond derived by theremoval of one molecule of hydrogen from adjacent carbon atoms of theparent alkyl. The group may be in either the cis or trans configurationabout the double bond(s). Typical alkenyl groups include, but are notlimited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl,prop-2-en-1-yl (allyl), prop-2-en-2-yl; butenyls such as but-1-en-1-yl,but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl,but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl; and the like. Insome embodiments, an alkenyl group has from 2 to 20 carbon atoms and inother embodiments, from 2 to 6 carbon atoms.

“Cycloalkyl” indicates a saturated hydrocarbon ring group, having thespecified number of carbon atoms, usually from 3 to 7 ring carbon atoms.Examples of cycloalkyl groups include cyclopropyl, cyclobutyl,cyclopentyl, and cyclohexyl as well as bridged and caged saturated ringgroups such as norbornane.

By “alkoxy” is meant an alkyl group of the indicated number of carbonatoms attached through an oxygen bridge such as, for example, methoxy,ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy,2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy,3-methylpentoxy, and the like. Alkoxy groups will usually have from 1 to6 carbon atoms attached through the oxygen bridge. “Lower alkoxy” refersto alkoxy groups having 1 to 4 carbons.

“Aminocarbonyl” encompasses a group of the formula —(C═O)NR_(a)R_(b)where R_(a) and R_(b) are independently chosen from hydrogen and theoptional substituents for “substituted amino” described below.

“Acyl” refers to the groups (alkyl)-C(O)—; (cycloalkyl)-C(O)—;(aryl)-C(O)—; (heteroaryl)-C(O)—; and (heterocycloalkyl)-C(O)—, whereinthe group is attached to the parent structure through the carbonylfunctionality and wherein alkyl, cycloalkyl, aryl, heteroaryl, andheterocycloalkyl are as described herein. Acyl groups have the indicatednumber of carbon atoms, with the carbon of the keto group being includedin the numbered carbon atoms. For example a C₂ acyl group is an acetylgroup having the formula CH₃(C═O)—.

By “alkoxycarbonyl” is meant an ester group of the formula(alkoxy)(C═O)— attached through the carbonyl carbon wherein the alkoxygroup has the indicated number of carbon atoms. Thus aC₁-C₆alkoxycarbonyl group is an alkoxy group having from 1 to 6 carbonatoms attached through its oxygen to a carbonyl linker.

By “amino” is meant the group —NH₂.

“Aryl” encompasses:

-   -   5- and 6-membered carbocyclic aromatic rings, for example,        benzene;    -   bicyclic ring systems wherein at least one ring is carbocyclic        and aromatic, for example, naphthalene, indane, and tetralin;        and    -   tricyclic ring systems wherein at least one ring is carbocyclic        and aromatic, for example, fluorene.        For example, aryl includes 5- and 6-membered carbocyclic        aromatic rings fused to a 5-to 7-membered heterocycloalkyl ring        containing 1 or more heteroatoms chosen from N, O, and S. For        such fused, bicyclic ring systems wherein only one of the rings        is a carbocyclic aromatic ring, the point of attachment may be        at the carbocyclic aromatic ring or the heterocycloalkyl ring.        Bivalent radicals formed from substituted benzene derivatives        and having the free valences at ring atoms are named as        substituted phenylene radicals. Bivalent radicals derived from        univalent polycyclic hydrocarbon radicals whose names end in        “-yl” by removal of one hydrogen atom from the carbon atom with        the free valence are named by adding “-idene” to the name of the        corresponding univalent radical, e.g., a naphthyl group with two        points of attachment is termed naphthylidene. Aryl, however,        does not encompass or overlap in any way with heteroaryl,        separately defined below. Hence, if one or more carbocyclic        aromatic rings is fused with a heterocycloalkyl aromatic ring,        the resulting ring system is heteroaryl, not aryl, as defined        herein.

The term “aryloxy” refers to the group —O-aryl.

The term “halo” includes fluoro, chloro, bromo, and iodo, and the term“halogen” includes fluorine, chlorine, bromine, and iodine.

“Heteroaryl” encompasses:

-   -   5- to 7-membered aromatic, monocyclic rings containing one or        more, for example, from 1 to 4, or In some embodiments, from 1        to 3, heteroatoms chosen from N, O, and S, with the remaining        ring atoms being carbon; and    -   bicyclic heterocycloalkyl rings containing one or more, for        example, from 1 to 4, or In some embodiments, from 1 to 3,        heteroatoms chosen from N, O, and S, with the remaining ring        atoms being carbon and wherein at least one heteroatom is        present in an aromatic ring.        For example, heteroaryl includes a 5- to 7-membered        heterocycloalkyl, aromatic ring fused to a 5- to 7-membered        cycloalkyl ring. For such fused, bicyclic heteroaryl ring        systems wherein only one of the rings contains one or more        heteroatoms, the point of attachment may be at the        heteroaromatic ring or the cycloalkyl ring. When the total        number of S and O atoms in the heteroaryl group exceeds 1, those        heteroatoms are not adjacent to one another. In some        embodiments, the total number of S and O atoms in the heteroaryl        group is not more than 2. In some embodiments, the total number        of S and O atoms in the aromatic heterocycle is not more than 1.        Examples of heteroaryl groups include, but are not limited to,        (as numbered from the linkage position assigned priority 1),        2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4-pyrazinyl,        2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,3-pyrazolinyl,        2,4-imidazolinyl, isoxazolinyl, oxazolinyl, thiazolinyl,        thiadiazolinyl, tetrazolyl, thienyl, benzothiophenyl, furanyl,        benzofuranyl, benzoimidazolinyl, indolinyl, pyridizinyl,        triazolyl, quinolinyl, pyrazolyl, and        5,6,7,8-tetrahydroisoquinoline. Bivalent radicals derived from        univalent heteroaryl radicals whose names end in “-yl” by        removal of one hydrogen atom from the atom with the free valence        are named by adding “-idene” to the name of the corresponding        univalent radical, e.g., a pyridyl group with two points of        attachment is a pyridylidene. Heteroaryl does not encompass or        overlap with aryl as defined above.

Substituted heteroaryl also includes ring systems substituted with oneor more oxide (—O³¹) substituents, such as pyridinyl N-oxides.

The term “heteroaryloxy” refers to the group —O-heteroaryl.

By “heterocycloalkyl” is meant a single aliphatic ring, usually with 3to 7 ring atoms, containing at least 2 carbon atoms in addition to 1-3heteroatoms independently selected from oxygen, sulfur, and nitrogen, aswell as combinations comprising at least one of the foregoingheteroatoms. Suitable heterocycloalkyl groups include, for example (asnumbered from the linkage position assigned priority 1), 2-pyrrolinyl,2,4-imidazolidinyl, 2,3-pyrazolidinyl, 2-piperidyl, 3-piperidyl,4-piperdyl, and 2,5-piperzinyl. Morpholinyl groups are alsocontemplated, including 2-morpholinyl and 3-morpholinyl (numberedwherein the oxygen is assigned priority 1). Substituted heterocycloalkylalso includes ring systems substituted with one or more oxo moieties,such as piperidinyl N-oxide, morpholinyl-N-oxide,1-oxo-1-thiomorpholinyl and 1,1-dioxo-1-thiomorpholinyl.

“Heterocycloalkyl” also includes bicyclic ring systems wherein neitherof the rings is aromatic and wherein at least one of the rings in thebicyclic ring system contains at least 2 carbon atoms in addition to 1-3heteroatoms independently chosen from oxygen, sulfur, and nitrogen.

The term “heterocycloalkyloxy” refers to the group —O-heterocylcoalkyl.

The term “nitro” refers to the group —NO₂.

The term “phosphono” refers to the group —PO₃H₂.

“Thiocarbonyl” refers to the group —C(═O)SH.

The term “optionally substituted thiocarbonyl” includes the followinggroups: —C(═O)S-(optionally substituted (C₁-C₆)alkyl),—C(═O)S-(optionally substituted aryl), —C(═O)S-(optionally substitutedheteroaryl), and C(═O)S-(optionally substituted heterocycloalkyl).

The term “sulfanyl” includes the groups: —S-(optionally substituted(C₁-C₆)alkyl), —S-(optionally substituted aryl), —S-(optionallysubstituted heteroaryl), and —S-(optionally substitutedheterocycloalkyl). Hence, sulfanyl includes the group C₁-C₆alkylsulfanyl.

The term “sulfinyl” includes the groups: —S(O)—H, —S(O)-(optionallysubstituted (C₁-C₆)alkyl), —S(O)-optionally substituted aryl),—S(O)-optionally substituted heteroaryl), —S(O)-(optionally substitutedheterocycloalkyl); and —S(O)-(optionally substituted amino).

The term “sulfonyl” includes the groups: —S(O₂)—H, —S(O₂)-(optionallysubstituted (C₁-C₆)alkyl), —S(O₂)-optionally substituted aryl),—S(O₂)-optionally substituted heteroaryl), —S(O₂)-(optionallysubstituted heterocycloalkyl), —S(O₂)-(optionally substituted alkoxy),—S(O₂)-optionally substituted aryloxy), —S(O₂)-optionally substitutedheteroaryloxy), —S(O₂)-(optionally substituted heterocyclyloxy); and—S(O₂)-(optionally substituted amino).

The term “substituted”, as used herein, means that any one or morehydrogens on the designated atom or group is replaced with a selectionfrom the indicated group, provided that the designated atom's normalvalence is not exceeded. When a substituent is oxo (i.e., ═O) then 2hydrogens on the atom are replaced. Combinations of substituents and/orvariables are permissible only if such combinations result in stablecompounds or useful synthetic intermediates. A stable compound or stablestructure is meant to imply a compound that is sufficiently robust tosurvive isolation from a reaction mixture, and subsequent formulation asan agent having at least practical utility. Unless otherwise specified,substituents are named into the core structure. For example, it is to beunderstood that when (cycloalkyl)alkyl is listed as a possiblesubstituent, the point of attachment of this substituent to the corestructure is in the alkyl portion.

The terms “substituted” alkyl, cycloalkyl, aryl, heterocycloalkyl, andheteroaryl (including without limitation dihydrobenzoxazinyl,dihydroquinoxalinyl, dihydrobenzodiazolyl, dihydroindolyl, pyrimidinyl,quinolinyl, indazolyl, indolyl, benzoimidazolyl, benzothiozolyl,benzotriazolyl, quinoxalinyl, quinazolinyl, morpholinyl, azetidinyl,pyrrolidinyl, oxanyl, pyridinyl, oxazolyl, piperazinyl, and pyradazinylgroup), unless otherwise expressly defined, refer respectively to alkyl,cycloalkyl, aryl, heterocycloalkyl, and heteroaryl (including withoutlimitation dihydrobenzoxazinyl, dihydroquinoxalinyl,dihydrobenzodiazolyl, dihydroindolyl, pyrimidinyl, quinolinyl,indazolyl, indolyl, benzoimidazolyl, benzothiozolyl, benzotriazolyl,quinoxalinyl, quinazolinyl, morpholinyl, azetidinyl, pyrrolidinyl,oxanyl, pyridinyl, oxazolyl, piperazinyl, and pyradazinyl group) whereinone or more (such as up to 5, for example, up to 3) hydrogen atoms arereplaced by a substituent independently chosen from:

—R^(a), —OR^(b), —O(C₁-C₂ alkyl)O— (e.g., methylenedioxy-), —SR^(b),guanidine, guanidine wherein one or more of the guanidine hydrogens arereplaced with a lower-alkyl group, —NR^(b)R^(c), halo, cyano, oxo (as asubstituent for heterocycloalkyl), nitro, —COR^(b), —CO₂R^(b),—CONR^(b)R^(c), —OCOR^(b), —OCO₂R^(a), —OCONR^(b)R^(c), —NR^(c)COR^(b),—NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c), —SOR^(a), —SO₂R^(a),—SO₂NR^(b)R^(c), and —NR^(c)SO₂R^(a),

where R^(a) is chosen from optionally substituted C₁-C₆ alkyl,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heterocycloalkyl, and optionally substitutedheteroaryl;

R^(b) is chosen from H, optionally substituted C₁-C₆ alkyl, optionallysubstituted aryl, and optionally substituted heteroaryl; and

R^(c) is chosen from hydrogen and optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently selected from C₁-C₄ alkyl, C₃-C₆ cycloalkyl,aryl, heteroaryl, aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄haloalkyl-, —OC₁-C₄ alkyl, —OC₁-C₄ alkylphenyl, —C₁-C₄ alkyl-OH, —C₁-C₄alkyl-O—C₁-C₄ alkyl, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo (asa substitutent for heteroaryl), —CO₂H, —C(O)OC₁-C₄ alkyl, —CON(C₁-C₄alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂, —NHC(O)(C₁-C₄ alkyl),—NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl), —N(C₁-C₄alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ phenyl, —C(O)C₁-C₄haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl), —SO₂(phenyl),—SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl), —SO₂NH(phenyl),—NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), and —NHSO₂(C₁-C₄ haloalkyl).

The term “substituted acyl” refers to the groups (substitutedalkyl)-C(O)—; (substituted cycloalkyl)-C(O)—; (substituted aryl)-C(O)—;(substituted heteroaryl)-C(O)—; and (substitutedheterocycloalkyl)-C(O)—, wherein the group is attached to the parentstructure through the carbonyl functionality and wherein substitutedalkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are asdescribed herein.

The term “substituted alkoxy” refers to alkoxy wherein the alkylconstituent is substituted (i.e., —O-(substituted alkyl)) wherein“substituted alkyl” is as described herein.

The term “substituted alkoxycarbonyl” refers to the group (substitutedalkyl)-O—C(O)— wherein the group is attached to the parent structurethrough the carbonyl functionality and wherein “substituted alkyl” is asdescribed herein.

The term “substituted aryloxy” refers to aryloxy wherein the arylconstituent is substituted (i.e., —O-(substituted aryl)) wherein“substituted aryl” is as described herein.

The term “substituted heteroaryloxy” refers to heteroaryloxy wherein thearyl constituent is substituted (i.e., —O-(substituted heteroaryl))wherein “substituted heteroaryl” is as described herein.

The term “substituted cycloalkyloxy” refers to cycloalkyloxy wherein thecycloalkyl constituent is substituted (i.e., —O-(substitutedcycloalkyl)) wherein “substituted cycloalkyl” is as described herein.

The term “substituted heterocycloalkyloxy” refers to heterocycloalkyloxywherein the alkyl constituent is substituted (i.e., —O-(substitutedheterocycloalkyl)) wherein “substituted heterocycloalkyl” is asdescribed herein.

The term “substituted amino” refers to the group —NHR^(d) or—NR^(d)R^(d) where each R^(d) is independently chosen from: hydroxy,optionally substituted alkyl, optionally substituted cycloalkyl,optionally substituted acyl, aminocarbonyl, optionally substituted aryl,optionally substituted heteroaryl, optionally substitutedheterocycloalkyl, alkoxycarbonyl, sulfinyl and sulfonyl, provided thatonly one R^(d) may be hydroxyl, and wherein substituted alkyl,cycloalkyl, aryl, heterocycloalkyl, and heteroaryl refer respectively toalkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl wherein one ormore (such as up to 5, for example, up to 3) hydrogen atoms are replacedby a substituent independently chosen from:

—R^(a), —OR^(b), —O(C₁-C₂ alkyl)O— (e.g., methylenedioxy-), —SR^(b),guanidine, guanidine wherein one or more of the guanidine hydrogens arereplaced with a lower-alkyl group, —NR^(b)R^(c), halo, cyano, nitro,—COR^(b), —CO₂R^(b), —CONR^(b)R^(c), —OCOR^(b), —OCO₂R^(a),—OCONR^(b)R^(c), —NR^(c)COR^(b), —NR^(c)CO₂R^(a), —NR^(c)CONR^(b)R^(c),—SOR^(a), —SO₂R^(a), —SO₂NR^(b)R^(c), and —NR^(c)SO₂R^(a),

where R^(a) is chosen from optionally substituted C₁-C₆ alkyl,optionally substituted aryl, and optionally substituted heteroaryl;

R^(b) is chosen from H, optionally substituted C₁-C₆ alkyl, optionallysubstituted aryl, and optionally substituted heteroaryl; and

R^(c) is chosen from hydrogen and optionally substituted C₁-C₄ alkyl; or

R^(b) and R^(c), and the nitrogen to which they are attached, form anoptionally substituted heterocycloalkyl group; and

where each optionally substituted group is unsubstituted orindependently substituted with one or more, such as one, two, or three,substituents independently selected from C₁-C₄ alkyl, aryl, heteroaryl,aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl-, —OC₁-C₄alkyl, —OC₁-C₄ alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo,—OH, —NH₂, —C₁-C₄ alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄alkyl), —N(C₁-C₄ alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl),cyano, nitro, oxo (as a substitutent for heteroaryl), —CO₂H, —C(O)OC₁-C₄alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂,—NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl),—N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ phenyl,—C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl),—SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl),—SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), and —NHSO₂(C₁-C₄haloalkyl); and

wherein optionally substituted acyl, aminocarbonyl, alkoxycarbonyl,sulfinyl and sulfonyl are as defined herein.

The term “substituted amino” also refers to N-oxides of the groups—NHR^(d), and NR^(d)R^(d) each as described above. N-oxides can beprepared by treatment of the corresponding amino group with, forexample, hydrogen peroxide or m-chloroperoxybenzoic acid. The personskilled in the art is familiar with reaction conditions for carrying outthe N-oxidation.

Compounds described herein include, but are not limited to, theiroptical isomers, racemates, and other mixtures thereof. In thosesituations, the single enantiomers or diastereomers, i.e., opticallyactive forms, can be obtained by asymmetric synthesis or by resolutionof the racemates. Resolution of the racemates can be accomplished, forexample, by conventional methods such as crystallization in the presenceof a resolving agent, or chromatography, using, for example a chiralhigh-pressure liquid chromatography (HPLC) column. In addition, suchcompounds include Z- and E-forms (or cis- and trans-forms) of compoundswith carbon-carbon double bonds. Where compounds described herein existin various tautomeric forms, chemical entities include all tautomericforms of the compound. Such compounds also include crystal formsincluding polymorphs and clathrates.

Compounds of Formula I also include crystalline and amorphous forms ofthose compounds, including, for example, polymorphs, pseudopolymorphs,solvates, hydrates, unsolvated polymorphs (including anhydrates),conformational polymorphs, and amorphous forms of the compounds, as wellas mixtures thereof. “Crystalline form,” “polymorph,” and “novel form”may be used interchangeably herein, and are meant to include allcrystalline and amorphous forms of the compound, including, for example,polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs(including anhydrates), conformational polymorphs, and amorphous forms,as well as mixtures thereof, unless a particular crystalline oramorphous form is referred to. Compounds of Formula I also includepharmaceutically acceptable forms of the recited compounds, includingchelates, non-covalent complexes, prodrugs, and mixtures thereof.

Chemical entities include, but are not limited to compounds describedherein and all pharmaceutically acceptable forms thereof. Hence, theterms “chemical entity” and “chemical entities” also encompasspharmaceutically acceptable salts.

“Pharmaceutically acceptable salts” include, but are not limited tosalts with inorganic acids, such as hydrochlorate, phosphate,diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts;as well as salts with an organic acid, such as malate, maleate,fumarate, tartrate, succinate, citrate, acetate, lactate,methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate,salicylate, stearate, and alkanoate such as acetate, HOOC—(CH₂)_(n)—COOHwhere n is 0-4, and like salts. Similarly, pharmaceutically acceptablecations include, but are not limited to sodium, potassium, calcium,aluminum, lithium, and ammonium.

In addition, if the compounds described herein are obtained as an acidaddition salt, the free base can be obtained by basifying a solution ofthe acid salt. Conversely, if the product is a free base, an additionsalt, particularly a pharmaceutically acceptable addition salt, may beproduced by dissolving the free base in a suitable organic solvent andtreating the solution with an acid, in accordance with conventionalprocedures for preparing acid addition salts from base compounds. Thoseskilled in the art will recognize various synthetic methodologies thatmay be used to prepare non-toxic pharmaceutically acceptable additionsalts.

As noted above, prodrugs also fall within the scope of compounds ofFormula I. In some embodiments, the “prodrugs” described herein includeany compound that becomes a compound of Formula I when administered to apatient, e.g., upon metabolic processing of the prodrug. Examples ofprodrugs include derivatives of functional groups, such as a carboxylicacid group, in the compounds of Formula I. Exemplary prodrugs of acarboxylic acid group include, but are not limited to, carboxylic acidesters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters, andaryloxyalkyl esters.

A “solvate” is formed by the interaction of a solvent and a compound.The term “compound” is intended to include solvates of compounds.Similarly, “salts” includes solvates of salts. Suitable solvates arepharmaceutically acceptable solvates, such as hydrates, includingmonohydrates and hemi-hydrates.

A “chelate” is formed by the coordination of a compound to a metal ionat two (or more) points. The term “compound” is intended to includechelates of compounds. Similarly, “salts” includes chelates of salts.

A “non-covalent complex” is formed by the interaction of a compound andanother molecule wherein a covalent bond is not formed between thecompound and the molecule. For example, complexation can occur throughvan der Waals interactions, hydrogen bonding, and electrostaticinteractions (also called ionic bonding). Such non-covalent complexesare included in the term “compound'.

The term “hydrogen bond” refers to a form of association between anelectronegative atom (also known as a hydrogen bond acceptor) and ahydrogen atom attached to a second, relatively electronegative atom(also known as a hydrogen bond donor). Suitable hydrogen bond donor andacceptors are well understood in medicinal chemistry (G. C. Pimentel andA. L. McClellan, The Hydrogen Bond, Freeman, San Francisco, 1960; R.Taylor and O. Kennard, “Hydrogen Bond Geometry in Organic Crystals”,Accounts of Chemical Research, 17, pp. 320-326 (1984)).

“Hydrogen bond acceptor” refers to a group comprising an oxygen ornitrogen, especially an oxygen or nitrogen that is sp²-hybridized, anether oxygen, or the oxygen of a sulfoxide or N-oxide.

The term “hydrogen bond donor” refers to an oxygen, nitrogen, orheteroaromatic carbon that bears a hydrogen group containing a ringnitrogen or a heteroaryl group containing a ring nitrogen.

As used herein the terms “group”, “radical” or “fragment” are synonymousand are intended to indicate functional groups or fragments of moleculesattachable to a bond or other fragments of molecules.

The term “active agent” is used to indicate a chemical entity which hasbiological activity. In some embodiments, an “active agent” is acompound having pharmaceutical utility. For example an active agent maybe an anti-cancer therapeutic.

The term “therapeutically effective amount” of a chemical entitydescribed herein means an amount effective, when administered to a humanor non-human patient, to provide a therapeutic benefit such asamelioration of symptoms, slowing of disease progression, or preventionof disease e.g., a therapeutically effective amount may be an amountsufficient to decrease the symptoms of a disease responsive toinhibition of Syk activity. In some embodiments, a therapeuticallyeffective amount is an amount sufficient to reduce cancer symptoms, thesymptoms of an allergic disorder, the symptoms of an autoimmune and/orinflammatory disease, or the symptoms of an acute inflammatory reaction.In some embodiments a therapeutically effective amount is an amountsufficient to decrease the number of detectable cancerous cells in anorganism, detectably slow, or stop the growth of a cancerous tumor. Insome embodiments, a therapeutically effective amount is an amountsufficient to shrink a cancerous tumor. In some circumstances a patientsuffering from cancer may not present symptoms of being affected. Insome embodiments, a therapeutically effective amount of a chemicalentity is an amount sufficient to prevent a significant increase orsignificantly reduce the detectable level of cancerous cells or cancermarkers in the patient's blood, serum, or tissues. In methods describedherein for treating allergic disorders and/or autoimmune and/orinflammatory diseases and/or acute inflammatory reactions, atherapeutically effective amount may also be an amount sufficient, whenadministered to a patient, to detectably slow progression of thedisease, or prevent the patient to whom the chemical entity is givenfrom presenting symptoms of the allergic disorders and/or autoimmuneand/or inflammatory disease, and/or acute inflammatory response. In somemethods described herein for treating allergic disorders and/orautoimmune and/or inflammatory diseases and/or acute inflammatoryreactions, a therapeutically effective amount may also be an amountsufficient to produce a detectable decrease in the amount of a markerprotein or cell type in the patient's blood or serum. For example, insome embodiments a therapeutically effective amount is an amount of achemical entity described herein sufficient to significantly decreasethe activity of B-cells. In another example, in some embodiments atherapeutically effective amount is an amount of a chemical entitydescribed herein sufficient to significantly decrease the number ofB-cells. In another example, in some embodiments a therapeuticallyeffective amount is an amount of a chemical entity described hereinsufficient to decrease the level of anti-acetylcholine receptor antibodyin a patient's blood with the disease myasthenia gravis.

The term “inhibition” indicates a significant decrease in the baselineactivity of a biological activity or process. “Inhibition of Sykactivity” refers to a decrease in Syk activity as a direct or indirectresponse to the presence of at least one chemical entity describedherein, relative to the activity of Syk in the absence of the at leastone chemical entity. The decrease in activity may be due to the directinteraction of the compound with Syk, or due to the interaction of thechemical entity(ies) described herein with one or more other factorsthat in turn affect Syk activity. For example, the presence of thechemical entity(ies) may decrease Syk activity by directly binding tothe Syk, by causing (directly or indirectly) another factor to decreaseSyk activity, or by (directly or indirectly) decreasing the amount ofSyk present in the cell or organism.

Inhibition of Syk activity also refers to observable inhibition of Sykactivity in a standard biochemical assay for Syk activity, such as theATP hydrolysis assay described below. In some embodiments, the chemicalentity described herein has an IC₅₀ value less than or equal to 1micromolar. In some embodiments, the chemical entity has an IC₅₀ valueless than or equal to less than 100 nanomolar. In some embodiments, thechemical entity has an IC₅₀ value less than or equal to 10 nanomolar.

“Inhibition of B-cell activity” refers to a decrease in B-cell activityas a direct or indirect response to the presence of at least onechemical entity described herein, relative to the activity of B-cells inthe absence of the at least one chemical entity. The decrease inactivity may be due to the direct interaction of the compound with Sykor with one or more other factors that in turn affect B-cell activity.

Inhibition of B-cell activity also refers to observable inhibition ofCD86 expression in a standard assay such as the assay described below.In some embodiments, the chemical entity described herein has an IC₅₀value less than or equal to 10 micromolar. In some embodiments, thechemical entity has an IC₅₀ value less than or equal to less than 1micromolar. In some embodiments, the chemical entity has an IC₅₀ valueless than or equal to 500 nanomolar.

“B cell activity” also includes activation, redistribution,reorganization, or capping of one or more various B cell membranereceptors, or membrane-bound immunoglobulins, e.g, IgM, IgG, and IgD.Most B cells also have membrane receptors for Fc portion of IgG in theform of either antigen-antibody complexes or aggregated IgG. B cellsalso carry membrane receptors for the activated components ofcomplement, e.g., C3b, C3d, C4, and Clq. These various membranereceptors and membrane-bound immunoglobulins have membrane mobility andcan undergo redistribution and capping that can initiate signaltransduction.

B cell activity also includes the synthesis or production of antibodiesor immunoglobulins. Immunoglobulins are synthesized by the B cell seriesand have common structural features and structural units. Fiveimmunoglobulin classes, i.e., IgG, IgA, IgM, IgD, and IgE, arerecognized on the basis of structural differences of their heavy chainsincluding the amino acid sequence and length of the polypeptide chain.Antibodies to a given antigen may be detected in all or several classesof immunoglobulins or may be restricted to a single class or subclass ofimmunoglobulin. Autoantibodies or autoimmune antibodies may likewisebelong to one or several classes of immunoglobulins. For example,rheumatoid factors (antibodies to IgG) are most often recognized as anIgM immunoglobulin, but can also consist of IgG or IgA.

In addition, B cell activity also is intended to include a series ofevents leading to B cell clonal expansion (proliferation) from precursorB lymphocytes and differentiation into antibody-synthesizing plasmacells which takes place in conjunction with antigen-binding and withcytokine signals from other cells.

“Inhibition of B-cell proliferation” refers to inhibition ofproliferation of abnormal B-cells, such as cancerous B-cells, e.g.lymphoma B-cells and/or inhibition of normal, non-diseased B-cells. Theterm “inhibition of B-cell proliferation” indicates any significantdecrease in the number of B-cells, either in vitro or in vivo. Thus aninhibition of B-cell proliferation in vitro would be any significantdecrease in the number of B-cells in an in vitro sample contacted withat least one chemical entity described herein as compared to a matchedsample not contacted with the chemical entity(ies).

Inhibition of B-cell proliferation also refers to observable inhibitionof B-cell proliferation in a standard thymidine incorporation assay forB-cell proliferation, such as the assay described herein. In someembodiments, the chemical entity has an IC₅₀ value less than or equal to10 micromolar. In some embodiments, the chemical entity has an IC₅₀value less than or equal to less than 1 micromolar. In some embodiments,the chemical entity has an IC₅₀ value less than or equal to 500nanomolar.

An “allergy” or “allergic disorder” refers to acquired hypersensitivityto a substance (allergen). Allergic conditions include eczema, allergicrhinitis or coryza, hay fever, bronchial asthma, urticaria (hives) andfood allergies, and other atopic conditions.

“Asthma” refers to a disorder of the respiratory system characterized byinflammation, narrowing of the airways and increased reactivity of theairways to inhaled agents. Asthma is frequently, although notexclusively associated with atopic or allergic symptoms.

By “significant” is meant any detectable change that is statisticallysignificant in a standard parametric test of statistical significancesuch as Student's T-test, where p<0.05.

A “disease responsive to inhibition of Syk activity” is a disease inwhich inhibiting Syk kinase provides a therapeutic benefit such as anamelioration of symptoms, decrease in disease progression, prevention ordelay of disease onset, or inhibition of aberrant activity of certaincell-types (monocytes, B-cells, and mast cells).

“Treatment or treating means any treatment of a disease in a patient,including:

-   -   a) preventing the disease, that is, causing the clinical        symptoms of the disease not to develop;    -   b) inhibiting the disease;    -   c) slowing or arresting the development of clinical symptoms;        and/or    -   d) relieving the disease, that is, causing the regression of        clinical symptoms.

“Patient” refers to an animal, such as a mammal, that has been or willbe the object of treatment, observation or experiment. The methodsdescribed herein may be useful in both human therapy and veterinaryapplications. In some embodiments, the patient is a mammal; in someembodiments the patient is human; and in some embodiments the patient ischosen from cats and dogs.

Provided is at least one chemical entity chosen from compounds ofFormula I:

and pharmaceutically acceptable salts thereof, wherein

-   R₁ is phenyl substituted with one or two groups chosen from    -   halo,    -   hydroxy,    -   carboxy,    -   cyano,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   cycloalkyloxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from acyl, halo, optionally substituted amino, hydroxy,        lower alkoxy, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with lower alkoxy, lower alkyl        substituted with one, two, or three halo groups, optionally        substituted amino, optionally substituted heterocycloalkyl, and        oxo,    -   heterocycloalkyloxy optionally substituted with one or two        groups chosen from halo, optionally substituted amino, hydroxy,        lower alkoxy, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with lower alkoxy, lower alkyl        substituted with one, two, or three halo groups, optionally        substituted amino, optionally substituted heterocycloalkyl, and        oxo,    -   heteroaryl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with halo, lower alkyl        substituted with hydroxy, and lower alkyl substituted with lower        alkoxy,    -   —C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy, provided that at least one of R₆ and        R₇ is not hydrogen,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, optionally substituted        aminocarbonyl, optionally substituted amino, carboxy,        aminocarbonyl, and heterocycloalkyl,    -   heteroaryloxy, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, optionally        substituted amino, and heterocycloalkyl optionally substituted        with lower alkyl; or-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted;

-   R₂ is chosen from optionally substituted aryl and optionally    substituted heteroaryl;-   R₃ is chosen from hydrogen, lower alkyl, and halo;-   R₄ is chosen from hydrogen and lower alkyl; and-   R₅ is hydrogen,    provided that-   if R₃ and R₄ are hydrogen and R₁ is    3-methoxy-4-(morpholin-4-ylcarbonyl)phenyl,    4-(morpholin-4-yl)phenyl, 3,4-diethoxyphenyl,    3-fluoro-4-methoxyphenyl, 4-(4-ethylpiperazin-1-yl)phenyl,    4-(3-oxopiperazin-1-yl)phenyl, 4-(morpholin-4-yl)phenyl,    3-methoxy-4-(morpholin-4-yl)phenyl, 3-methoxy-4-methylphenyl,    4-methoxy-3-methylphenyl, 2-(dimethylamino)ethoxy-3-methoxyphenyl,    3-ethoxy-4-methoxyphenyl, or 4-ethoxy-3-methoxyphenyl, then R₂ is    not phenyl substituted with —(CO)NHR₆ where R₆ is optionally    substituted aryl;-   if R₃ and R₄ are hydrogen and R₁ is 3,4-dimethoxyphenyl, then R₂ is    not phenyl substituted with    -   —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionally        substituted heterocycloalkyl or optionally substituted        heteroaryl or where R₈ is hydrogen, methyl or ethyl and R₉ is        hydrogen, optionally substituted aryl, optionally substituted        cycloalkyl, optionally substituted heterocycloalkyl, optionally        substituted alkyl, or optionally substituted heteroaryl wherein        said phenyl is further optionally substituted with a group        chosen from methyl, methoxy, and halo, or    -   —(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl;-   if R₃ and R₄ are hydrogen and R₁ is 4-(morpholin-4-yl)phenyl, then    R₂ is not pyridinyl, 2-fluorophenyl, benzo[d][1,3]dioxolyl,    2-methoxyphenyl, 2,6-dimethoxyphenyl, 3-acetamidophenyl,    3-carboxyphenyl, 2-(hydroxymethyl)phenyl, furanyl, or    3-(hydroxyethylcarbamoyl)phenyl;-   if R₃ and R₄ are hydrogen and R₁ is chlorophenyl, then R₂ is not    phenyl substituted with piperidin-1-yl-carbonyl or NH(CO)NHR₁₂ where    R₁₂ is phenyl substituted with trifluoromethyl or one or more    halogens;-   if R₃ and R₄ are hydrogen and R₁ is phenyl substituted with    optionally substituted piperazinyl then R₂ is not 3-aminophenyl;-   if R₃ and R₄ are hydrogen and R₁ is 4-chlorophenyl, then R₂ is not    4-carboxyphenyl, 3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or    4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and-   if R₃ and R₄ are hydrogen and R₁ is 4-(2-hydroxy-ethyl)phenyl or    4-(hydroxyethyl)phenyl, then R₂ is not 2-methoxyphenyl or    2-fluorophenyl;-   if R₃ and R₄ are hydrogen and R₁ is    4-[(4-ethylpiperazin-1-yl)methyl]phenyl or    4-(2-hydroxypropan-2-yl)phenyl, then R₂ is not phenyl substituted    with —(CO)NR₈R₉ where R₈ is hydrogen and R₉ is hydrogen, methyl or    optionally substituted aryl wherein said phenyl is optionally    further substituted with a group chosen from methyl;-   if R₃ and R₄ are hydrogen and R₂ is 4-carbamoylphenyl, then R₁ is    not 4-(hydroxymethyl)phenyl, 3-(1-hydroxyethyl)phenyl,    4-(1H-imidazol-2-yl)-3-methylphenyl,    3-methoxy-4-(piperidin-4-yloxy)phenyl,    3-methoxy-4-(2-methoxyethoxy)phenyl,    4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl,    4-(2-hydroxyethoxy)-3-methoxyphenyl,    3-methoxy-4-(propan-2-yloxy)phenyl, 3-methoxy-4-propoxyphenyl,    4-(propylcarbamoyl)phenyl, 4-ethoxy-3-methoxyphenyl,    4-(1H-imidazol-2-yl)phenyl, 3-methoxy-4-(1H-pyrazol-5-yl)phenyl,-   if R₃ and R₄ are hydrogen and R₂ is pyridin-3-yl substituted with    carbamoyl, then R₁ is not 3,4-dimethoxyphenyl,-   if R₃ and R₄ are hydrogen and R₁ is 4-ethoxy-3-methoxyphenyl, then    R₂ is not phenyl substituted with methyl and further substituted    with —(CO)NR₈R₉ where R₈ is hydrogen and R₉ is    4-(methylcarbamoyl)phenyl, and-   further provided that R₂ is not phenyl substituted with —NHC(O)R₁₁    where R₁₁ is optionally substituted aryl.

In some embodiments, R₃ is chosen from hydrogen, methyl, ethyl, andchloro. In some embodiments, R₃ is hydrogen.

In some embodiments, R₄ is chosen from hydrogen and methyl. In someembodiments, R₄ is hydrogen.

Also provided is at least one chemical entity chosen from compounds ofFormula I:

and pharmaceutically acceptable salts thereof, wherein

-   R₁ is phenyl substituted with one or two groups chosen from    -   halo,    -   hydroxy,    -   carboxy,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, lower alkyl, lower alkyl        substituted with hydroxy, optionally substituted amino, and oxo,    -   heteroaryl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with halo, lower alkyl        substituted with hydroxy, and lower alkyl substituted with lower        alkoxy,    -   —C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy, provided that at least one of R₆ and        R₇ is not hydrogen,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, optionally substituted amino,        carboxy, aminocarbonyl, and heterocycloalkyl,    -   heteroaryloxy, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, optionally        substituted amino, and heterocycloalkyl optionally substituted        with lower alkyl; or-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted;

-   R₂ is chosen from optionally substituted aryl and optionally    substituted heteroaryl;-   R₃ is hydrogen;-   R₄ is hydrogen; and-   R₅ is hydrogen,    provided that-   if R₁ is 3-methoxy-4-methylphenyl, 4-methoxy-3-methylphenyl,    2-(dimethylamino)ethoxy-3-methoxyphenyl, 3-ethoxy-4-methoxyphenyl,    or 4-ethoxy-3-methoxyphenyl, then R₂ is not phenyl substituted with    —(CO)NHR₆ where R₆ is optionally substituted aryl;-   if R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenyl substituted with    -   —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionally        substituted heterocycloalkyl or optionally substituted        heteroaryl or where R₈ is hydrogen and R₉ is optionally        substituted aryl, optionally substituted cycloalkyl, optionally        substituted heterocycloalkyl, optionally substituted alkyl, or        optionally substituted heteroaryl, or    -   —(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl;-   if R₁ is 4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl,    2-fluorophenyl, benzo[d][1,3]dioxolyl, 2-methoxyphenyl,    2,6-dimethoxyphenyl, 3-acetamidophenyl, 3-carboxyphenyl,    2-(hydroxymethyl)phenyl, furanyl, or 3-(hyroxyethylcarbamoyl)phenyl;-   if R₁ is chlorophenyl, then R₂ is not phenyl substituted with    piperidin-1-yl-carbonyl or NH(CO)NR₁₂ where R₁₂ is phenyl    substituted with trifluoromethyl or one or more halogens;-   if R₁ is optionally substituted piperazinyl then R₂ is not    3-aminophenyl;-   if R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,    3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or    4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and-   if R₁ is 4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then    R₂ is not 2-methoxyphenyl or 2-fluorophenyl; and-   further provided that R₂ is not phenyl substituted with —NHC(O)R₁₁    where R₁₁ is optionally substituted aryl.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   halo,    -   hydroxy,    -   carboxy,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, lower alkyl, lower alkyl        substituted with hydroxy, optionally substituted amino, and oxo,    -   heteroaryl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with halo, lower alkyl        substituted with hydroxy, and lower alkyl substituted with lower        alkoxy,    -   —C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy, provided that at least one of R₆ and        R₇ is not hydrogen,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, optionally substituted amino,        carboxy, aminocarbonyl, and heterocycloalkyl,    -   heteroaryloxy, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, optionally        substituted amino, and heterocycloalkyl optionally substituted        with lower alkyl.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   halo,    -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with hydroxy, and lower        alkyl substituted with lower alkoxy,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and optionally substituted        amino,    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, trifluoromethyl, optionally        substituted amino, and heterocycloalkyl, and    -   —C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from        hydrogen, lower alkyl, lower alkyl substituted with hydroxy,        lower alkyl substituted with optionally substituted amino,        cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇        together with the nitrogen to which they are bound form a 3- to        7-membered heterocycloalkyl ring optionally substituted with one        or two groups chosen from hydroxy, lower alkyl, and lower alkyl        substituted with hydroxy.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, lower alkyl, and lower alkyl        substituted with hydroxy,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy and lower alkoxy, and    -   lower alkyl substituted with one or two groups chosen from        hydroxy, lower alkoxy, trifluoromethyl, optionally substituted        amino, and heterocycloalkyl.

Also provided is at least one chemical entity chosen from compounds ofFormula I:

and pharmaceutically acceptable salts thereof, wherein

-   R₁ is phenyl substituted with one or two groups chosen from    -   halo,    -   hydroxy,    -   cycloalkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and lower alkyl,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with halo, lower alkyl        substituted with hydroxy, and lower alkyl substituted with lower        alkoxy,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and optionally substituted        amino, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, halo, trifluoromethyl, and        optionally substituted amino; or-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted;

-   R₂ is chosen from optionally substituted aryl and optionally    substituted heteroaryl;-   R₃ is hydrogen;-   R₄ is hydrogen; and-   R₅ is hydrogen,    provided that-   if R₁ is 3-methoxy-4-methylphenyl, 4-methoxy-3-methylphenyl,    2-(dimethylamino)ethoxy-3-methoxyphenyl, 3-ethoxy-4-methoxyphenyl,    or 4-ethoxy-3-methoxyphenyl, then R₂ is not phenyl substituted with    —(CO)NHR₆ where R₆ is optionally substituted aryl;-   if R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenyl substituted with    -   —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionally        substituted heterocycloalkyl or optionally substituted        heteroaryl or where R₈ is hydrogen and R₉ is optionally        substituted aryl, optionally substituted cycloalkyl, optionally        substituted heterocycloalkyl, optionally substituted alkyl, or        optionally substituted heteroaryl, or    -   —(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl;-   if R₁ is 4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl,    2-fluorophenyl, benzo[d][1,3]dioxolyl, 2-methoxyphenyl,    2,6-dimethoxyphenyl, 3-acetamidophenyl, 3-carboxyphenyl,    2-(hydroxymethyl)phenyl, furanyl, or 3-(hyroxyethylcarbamoyl)phenyl;-   if R₁ is chlorophenyl, then R₂ is not phenyl substituted with    piperidin-1-yl-carbonyl or NH(CO)NR₁₂ where R₁₂ is phenyl    substituted with trifluoromethyl or one or more halogens;-   if R₁ is optionally substituted piperazinyl then R₂ is not    3-aminophenyl;-   if R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,    3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or    4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and-   if R₁ is 4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then    R₂ is not 2-methoxyphenyl or 2-fluorophenyl; and-   further provided that R₂ is not phenyl substituted with —NHC(O)R₁₁    where R₁₁ is optionally substituted aryl.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   halo,    -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   lower alkoxy optionally substituted with optionally substituted        amino, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and optionally substituted amino; or

-   R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   amino optionally substituted with one or two groups chosen from        lower alkyl, lower alkyl substituted with hydroxy, and lower        alkyl substituted with lower alkoxy,    -   lower alkoxy optionally substituted with one or two groups        chosen from hydroxy and optionally substituted amino, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, trifluoromethyl, and optionally        substituted amino.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   lower alkoxy, and    -   lower alkyl substituted with one or two groups chosen from        hydroxy, lower alkoxy, trifluoromethyl, and optionally        substituted amino.

In some embodiments, R₁ is chosen from (1-hydroxycyclobutyl)phenyl,(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl,(2,2,2-trifluoro-1-hydroxyethyl)phenyl,(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl,(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl,(2-hydroxyethyl)(methyl)amino)-3-methoxyphenyl,(2-methoxyethyl)(methyl)amino)-3-methoxyphenyl, (1-hydroxyethyl)phenyl,3,4-dimethoxyphenyl, 3-methoxyphenyl, 4-ethoxy-3-methoxyphenyl,4-hydroxymethyl-3-methoxyphenyl, 3-hydroxymethyl-4-methoxyphenyl,2-fluoro-4-methoxyphenyl, 4-(dimethylamino)propoxy-3-methoxyphenyl,4-hydroxypropoxy-3-methoxyphenyl, 4-(2-hydroxy-1,1-dimethylethyl)phenyl,4-(1-hydroxy-1-methylethyl)phenyl, 4-methoxy-3-(pyrrolidin-1-yl)phenyl,3-methoxy-4-(pyrrolidin-1-yl)phenyl, 3-methoxy-4-(propan-2-yloxy)phenyl,3-methoxy-4-(morpholin-4-yl)phenyl, 4-(pyrrolidin-1-yl)phenyl,4-(3-hydroxypyrrolidinyl)phenyl,4-(4-hydroxypiperidinyl)-3-methoxyphenyl,4-(3-hydroxyazetidinyl)-3-methoxyphenyl,4-(3-hydroxypyrrolidinyl)-3-methoxyphenyl,4-(2-methoxypropan-2-yl)phenyl,4-(4-ethylpiperazin-1-yl)-3-methoxyphenyl,4-(4-ethylpiperazin-1-yl)phenyl,4-(3-hydroxy-3-methylpiperidinyl)phenyl, and 3-hydroxymethylphenyl.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   lower alkoxy optionally substituted with optionally substituted        amino, and    -   lower alkyl optionally substituted with one or two groups chosen        from hydroxy, lower alkoxy, and optionally substituted amino.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy, lower alkoxy, and lower alkyl,    -   lower alkoxy, and    -   lower alkyl substituted with one or two groups chosen from        hydroxy, lower alkoxy, and optionally substituted amino.

In some embodiments, R₁ is phenyl substituted with one or two groupschosen from

-   -   hydroxy,    -   heterocycloalkyl optionally substituted with one or two groups        chosen from hydroxy and lower alkyl,    -   lower alkoxy, and    -   lower alkyl substituted with one or two groups chosen from        hydroxy and lower alkoxy.

In some embodiments, R₁ is chosen from (1-hydroxyethyl)phenyl,3,4-dimethoxyphenyl, 3-methoxyphenyl, 4-ethoxy-3-methoxyphenyl,4-hydroxymethyl-3-methoxyphenyl, 3-hydroxymethyl-4-methoxyphenyl,2-fluoro-4-methoxyphenyl, 4-(dimethylamino)propoxy-3-methoxyphenyl,4-hydroxypropoxy-3-methoxyphenyl, 4-(2-hydroxy-1,1-dimethylethyl)phenyl,4-(1-hydroxy-1-methylethyl)phenyl, 4-methoxy-3-(pyrrolidin-1-yl)phenyl,3-methoxy-4-(pyrrolidin-1-yl)phenyl, 3-methoxy-4-(propan-2-yloxy)phenyl,3-methoxy-4-(morpholin-4-yl)phenyl, 4-(pyrrolidin-1-yl)phenyl,4-(3-hydroxypyrrolidinyl)phenyl,4-(4-hydroxypiperidinyl)-3-methoxyphenyl,4-(3-hydroxyazetidinyl)-3-methoxyphenyl,4-(3-hydroxypyrrolidinyl)-3-methoxyphenyl,4-(2-methoxypropan-2-yl)phenyl,4-(4-ethylpiperazin-1-yl)-3-methoxyphenyl,4-(4-ethylpiperazin-1-yl)phenyl,4-(3-hydroxy-3-methylpiperidinyl)phenyl, and 3-hydroxymethylphenyl.

In some embodiments, R₁ is

In some embodiments, A is an optionally substituted heterocycloalkylgroup comprising one or more heteroatoms chosen from O and N. In someembodiments, the heterocylcloalkyl group is substituted with one or moregroups chosen from lower alkyl and oxo. In some embodiments, theheteroatom N is substituted by lower alkyl.

In some embodiments, R₁ is chosen from3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl,5-methyl-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl,2,3-dihydro-1H-indol-2-one-6-yl, and 2,3-dihydro-1H-indol-2-one-5-yl.

In some embodiments, R₂ is chosen from

-   optionally substituted heteroaryl;-   dihydrobenzoxazinyl optionally substituted with one or more groups    chosen from lower alkyl, halo, and oxo,-   dihydroquinoxalinyl optionally substituted with one or more groups    chosen from lower alkyl and oxo;-   dihydrobenzodiazolyl optionally substituted with oxo;-   dihydroindolyl optionally substituted with one or more groups chosen    from lower alkyl and oxo, and-   phenyl substituted with one or more groups chosen from optionally    substituted alkyl, cyano, nitro, lower alkoxy, halo, sulfonyl,    optionally substituted amino, and optionally substituted heteroaryl.

In some embodiments, R₂ is chosen from

-   -   optionally substituted pyridinyl,    -   pyrimidinyl,    -   thiophenyl,    -   quinolinyl optionally substituted with amino,    -   indazolyl optionally substituted with one or two groups chosen        from carbamoyl, halo, lower alkyl, and amino,    -   indolyl optionally substituted with one or two groups chosen        from lower alkyl, carbamoyl,    -   benzoimidazolyl optionally substituted with methyl or amino,    -   benzothiozolyl optionally substituted with lower alkyl,    -   benzoxazolyl,    -   benzotriazolyl,    -   quinoxalinyl optionally substituted with amino,    -   quinazolinyl optionally substituted with amino,        dihydrobenzoxazinyl optionally substituted with one or more        groups chosen from methyl, halo, and oxo,        1H-pyrrolo[3,2-b]pyridinyl,    -   dihydrobenzoxazinyl optionally substituted with one or more        groups chosen from lower alkyl, halo, and oxo,    -   dihydroindolyl optionally substituted with one or more groups        chosen from lower alkyl and oxo, and    -   phenyl substituted with one or more groups chosen from        optionally substituted alkyl, cyano, chloro, fluoro, nitro,        methoxy, sulfonyl, heteroaryl, amino, and NHC(O)R₁₂ where R₁₂ is        lower alkyl.

In some embodiments, R₂ is chosen from 2,3-dihydro-1,4-benzodioxin-6-yl,4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl, 1,3-benzoxazol-5-yl,2H-1,3-benzodioxol-5-yl, 2,3-dihydro-1H-indol-6-yl,2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl,1-methyl-2,3-dihydro-1H-indol-2-one-6-yl,1,2,3,4-tetrahydroisoquinolin-2-yl-ethan-1-one-6-yl,2-ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl, 2-aminoquinazolin-6-yl,2-hydroxyethyl-2H-indazol-6-yl, 1-hydroxyethyl-2H-indazol-6-yl1H-indazol-7-yl, 1,2,3,4-tetrahydroisoquinolin-6-yl,3-(diethylamino)methyl-1H-indazol-6-yl,1,2-dihydroquinoxalin-2-one-6-yl, 1,2-dihydroquinolin-2-one-6-yl,1H-pyrazol-4-yl, 1,3-thiazol-5-yl, 2-methyl-1,3-benzothiazol-5-yl,1′2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one-6-yl,3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl,3-(1,3-thizaol-4-ylmethylidene)-2,3-dihydro-1H-indole-2-one-6-yl,1-methyl-1H-indazol-6-yl, (N,N-dimethylaminocarbonyl)indol-6-yl,1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl,1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one-6-yl,2,2-difluoro-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,3-ethyl-1H-indazol-6-yl, 1H-indol-2-yl, 1H-indol-3-yl,4-fluoro-1H-indazol-6-yl, 1H-1,2,3-benzotriazol-6-yl,2,3-dihydro-1H-1,3-benzodiazol-2-one-6-yl, 1H-1,3-benzodiazol-6-yl,1H-indol-6-yl, 1H-pyrrolo[3,2-b]pyridin-6-yl,1-methyl-1H-1,3-benzodiazol-5-yl, 1-methyl-1H-1,3-benzodiazol-6-yl,1-methyl-1H-benzo[d]imidazol-5-yl, 2-methyl-1H-benzo[d]imidazol-5-yl,2-oxoindolin-6-yl, 3,3-dimethyl-2-oxoindolin-6-yl,3,4-dihydro-2H-1,4-benzoxazin-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-7-yl,3-amino-1H-indazol-5-yl, 3-amino-1H-indazol-6-yl,3-carbamoyl-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl,3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,4-(1-hydroxy-2-methylpropan-2-yl)phenyl, 5-fluoro-1H-indazol-6-yl, andindolin-6-yl.

In some embodiments, R₂ is chosen from optionally substitutedheteroaryl, dihydrobenzoxazinyl optionally substituted with lower alkyland oxo, and phenyl substituted with one or more groups chosen fromoptionally substituted alkyl, cyano, nitro, lower alkoxy, halo,sulfonyl, optionally substituted amino, and optionally substitutedheteroaryl.

In some embodiments, R₂ is chosen from optionally substituted pyridinyl,pyrimidinyl, thiophenyl, quinolinyl optionally substituted with amino,indazolyl optionally substituted with halo, carbamoyl, methyl or amino,indolyl, indolinyl optionally substituted with one or two groups chosenfrom lower alkyl and oxo, benzoimidazolyl optionally substituted withmethyl or amino, benzothiozolyl, benzoxazolyl, benzotriazolyl,quinoxalinyl optionally substituted with amino, quinazolinyl optionallysubstituted with amino, dihydrobenzoxazinyl optionally substituted withmethyl and oxo, 1H-pyrrolo[3,2-b]pyridinyl, and phenyl substituted withone or more groups chosen from optionally substituted alkyl, cyano,chloro, fluoro, nitro, methoxy, sulfonyl, heteroaryl, amino, andNHC(O)R₁₂ where R₁₂ is lower alkyl.

In some embodiments, R₂ is chosen from 1H-1,3-benzodiazol-6-yl,1H-indol-6-yl, 1H-pyrrolo[3,2-b]pyridin-6-yl,1-methyl-1H-1,3-benzodiazol-5-yl, 1-methyl-1H-1,3-benzodiazol-6-yl,1-methyl-1H-benzo[d]imidazol-5-yl, 2-methyl-1H-benzo[d]imidazol-5-yl,2-oxoindolin-6-yl, 3,3-dimethyl-2-oxoindolin-6-yl,3,4-dihydro-2H-1,4-benzoxazin-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-7-yl,3-amino-1H-indazol-5-yl, 3-amino-1H-indazol-6-yl,3-carbamoyl-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl,3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,4-(1-hydroxy-2-methylpropan-2-yl)phenyl, 5-fluoro-1H-indazol-6-yl, andindolin-6-yl.

In some embodiments, R₂ is chosen from optionally substituted pyridinyl,pyrimidinyl, thiophenyl, quinolinyl optionally substituted with amino,indazolyl optionally substituted with methyl or amino, indolyl,benzoimidazolyl optionally substituted with methyl or amino,benzothiozolyl, benzoxazolyl, benzotriazolyl, quinoxalinyl optionallysubstituted with amino, quinazolinyl optionally substituted with amino,dihydrobenzoxazinyl optionally substituted with methyl and oxo, andphenyl substituted with one or more groups chosen from optionallysubstituted alkyl, cyano, chloro, fluoro, nitro, methoxy, sulfonyl,heteroaryl, amino, and NHC(O)R₁₂ where R₁₂ is lower alkyl.

In some embodiments, R₂ is chosen from 3-methylphenyl, 4-methylphenyl,3-nitrophenyl, 3-[(ethylamino)methyl]phenyl,4-[(ethylamino)methyl]phenyl, 3-(trifluoromethyl)phenyl,3-methoxyphenyl, 4-pyridinyl, 3-pyridinyl, 4-cyanophenyl, 3-cyanophenyl,4-chlorophenyl, 3-chlorophenyl, 4-chloro-3-methylphenyl,3-chloro-4-methylphenyl, 4-fluorophenyl, 3-fluorophenyl,4-fluoro-3-methylphenyl, 3-fluoro-4-methylphenyl, 3,4-difluorophenyl,4-sulfonamidophenyl, 3-sulfonamidophenyl, 4-methanesulfonylphenyl,3-methanesulfonylphenyl, 2-fluoropyridin-4-yl, 5-methylpyridin-3-yl,5-chloropyridin-3-yl, pyrimidin-5-yl,(4-acetylpiperazin-1-yl)methylphenyl,(3-acetylpiperazin-1-yl)methylphenyl, (3-piperazin-1-ylmethyl)phenyl,(4-piperazin-1-ylmethyl)phenyl, 3-acetamidophenyl, 4-acetamidophenyl,4-aminophenyl, 3-aminophenyl, thiophen-3-yl, thiophen-2-yl,1H-indazol-5-yl, 1H-indazol-6-yl, 3-amino-1H-indazol-5-yl,1-methyl-1H-indazol-5-yl, 1-methyl-1H-indazol-6-yl,3-methyl-IN-indazol-5-yl, 2,3-dimethyl-2H-indazol-5-yl,3-amino-1H-indazol-6-yl, 3-amino-1H-indazol-5-yl,4-(1H-imidazol-2-yl)phenyl, 4-(1H-imidazol-5-yl)phenyl,3-(1H-imidazol-5-yl)phenyl, quinolin-6-yl, 2-aminoquinoline-6-yl,3-aminoquinoline-6-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl,2-aminoquinazoline-6-yl, 3-(1,3-thiazol-2-yl)phenyl,4-(1,3-thiazol-2-yl)phenyl, 3-(1,3-thiazol-2-yl)phenyl,1,2-dihydropyridin-2-one-5-yl, 4-(1,3-oxazol-2-yl)phenyl,3-(1,3-oxazol-2-yl)phenyl, 2-aminopyridine-5-yl,1H-1,2,3-benzotriazol-6-yl, 1H-imidazo[4,5-b]pyridin-6-yl,1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1H-indol-6-yl, 1H-indol-5-yl,1-methyl-1H-1,3-benzodiazol-5-yl, 2-amino-1H-1,3-benzodiazol-6-yl,1-methyl-1H-1,3-benzodiazol-6-yl,2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one-6-yl,1H,2H,3H-pyrido[3,2-b][1,4]oxazin-3-one-6-yl,3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,3,4-dihydro-2H-1,4-benzoxazin-3-one-7-yl,4-methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,2-methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,2-hydroxyquinolin-6-yl, 1-methyl-1,2-dihydropyridin-2-one-5-yl, andquinoxalin-2-ol-7-yl.

Also provided is at least one chemical entity chosen from:

-   N-(3,4-dimethoxyphenyl)-6-(3-methylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(3-nitrophenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-{3-[(ethylamino)methyl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(pyridin-4-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(pyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-phenylimidazo[1,2-a]pyrazin-8-amine;-   3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzonitrile;-   N-(3,4-dimethoxyphenyl)-6-(4-fluorophenyl)imidazo[1,2-a]pyrazin-8-amine;-   4-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzene-1-sulfonamide;-   N-(3,4-dimethoxyphenyl)-6-{4-[(ethylamino)methyl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   6-(4-chlorophenyl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(3-chlorophenyl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(4-methanesulfonylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   4-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzonitrile;-   N-(3,4-dimethoxyphenyl)-6-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(3-methylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(3-fluorophenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(3,4-difluorophenyl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(4-chloro-3-methylphenyl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   3-{8-[(4-ethoxy-3-methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzene-1-sulfonamide;-   N-(4-ethoxy-3-methoxyphenyl)-6-(3-methanesulfonylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(4-fluoro-3-methylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(3-fluoro-4-methylphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(3-chloro-4-methylphenyl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(2-fluoropyridin-4-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(5-methylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(5-chloropyridin-3-yl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(pyrimidin-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   1-[4-{(4-{8-[(4-ethoxy-3-methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}phenyl)methyl]piperazin-1-yl}ethan-1-one;-   1-{4-[(3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}phenyl)methyl]piperazin-1-yl}ethan-1-one;-   N-(3,4-dimethoxyphenyl)-6-[3-(piperazin-1-ylmethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[4-(piperazin-1-ylmethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}phenyl)acetamide;-   6-(3-aminophenyl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}phenyl)acetamide;-   N-(3,4-dimethoxyphenyl)-6-(thiophen-3-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[4-(1H-imidazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(quinolin-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-(1,3-benzothiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzothiazol-6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinazolin-2-amine;-   N-(3,4-dimethoxyphenyl)-6-(thiophen-2-yl)imidazo[1,2-a]pyrazin-8-amine;-   3-amino-5-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1-methyl-1,2-dihydropyridin-2-one;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinolin-2-amine;-   6-(4-aminophenyl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-1,3-benzodiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[3-(1H-imidazol-5-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   7-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[4-(1H-imidazol-5-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzothiazol-6-yl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[3-(1,3-thiazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   5-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1,2-dihydropyridin-2-one;-   6-(1,3-benzothiazol-5-yl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-[4-(1,3-oxazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   (3-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)methanol;-   5-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}pyridin-2-amine;-   N-(3,4-dimethoxyphenyl)-6-[3-(1,3-oxazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol;-   N-(3,4-dimethoxyphenyl)-6-[4-(1,3-thiazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   (5-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)methanol;-   N-(3,4-dimethoxyphenyl)-6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-1,2,3-benzotriazol-6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-{1H-imidazo[4,5-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzoxazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzoxazol-6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   N-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(3,4-dimethoxyphenyl)-6-(1H-indol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinolin-3-amine;-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   5-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3-amine;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-1,3-benzodiazol-2-amine;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2-methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   7-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinolin-2-ol;-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   6-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3-amine;-   (4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)methanol;-   6-(2,3-dihydro-1H-indol-6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(3-amino-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6-amine;-   N-{4-[3-(dimethylamino)propoxy]-3-methoxyphenyl}-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   3-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)propan-1-ol;-   6-(1H-indazol-6-yl)-N-[4-methoxy-3-(pyrrolidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   5-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2,3-dihydro-1H-indol-2-one;-   7-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinoxalin-2-ol;-   7-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-amine;-   N-(2-fluoro-4-methoxyphenyl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-[3-methoxy-4-(pyrrolidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-amine;-   1-(4-{[6-(3-amino-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol;-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-amine;-   6-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2,3-dihydro-1H-indol-2-one;-   N-(3,4-dimethoxyphenyl)-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-7-amine;-   6-{8-[(4-ethoxy-3-methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3-amine;-   N-[6-(2-aminoquinazolin-6-yl)imidazo[1,2-a]pyrazin-8-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-amine;-   2-methyl-2-(4-{[6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-1-ol;-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-(4-ethoxy-3    methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(2,3-dihydro-1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6-amine;-   (2-methoxy-5-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)methanol;-   6-(1H-indazol-6-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   N-[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6-amine;-   7-{8-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]imidazo[1,2-a]pyrazin-6-yl}quinoxalin-2-ol;-   1-(4-{[6-(1,3-benzothiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol;-   6-(1H-1,2,3-benzotnazol-6-yl)-N-[3-methoxy-4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   5-(8-{[3-methoxy-4-(pyrrolidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine;-   2-(4-{[6-(2-aminoquinazolin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   6-(1H-indazol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   2-(4-{[6-(1,3-benzothiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   6-(8-{[4-(2-hydroxypropan-2-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-(1H-indazol-6-yl)-N-(3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   2-(4-{[6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   2-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)piperidin-4-ol;-   6-(1H-indazol-6-yl)-N-[4-(pyrrolidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol;-   2-(4-{[6-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   2-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   2-(4-{[6-(1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)azetidin-3-ol;-   2-(4-{[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol-   2-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   2-(4-{[6-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   2-(4-{[6-(2,3-dimethyl-2H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   2-(4-{[6-(3-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)quinazolin-2-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol;-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-[4-(2-methoxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(4-ethylpiperazin-1-yl)-3-methoxyphenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;    and-   N-[4-(4-ethylpiperazin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   and pharmaceutically acceptable salts thereof.

Also provided is at least one chemical entity chosen from:

-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine;-   5-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine;-   6-(8-{[4-(2-hydroxypropan-2-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-2-methylpropan-2-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-4-methylpiperidin-4-ol;-   2-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)(methyl)amino]ethan-1-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenol;-   2-(4-{[6-(2,3-dihydro-1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpyrrolidin-3-ol;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(2-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   (3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol;-   (3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol;-   (3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol;-   [4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2-yl]methanol;-   N-(4-ethoxy-3-methoxyphenyl)-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(5-fluoro-1H-indazol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   2-[1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-yl]propan-2-ol;-   (3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(3-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylpyrrolidin-3-ol;-   6-(1H-1,3-benzodiazol-6-yl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one;-   N-(4-ethoxy-3-methoxyphenyl)-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine;-   4-N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-2-methoxy-1-N-(2-methoxyethyl)-1-N-methylbenzene-1,4-diamine;-   4-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-ol;-   6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[4-(1-hydroxy-2-methylpropan-2-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   1-(4-{[6-(1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-2-ol;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine;-   2-(4-{[6-(1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol;-   2-methyl-2-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-1-ol;-   2-methyl-2-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}propan-1-ol;-   2,2,2-trifluoro-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol;-   2-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   6-(8-{[4-(4-hydroxy-4-methylpiperidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   4-methyl-1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-4-ol;-   1-(4-{[6-(1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   6-(1H-indazol-6-yl)-N-[4-(1-methoxy-2-methylpropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   4-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-ol;-   6-(1H-1,3-benzodiazol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1,1,1-trifluoro-2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-2-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)cyclobutan-1-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylpiperidin-3-ol;-   4-N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1-N-(2-methoxyethyl)-1-N-methylbenzene-1,4-diamine;-   6-{8-[(4-ethoxy-3-methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazole-3-carboxamide;-   2-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(methyl)amino]ethan-1-ol;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(morpholin-4-yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol;-   6-(1H-indol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   2-(4-{[6-(1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   6-(8-{[4-(1-hydroxy-2-methylpropan-2-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   2-(4-{[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   6-{8-[(4-ethoxy-3-methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2,3-dihydro-1H-indol-2-one;-   2-(4-{[6-(3-amino-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   5-{8-[(4-ethoxy-3-methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3-amine;    and-   2-(4-{[6-(3-amino-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   and pharmaceutically acceptable salts thereof.

Also provided is at least one chemical entity chosen from:

-   (3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylpyrrolidin-3-ol;-   (3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylpyrrolidin-3-ol;-   7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2-dihydroquinoxalin-2-one;-   N,N-dimethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazole-3-carboxamide;-   5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-2-ol;-   N-methyl-2-(4-{[6-(2-oxo-2,3-dihydro-1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)acetamide;-   N-[3-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]methanesulfonamide;-   N-[4-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]methanesulfonamide;-   [(2S)-4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2-yl]methanol;-   [(2R)-4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2-yl]methanol;-   6-(8-{[4-(2-hydroxy-2-methylpropyl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-4-methylpiperidin-4-ol;-   N-(2-hydroxyethyl)-N-methyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indole-3-carboxamide;-   6′-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1′,2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one;-   3-methyl-1-(4-{[6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenol;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(6-methoxypyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-1,2,3-benzotriazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N,N-dimethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indole-3-carboxamide;-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(5-methoxypyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine;-   7-[8-({4-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-methyl-N-(oxan-4-yl)benzamide;-   6-(3-ethyl-1H-indazol-6-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   2,2-difluoro-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylazetidin-3-ol;-   6-(1H-indol-2-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol;-   1-(4-{[6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol;-   6-(1H-indazol-6-yl)-N-[4-(2H-1,2,3,4-tetrazol-5-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   7-(8-{[4-(3-hydroxy-3-methylazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one;-   6-(1H-indazol-6-yl)-N-[3-methoxy-4-(2-methoxyethoxy)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(2-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   4-{[6-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-propylbenzamide;-   6-(8-{[3-ethoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one;-   6-(1H-indol-3-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzothiazol-5-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   (3E)-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3-(1,3-thiazol-4-ylmethylidene)-2,3-dihydro-1H-indol-2-one;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-(oxan-4-yl)benzamide;-   6-(2-methyl-1,3-benzothiazol-5-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-[4-(2-methoxyethoxy)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)quinazolin-2-amine;-   6-(8-{[4-(4-hydroxy-4-methylpiperidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one;-   6-(1H-indazol-6-yl)-N-{4-[(2S)-oxolan-2-ylmethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   6-(3-ethyl-1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-(2H-1,3-benzodioxol-5-yl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   1-(2-ethoxy-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   6-[8-({4-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,3-dimethyl-2,3-dihydro-1H-indol-2-one;-   6-(8-{[4-(3-hydroxy-3-methylazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3-dihydro-1H-indol-2-one;-   6-(2H-1,3-benzodioxol-5-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indol-6-yl)-N-{14-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-[4-(pyridin-4-yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   (3E)-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3-(pyridin-4-ylmethylidene)-2,3-dihydro-1H-indol-2-one;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-(oxetan-3-yl)benzamide;-   6-{3-[(diethylamino)methyl]-1H-indazol-6-yl}-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]-3-methylazetidin-3-ol;-   [6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-yl]methanol;-   N-[4-(morpholin-4-yl)phenyl]-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(4-fluoro-1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(morpholin-4-yl)phenyl]-6-{1H,2H,3H-pyrido[2,3-b][1,4]oxazin-6-yl}imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(morpholin-4-yl)phenyl]-6-(1,3-thiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine;-   {4-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]morpholin-2-yl}methanol;-   1-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]piperidin-4-ol;-   N-ethyl-N-(2-hydroxyethyl)-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}benzamide;-   2-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-N-methylacetamide;-   7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2-dihydroquinolin-2-one;-   6-(2-ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]-4-methylpiperidin-4-ol;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxybenzoic    acid;-   6-(1H-indazol-6-yl)-N-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   1-[(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]azetidin-3-ol;-   3,3-dimethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   6-(1H-indazol-6-yl)-N-[4-(1-methylpiperidin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   2-(4-{[6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   2-[ethyl(4-{[6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)amino]ethan-1-ol;-   6-(1H-indazol-7-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-[8-({4-[ethyl(2-hydroxyethyl)amino]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,3-dimethyl-2,3-dihydro-1H-indol-2-one;-   N-{14-[2-(dimethylamino)ethoxy]phenyl}-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-{4-[2-(dimethylamino)ethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol;-   2-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2H-indazol-2-yl]ethan-1-ol;-   3-(2-ethoxy-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2,2-dimethylpropan-1-ol;-   3-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2,2-dimethylpropan-1-ol;-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-N-methylacetamide;-   2-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-N-methylacetamide;-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-N-methylacetamide;-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)acetic    acid;-   N-(2-hydroxyethyl)-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxybenzamide;-   6-(1,3-benzothiazol-5-yl)-N-[3-ethoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-{3-methoxy-4-[(2R)-oxolan-2-ylmethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-{4-[(2R)-oxolan-2-ylmethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[4-(3-hydroxy-3-methylazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-(1H-indazol-6-yl)-N-[4-(morpholin-4-ylcarbonyl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-(2-hydroxyethyl)-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-methylbenzamide;-   2-[(2-ethoxy-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(methyl)amino]ethan-1-ol;-   N-[2-(dimethylamino)ethyl]-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-methylbenzamide;-   1-(2-fluoro-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol;-   (3S)-1-(4-{[6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol;-   2-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-1-yl]ethan-1-ol;-   6-(8-{[4-(3-hydroxy-3-methylazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-amine;-   N-[3-ethoxy-4-(morpholin-4-yl)phenyl]-6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   1-(2-ethoxy-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2-methylpropan-2-ol;-   (3R)-3-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-1,4-dimethylpiperazin-2-one;-   N-(2-hydroxyethyl)-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}benzamide;-   6-(8-{[3-ethoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-[3-ethoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-N,N-dimethylpiperidin-4-amine;-   1-(4-{[6-(1,3-benzothiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2-methylpropan-2-ol;-   (3R)-1-(2-ethoxy-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol;-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)ethan-1-ol;-   1-(2-ethoxy-4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylazetidin-3-ol;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}benzoic    acid;-   N-[3-ethoxy-4-(4-ethylpiperazin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-propylbenzamide;-   1-(4-{[6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   3-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-2,2-dimethylpropan-1-ol;-   6-(4-fluoro-1H-indazol-6-yl)-N-[4-(1,4-oxazepan-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[3-ethoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2-methylpropan-2-ol;-   2-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)propan-2-ol;-   6-(8-{[4-(2-hydroxy-2-methylpropoxy)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   N-[3-fluoro-4-(morpholin-4-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1,3-benzothiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2,3,4-tetrahydroisoquinolin-6-amine;-   N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-2,3-dihydro-1H-indol-6-amine;-   1-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one;-   1-[7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one;-   N-[4-(morpholin-4-yl)phenyl]-6-{1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl}imidazo[1,2-a]pyrazin-8-amine;-   6-(1-methyl-1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(morpholin-4-yl)phenyl]-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one;-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;-   5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   1-methyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   6-(8-{[4-(2-hydroxy-2-methylpropoxy)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   2-[4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperazin-1-yl]ethan-1-ol;-   6-(1H-indazol-4-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[3-ethoxy-4-(morpholin-4-yl)phenyl]-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-6-yl)-N-[4-(piperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(morpholin-4-yl)phenyl]-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)imidazo[1,2-a]pyrazin-8-amine;-   N-[4-(morpholin-4-yl)phenyl]-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one;-   6-{1-methyl-1H-pyrrolo[3,2-b]pyridin-6-yl}-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1-methyl-1H-indol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzoxazol-5-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-[8-({4-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   (3R)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;-   6-[8-({4-[(3S)-3-hydroxy-3-methylpiperidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-[8-({4-[(3R)-3-hydroxy-3-methylpiperidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-[8-({4-[(3S)-3-hydroxy-3-methylpiperidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one;-   6-[8-({4-[(3R)-3-hydroxy-3-methylpiperidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one;-   (3R)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;-   (3S)-3-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol;-   (3R)-3-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol;-   (3R)-3-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol;-   6-(8-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-(1,3-benzothiazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzothiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1,3-benzoxazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-indazol-5-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;-   (3S)-3-methyl-1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol;-   N-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine;-   2-[ethyl(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)amino]ethan-1-ol;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one;-   6-(1-methyl-1H-indazol-5-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2-methylpropan-2-ol;-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperazin-2-one;-   6-(1-methyl-1H-1,3-benzodiazol-6-yl)-N-[4-(morpholin-4-ylmethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(1H-1,3-benzodiazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   6-(1H-indazol-6-yl)-N-[4-(1,4-oxazepan-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   (3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;-   (3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpiperidin-3-ol;-   (3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpyrrolidin-3-ol;-   (3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylpyrrolidin-3-ol;-   6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-(8-{[4-(3-hydroxyazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   6-(8-{[4-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   6-(1-methyl-1H-1,3-benzodiazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   1-(4-{[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol;-   1-(4-{[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   1-(4-{[6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol;-   6-(1-methyl-1H-1,3-benzodiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one;-   6-(8-{[4-(3-hydroxyazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;-   5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1,3-benzoxazol-2-one;-   4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N,N-dimethylbenzene-1-sulfonamide;-   6-(1H-indazol-6-yl)-N-{4-[4-(propan-2-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine;-   2-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol;-   4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)thiomorpholine-1,1-dione;-   6-(1H-indazol-6-yl)-N-[4-(2-methylmorpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine;-   and pharmaceutically acceptable salts thereof.

Also provided is at least one chemical entity chosen from:

-   N-(4-ethoxy-3-methoxyphenyl)-6-(1H-indazol-6-yl)-5-methylimidazo[1,2-a]pyrazin-8-amine,-   1-(4-{[6-(1H-indazol-6-yl)-5-methylimidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol,-   N,6-bis[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   2-[1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-yl]ethan-1-ol,-   6-[3-(morpholin-4-yl)phenyl]-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   2-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indol-3-yl]ethan-1-ol,-   [1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-yl]methanol,-   1-[4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperazin-1-yl]ethan-1-one,-   6-(5-chloro-8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   5-chloro-N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine,-   N-methyl-5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3-amine,-   6-(1H-indazol-6-yl)-N-(4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}phenyl)imidazo[1,2-a]pyrazin-8-amine,-   6-(2-methyl-1H-1,3-benzodiazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   5-(8-{[4-(3-hydroxy-3-methylazetidin-1-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   N-{4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   N-[6-(1H-indazol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-yl]-5-(morpholin-4-yl)pyridin-2-amine,-   [(2R)-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methanol,-   6-(1H-indazol-6-yl)-N-[3-(methoxymethyl)-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4-tetrahydroquinoxalin-2-one,-   5-chloro-6-(1H-indazol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-amine,-   [(2S)-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methanol,-   7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one,-   5-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-(morpholin-4-yl)benzonitrile,-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-3-methyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-3-methyl-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine,-   5-methyl-6-(2-methyl-1H-1,3-benzodiazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   5-ethyl-6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   1-methyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   6-(3-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   1,3-dimethyl-5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   2-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-yl]propan-2-ol,-   6-(4-fluoro-1H-indol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   5-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-(morpholin-4-yl)benzamide,-   5-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}-5-methylimidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   5-(5-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   [2-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]methanol,-   1-methyl-5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   2-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethan-1-ol,-   (3R)-2,2-dimethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-3-ol,-   6-(1H-indazol-6-yl)-N-{3-methoxy-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine,-   2-(4-{2-methoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperazin-1-yl)ethan-1-ol,-   1-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-yl]ethan-1-ol,-   2-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-yl]ethan-1-ol,-   2-{[5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3-yl]amino}ethan-1-ol,-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-5-methyl-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine,-   (3S)-2,2-dimethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-3-ol,-   N-{4-[4-(3-fluoropropyl)piperazin-1-yl]phenyl}-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-[4-(oxan-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-[4-(4-fluoropiperidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-[3-(2-methoxyethoxy)-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-[4-(4H-1,2,4-triazol-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-[4-(3,3-difluoropyrrolidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]-5-methylimidazo[1,2-a]pyrazin-8-amine,-   2,2-dimethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-3-one-   6-(1H-indazol-6-yl)-N-[3-methoxy-4-(methoxymethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-2-methylpropan-2-ol,-   [(2S)-4-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2-yl]methanol,-   N-[4-(4,4-difluoropiperidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-{3-methoxy-4-[(2-methoxyethoxy)methyl]phenyl}imidazo[1,2-a]pyrazin-8-amine,-   2-[2-(morpholin-4-yl)-5-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenoxy]ethan-1-ol,-   6-(1H-indazol-6-yl)-N-[4-(3-methoxy-3-methylazetidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3-amine,-   N-[4-(morpholin-4-yl)phenyl]-6-(1,5-naphthyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine,-   3-ethyl-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol,-   N-[4-(3-fluoro-3-methylazetidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   N-[4-(3,3-difluoropiperidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   [(2R)-4-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2-yl]methanol,-   N-[4-(3,3-difluoroazetidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol,-   (3R)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol,-   N-[4-(3-fluoroazetidin-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]-5-methylimidazo[1,2-a]pyrazin-8-amine,-   N,N-diethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine,-   (3S)-3-hydroxy-3-methyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   N-[4-(morpholin-4-yl)phenyl]-6-(quinoxalin-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   (3R)-3-hydroxy-3-methyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   6-(1H-indazol-6-yl)-N-{3-methoxy-4-[(2S)-oxolan-2-ylmethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine,-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}-5-methylimidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}-5-methylimidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one,-   (3S)-1-{4-[(6-{1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}pyrrolidin-3-ol,-   (3R)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol,-   6-[8-({4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one,-   N-[4-(1H-imidazol-1-yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-[4-(1H-pyrazol-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   6-[8-({4-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one,-   6-[8-({4-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one,-   1-(4-{[6-(1H-indazol-6-yl)-5-methylimidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol,-   (3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol,-   (3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol,-   2-[3-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]propan-2-ol,-   6-(5-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one,-   N-ethyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine,-   2-[4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)piperazin-1-yl]ethan-1-ol,-   6-[8-({4-[(3S)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one,-   2-(5-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-(morpholin-4-yl)phenoxy)ethan-1-ol,-   (3S)-1-(4-{[6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol,-   6-(5-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   2-methyl-1-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2H-indazol-2-yl]propan-2-ol,-   2-methyl-1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}propan-2-ol,-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol,-   2-[4-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]propan-2-ol,-   6-(1H-indazol-6-yl)-3-methyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-(2-hydroxyethyl)-N-methyl-6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazole-3-carboxamide,-   5-chloro-6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-(2-hydroxyethyl)-2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)acetamide,-   1-(4-{[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylazetidin-3-ol,-   1-(4-{[6-(1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol,-   2-methyl-1-[6-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-1-yl]propan-2-ol,-   6-(1H-indazol-6-yl)-N-[3-methoxy-4-(oxan-4-yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-[3-methoxy-4-(morpholin-4-yl)phenyl]-6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine,-   6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-5-methyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   2-methyl-2-(4-{[6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-1-ol,-   1-(3-hydroxy-3-methylazetidin-1-yl)-2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)ethan-1-one,-   1-[6-(1,3-benzothiazol-5-yl)imidazo[1,2-a]pyridin-8-yl]-3-methylurea,-   1-[6-(1,3-benzothiazol-5-yl)imidazo[1,2-a]pyridin-8-yl]-3-ethylurea,-   1-{2-ethoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}-3-methylazetidin-3-ol,-   1-{2-methoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}-3-methylazetidin-3-ol,-   6-(1H-indol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-[4-(oxan-4-yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one,-   6-(1H-indazol-6-yl)-N-[3-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-N,N-dimethylacetamide,-   3-methyl-1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}azetidin-3-ol,-   1-methyl-5-(5-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   1-ethyl-5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one,6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-5-ethyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   6-(5-ethyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   (3S)-1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-3-ol,-   (3S)-1-{2-methoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-3-ol,-   2-(1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-4-yl)ethan-1-ol,-   2-[6-(5-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-yl]ethan-1-ol,-   1-[4-({6-[3-(2-hydroxyethyl)-1H-indazol-6-yl]imidazo[1,2-a]pyrazin-8-yl}amino)phenyl]-3-methylazetidin-3-ol,-   6-[8-({4-[(2R)-2-(hydroxymethyl)morpholin-4-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one,-   6-[8-({4-[(2S)-2-(hydroxymethyl)morpholin-4-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one,-   5-(5-ethyl-8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   5-ethyl-N-[4-(morpholin-4-yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine,-   (3R)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)piperidin-3-ol,-   N-[4-(morpholin-4-yl)phenyl]-6-(1,2,3,5-tetrahydro-4,1-benzoxazepin-8-yl)imidazo[1,2-a]pyrazin-8-amine,-   [(3R)-4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-3-yl]methanol,-   [(3S)-4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-3-yl]methanol,-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)piperidin-3-ol,-   (1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-4-yl)methanol,-   [(2R)-4-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)morpholin-2-yl]methanol,-   [(2S)-4-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)morpholin-2-yl]methanol,-   4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)cyclohexan-1-ol,-   6-(1H-indazol-6-yl)-N-(4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}phenyl)imidazo[1,2-a]pyrazin-8-amine,-   2-[6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-yl]ethan-1-ol,-   [(2S)-4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)morpholin-2-yl]methanol,-   [(2R)-4-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)morpholin-2-yl]methanol,-   2-[1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-yl]ethan-1-ol,-   6-(1H-indazol-6-yl)-N-(4-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}phenyl)imidazo[1,2-a]pyrazin-8-amine,-   [(3R)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-yl]methanol,-   [(3S)-1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-yl]methanol,-   5-chloro-6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   2-[6-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indol-3-yl]ethan-1-ol,-   (3R)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol,-   [1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-yl]methanol,-   (3S)-1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol,-   [(2S)-4-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}morpholin-2-yl]methanol,-   [(2R)-4-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}morpholin-2-yl]methanol,-   2-[1-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-yl]ethan-1-ol,-   6-(1H-indazol-6-yl)-N-[4-(oxan-4-ylmethoxy)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   N-[5-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3-yl]acetamide,-   6-(8-{[3-methoxy-4-(oxan-4-yloxy)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-indol-2-one,-   6-(1H-indol-6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]-5-methylimidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indol-6-yl)-5-methyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   1-(4-{[6-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-5-methylimidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol,-   N-[3-methoxy-4-(oxan-4-yloxy)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine,-   6-(1H-indazol-6-yl)-N-(4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}phenyl)imidazo[1,2-a]pyrazin-8-amine,    and    6-(1H-indazol-6-yl)-N-[3-methoxy-4-(oxan-4-ylmethoxy)phenyl]imidazo[1,2-a]pyrazin-8-amine,-   1-(4-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperazin-1-yl)ethan-1-one,-   5-(8-{[3-(2-hydroxyethoxy)-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   [(3S)-1-{2-methoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}pyrrolidin-3-yl]methanol,-   5-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-N-methylpyridin-3-amine,-   5-(8-{[3-methoxy-4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   5-[8-({4-[(3R)-3-hydroxypiperidin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-1-methyl-2,3-dihydro-1H-1,3-benzodiazol-2-one,-   (3R)-1-{2-methoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-3-ol,-   4-methyl-7-(8-{[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4-tetrahydroquinoxalin-2-one,-   [(2R)-4-{2-methoxy-4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}morpholin-2-yl]methanol,    and-   (3R)-1-{4-[(6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-3-ol,-   and pharmaceutically acceptable salts thereof.

In all of the foregoing examples, the chemical entities can beadministered alone, as mixtures, or in combination with other activeagents.

Methods for obtaining the novel compounds described herein will beapparent to those of ordinary skill in the art, suitable proceduresbeing described, for example, in the reaction schemes and examplesbelow, and in the references cited herein.

Referring to Reaction Scheme 1, Step 1, an excess (such as about 3.5equivalents) of a compound of Formula 100, where L is a leaving groupsuch as bromide is combined with an aqueous solution of acid (such as48% aqueous hydrogen bromide), and the mixture is stirred at reflux forabout 2 h. The mixture is cooled to about 40° C. and base (such as solidsodium bicarbonate) is added. The reaction mixture is filtered and acompound of Formula 101, where L is a leaving group such as bromide isadded, and the reaction mixture is stirred at reflux for about 16 h. Theproduct, a compound of Formula 102, is isolated and optionally purified.

Referring to Reaction Scheme 1, Step 2, a solution of a compound ofFormula 103 in a polar solvent such as N,N-dimethylformamide is added anexcess (such as about 1.3 equivalents) to a compound of Formula 102,where L is a leaving group such as bromide. An organic base such asN,N-diisopropylethylamine is added and the mixture is stirred at about120° C. for about 13 h. The product, a compound of Formula 104, isisolated and optionally purified.

Referring to the Reaction Scheme 1, Step 3, a mixture of a compound ofFormula 105, where L is a leaving group such as bromide is combined withan excess of bis(pinacolato)diboron (such as about 1.1 equivalents) andan excess of an inorganic base (such as about 3.0 equivalents), such aspotassium acetate in a polar solvent such as dimethyl sulfoxide. Thereaction mixture is sparged with nitrogen and stirred for about 5 min.The reaction mixture is treated with about 0.2 equivalent of dichloro1,1-bis(diphenylphosphino)ferrocene palladium(II) dichloromethane andstirred at about 80° C. for about 3 h. The product, a compound ofFormula 106, is isolated and optionally purified.

Referring to Reaction Scheme 1, Step 4, an excess of compound of Formula106 (such as about 1.1 equivalents) and a compound of Formula 104 whereL is a leaving group such as bromide are taken up in an aqueous solutionof base (such as 1M sodium carbonate) and an inert solvent such as1,4-dioxane. The reaction mixture is sparged with nitrogen and stirredfor about 5 min. The resulting mixture is treated with about 0.1equivalent of tetrakis(triphenylphosphine)palladium(0) and reacted undermicrowave irradiation at about 135° C. for about 30 min. The resultingproduct, a compound of Formula 107, is isolated and optionally purified.

Accordingly, provided is a method of treating a patient, for example, amammal, such as a human, having a disease responsive to inhibition ofSyk activity, comprising administrating to the patient having such adisease, an effective amount of at least one chemical entity describedherein.

In some embodiments, the chemical entities described herein may alsoinhibit other kinases, such that disease, disease symptoms, andconditions associated with these kinases is also treated.

Methods of treatment also include inhibiting Syk activity and/orinhibiting B-cell activity, by inhibiting ATP binding or hydrolysis bySyk or by some other mechanism, in vivo, in a patient suffering from adisease responsive to inhibition of Syk activity, by administering aneffective concentration of at least one chemical entity chosen describedherein. An example of an effective concentration would be thatconcentration sufficient to inhibit Syk activity in vitro. An effectiveconcentration may be ascertained experimentally, for example by assayingblood concentration of the chemical entity, or theoretically, bycalculating bioavailability.

In some embodiments, the condition responsive to inhibition of Sykactivity and/or B-cell activity is cancer, an allergic disorder and/oran autoimmune and/or inflammatory disease, and/or an acute inflammatoryreaction.

Also provided is a method of treating a patient having cancer, anallergic disorder and/or an autoimmune and/or inflammatory disease,and/or an acute inflammatory reaction, by administering an effectiveamount of at least one chemical entity described herein.

In some embodiments, the conditions and diseases that can be affectedusing chemical entities described herein, include, but are not limitedto: allergic disorders, including but not limited to eczema, allergicrhinitis or coryza, hay fever, bronchial asthma, urticaria (hives) andfood allergies, and other atopic conditions; autoimmune and/orinflammatory diseases, including but not limited to psoriasis, Crohn'sdisease, irritable bowel syndrome, Sjogren's disease, tissue graftrejection, and hyperacute rejection of transplanted organs, asthma,systemic lupus erythematosus (and associated glomerulonephritis),dermatomyositis, multiple sclerosis, scleroderma, vasculitis(ANCA-associated and other vasculitides), autoimmune hemolytic andthrombocytopenic states, Goodpasture's syndrome (and associatedglomerulonephritis and pulmonary hemorrhage), atherosclerosis,rheumatoid arthritis, chronic Idiopathic thrombocytopenic purpura (ITP),Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes,septic shock, myasthenia gravis, and the like; acute inflammatoryreactions, including but not limited to skin sunburn, inflammatorypelvic disease, inflammatory bowel disease, urethritis, uvitis,sinusitis, pneumonitis, encephalitis, meningitis, myocarditis,nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis,dermatitis, gingivitis, appendicitis, pancreatitis, and cholocystitis;polycystic kidney disease, and cancer, including but not limited to,B-cell lymphoma, lymphoma (including Hodgkin's and non-Hodgkinslymphoma), hairy cell leukemia, multiple myeloma, chronic and acutemyelogenous leukemia, and chronic and acute lymphocytic leukemia.

Syk is a known inhibitor of apoptosis in lymphoma B-cells. Defectiveapoptosis contributes to the pathogenesis and drug resistance of humanleukemias and lymphomas. Thus, further provided is a method of promotingor inducing apoptosis in cells expressing Syk comprising contacting thecell with at least one chemical entity described herein.

Also provided are methods of treatment in which at least one chemicalentity described herein is the only active agent given to a patient andalso includes methods of treatment in which at least one chemical entitydescribed herein is given to a patient in combination with one or moreadditional active agents.

Thus in some embodiments, a method of treating cancer, an allergicdisorder and/or an autoimmune and/or inflammatory disease, and/or anacute inflammatory reaction comprises administering to a patient in needthereof an effective amount of at least one chemical entity describedherein, together with a second active agent, which can be useful fortreating a cancer, an allergic disorder and/or an autoimmune and/orinflammatory disease, and/or an acute inflammatory reaction. For examplethe second agent may be an anti-inflammatory agent. Treatment with thesecond active agent may be prior to, concomitant with, or followingtreatment with at least one chemical entity described herein. In someembodiments, at least one chemical entity described herein is combinedwith another active agent in a single dosage form. Suitable antitumortherapeutics that may be used in combination with at least one chemicalentity described herein include, but are not limited to,chemotherapeutic agents, for example mitomycin C, carboplatin, taxol,cisplatin, paclitaxel, etoposide, doxorubicin, or a combinationcomprising at least one of the foregoing chemotherapeutic agents.Radiotherapeutic antitumor agents may also be used, alone or incombination with chemotherapeutic agents.

Chemical entities described herein can be useful as chemosensitizingagents, and, thus, can be useful in combination with otherchemotherapeutic drugs, in particular, drugs that induce apoptosis.

A method for increasing sensitivity of cancer cells to chemotherapy,comprising administering to a patient undergoing chemotherapy achemotherapeutic agent together with at least one chemical entitydescribed herein in an amount sufficient to increase the sensitivity ofcancer cells to the chemotherapeutic agent is also provided herein.

Examples of other chemotherapeutic drugs that can be used in combinationwith chemical entities described herein include topoisomerase Iinhibitors (camptothesin or topotecan), topoisomerase II inhibitors(e.g. daunomycin and etoposide), alkylating agents (e.g.cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g.taxol and vinblastine), and biological agents (e.g. antibodies such asanti CD20 antibody, IDEC 8, immunotoxins, and cytokines).

In some embodiments, the chemical entities described herein are used incombination with Rituxan® (Rituximab) or other agents that work byselectively depleting CD20+ B-cells.

Included herein are methods of treatment in which at least one chemicalentity described herein is administered in combination with ananti-inflammatory agent. Anti-inflammatory agents include but are notlimited to NSAIDs, non-specific and COX-2 specific cyclooxygenase enzymeinhibitors, gold compounds, corticosteroids, methotrexate, tumornecrosis factor receptor (TNF) receptors antagonists, immunosuppressantsand methotrexate.

Examples of NSAIDs include, but are not limited to ibuprofen,flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations ofdiclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal,piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen,sodium nabumetone, sulfasalazine, tolmetin sodium, andhydroxychloroquine. Examples of NSAIDs also include COX-2 specificinhibitors (i.e., a compound that inhibits COX-2 with an IC₅₀ that is atleast 50-fold lower than the IC₅₀ for COX-1) such as celecoxib,valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.

In a further embodiment, the anti-inflammatory agent is a salicylate.Salicylates include but are not limited to acetylsalicylic acid oraspirin, sodium salicylate, and choline and magnesium salicylates.

The anti-inflammatory agent may also be a corticosteroid. For example,the corticosteroid may be chosen from cortisone, dexamethasone,methylprednisolone, prednisolone, prednisolone sodium phosphate, andprednisone.

In some embodiments, the anti-inflammatory therapeutic agent is a goldcompound such as gold sodium thiomalate or auranofin.

In some embodiments, the anti-inflammatory agent is a metabolicinhibitor such as a dihydrofolate reductase inhibitor, such asmethotrexate or a dihydroorotate dehydrogenase inhibitor, such asleflunomide.

In some embodiments, combinations in which at least oneanti-inflammatory compound is an anti-C5 monoclonal antibody (such aseculizumab or pexelizumab), a TNF antagonist, such as entanercept, orinfliximab, which is an anti-TNF alpha monoclonal antibody are used.

In some embodiments, combinations in which at least one active agent isan immunosuppressant compound such as methotrexate, leflunomide,cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil areused.

Dosage levels of the order, for example, of from 0.1 mg to 140 mg perkilogram of body weight per day can be useful in the treatment of theabove-indicated conditions (0.5 mg to 7 g per patient per day). Theamount of active ingredient that may be combined with the vehicle toproduce a single dosage form will vary depending upon the host treatedand the particular mode of administration. Dosage unit forms willgenerally contain from 1 mg to 500 mg of an active ingredient.

Frequency of dosage may also vary depending on the compound used and theparticular disease treated. In some embodiments, for example, for thetreatment of an allergic disorder and/or autoimmune and/or inflammatorydisease, a dosage regimen of 4 times daily or less is used. In someembodiments, a dosage regimen of 1 or 2 times daily is used. It will beunderstood, however, that the specific dose level for any particularpatient will depend upon a variety of factors including the activity ofthe specific compound employed, the age, body weight, general health,sex, diet, time of administration, route of administration, and rate ofexcretion, drug combination and the severity of the particular diseasein the patient undergoing therapy.

A labeled form of a chemical entity described herein can be used as adiagnostic for identifying and/or obtaining compounds that have thefunction of modulating an activity of a kinase as described herein. Thechemical entities described herein may additionally be used forvalidating, optimizing, and standardizing bioassays.

By “labeled” herein is meant that the compound is either directly orindirectly labeled with a label which provides a detectable signal,e.g., radioisotope, fluorescent tag, enzyme, antibodies, particles suchas magnetic particles, chemiluminescent tag, or specific bindingmolecules, etc. Specific binding molecules include pairs, such as biotinand streptavidin, digoxin and antidigoxin etc. For the specific bindingmembers, the complementary member would normally be labeled with amolecule which provides for detection, in accordance with knownprocedures, as outlined above. The label can directly or indirectlyprovide a detectable signal.

EXAMPLES

The invention is further illustrated by the following non-limitingexamples.

In the examples below, the following abbreviations have the followingmeanings. If an abbreviation is not defined, it has its generallyaccepted meaning.

DME=dimethyl ether

DMEM=Dulbecco's modified Eagle's medium

DMF=N,N-dimethylformamide

DMSO=dimethylsulfoxide

Et₂O=diethylether

g=gram

h=hour

mg=milligram

min=minutes

mL=milliliter

mmol=millimoles

mM=millimolar

ng=nanogram

nm=nanometer

nM=nanomolar

PBS=phosphate buffered saline

μL=microliter

μM=micromolar

Example I Preparation of6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxy-phenyl)imidazo[1,2-a]pyrazin-8-amine(4)

Preparation of 6,8-dibromoimidazo[1,2-a]pyrazine (1)

A 1-L four-neck round bottom flask equipped with a temperature probe,mechanical stirrer and reflux condenser was charged with2-bromo-1,1-diethoxyethane (68.1 g, 346 mmol) and 48% aqueous hydrogenbromide (11.3 mL, 99.2 mmol), and the reaction mixture was stirred atreflux for 2 h. The resulting mixture was allowed to cool to 40° C. andsolid sodium bicarbonate (8.50 g, 101 mmol) was added in small portionsuntil gas evolution was observed to cease. Caution: initial addition ofsodium bicarbonate to the warm solution resulted in vigorous gasevolution (foaming). The resulting suspension was filtered into a 1-Lfour-neck round bottomed flask and the filter cake was washed withethanol (200 mL). The flask was equipped with a temperature probe,mechanical stirrer and reflux condenser. 3,5-Dibromopyrazin-2-amine(50.0 g, 198 mmol) was added and the reaction mixture was heated atreflux, with vigorous stirring, for 16 h. After this time, thesuspension was cooled to 0° C. and filtered. The filter cake was washedwith cold ethanol (50 mL), dried under vacuum and added to a 1-Lthree-neck round bottomed flask equipped with a mechanical stirrer.Water (200 mL) was added and the vigorously stirred suspension wastreated portion-wise with solid potassium carbonate (27.4 g, 198 mmol).Caution: gas evolution upon the addition of potassium carbonateobserved. After stirring for 30 min, the resulting precipitate wasisolated by filtration and the filter cake washed with water (100 mL)followed by ethanol (50 mL). The filter cake was dried at 50° C. to aconstant weight, under vacuum to provide6,8-dibromoimidazo[1,2-a]pyrazine (1) (52.0 g, 94%) as a light yellowsolid: ¹H NMR (300 MHz, DMSO-d₆) δ 9.02 (s, 1H), 8.23 (s, 1H), 7.90 (s,1H).

Preparation of6-bromo-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine (2)

A mixture of 3,4-dimethoxyaniline (18.0 g, 118 mmol),6,8-dibromoimidazo[1,2-a]pyrazine (25.0 g, 90.4 mmol), andN,N-diisopropylethylamine (11.7 g, 90.4 mmol) in DMF (500 mL) wasstirred at 120° C. overnight. After this time, the reaction was cooledto room temperature and concentrated to approximately 100 mL underreduced pressure. The dark brown reaction mixture was poured intoice-cold water (300 mL) and stirred for 10 min. The resulting brownprecipitate was filtered and the filter cake washed with water (100 mL).The filter cake was dried under vacuum and recrystallization frommethanol (˜800 mL) to afford6-bromo-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine (2)(23.3 g, 74%) as a light brown needle-shaped solid: ¹H NMR (300 MHz,DMSO-d₆) 9.81 (s, 1H), 8.22 (s, 1H), 7.93 (s, 1H), 7.75 (d, J=2.4 Hz,1H), 7.62 (s, 1H), 7.53 (dd, J=8.7, 2.4, 1H), 6.94 (d, J=8.7 Hz, 1H),3.77 (s, 3H), 3.75 (s, 3H); ESI MS m/z 349.2 [M+H]⁺; HPLC, 6.92min, >99% (AUC).

Preparation of5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (3)

A mixture of 5-bromobenzo[d]thiazole (428 mg, 2.00 mmol),bis(pinacolato)diboron (558 mg, 2.20 mmol) and potassium acetate (588mg, 6.00 mmol) in dimethyl sulfoxide (7 mL) was sparged with nitrogenwhile stirring for 5 min. Dichloro 1,1-bis(diphenylphosphino)ferrocenepalladium(II) dichloromethane (293 mg, 0.40 mmol) was then added and thereaction stirred at 85° C. for 3 h. After this time, the mixture wasfiltered through a pad of Celite and the filter cake was washed withethyl acetate (75 mL) then water (20 mL). The filtrate was diluted withethyl acetate (100 mL) and washed with water (2×75 mL), then brine (75mL). The organic phase was dried over anhydrous sodium sulfate, filteredand concentrated under reduced pressure. The resulting residue waspurified by chromatography (silica, gradient 0% to 50% ethyl acetate inmethylene chloride) to afford5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (3) (200mg, 38%) as a light brown solid: ¹H NMR (300 MHz, DMSO-d₆) δ 9.41 (s,1H), 8.32 (s, 1H), 8.18 (d, 1H, J=8.0 Hz), 7.72 (d, 1H, J=8.0 Hz), 1.33(s, 12H); ESI MS m/z 262.1 [M+H]⁺.

Preparation of6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine(4)

A mixture of6-bromo-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine (2) (209mg, 0.601 mmol), and5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (3) (180mg, 0.689 mmol) in 1 M aqueous sodium carbonate (0.76 mL) and1,4-dioxane (2.4 mL) was sparged with nitrogen while stirring for 5 min.Tetrakis(triphenyl-phosphine) palladium(0) (69 mg, 0.06 mmol) was thenadded and the resulting mixture reacted under microwave irradiation at135° C. for 30 min. After this time, the reaction was cooled to ambienttemperature, diluted with 1:9 methanol/ethyl acetate (75 mL), and washedwith water (50 mL) then brine (50 mL). The organic phase was dried overanhydrous sodium sulfate, filtered and concentrated under reducedpressure. The resulting residue was purified by chromatography (silica,gradient 0% to 10% methanol in methylene chloride) to afford6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine(4) (169 mg, 70%) as an off-white solid: mp 179-181° C.; ¹H NMR (300MHz, DMSO-d₆) δ 9.56 (s, 1H), 9.45 (s, 1H), 8.78 (s, 1H), 8.76 (d, 1H,J=1.2 Hz), 8.26 (d, 1H, J=8.7 Hz), 8.14 (m, 2H), 8.00 (s, 1H), 7.66 (s,1H), 7.58 (dd, 1H, J=8.7, 2.4 Hz), 6.99 (d, 1H, J=8.7 Hz), 3.87 (s, 3H),3.76 (s, 3H); MS m/z 404.6 [M+H]⁺; HPLC, 6.475 min, 98.6% (AUC).

Example 2

The following compounds were prepared using procedures similar to thosedescribed above. Those of ordinary skill in the art of organic synthesiswill recognize when starting materials or reaction conditions should bevaried to obtain the desired compound.

MS data reported in this example was obtained as follows:

MS conditions: Electrospray MS is performed on a MICROMASS LCT equippedwith a LockSpray source for accurate mass measurements. Spectra areacquired in positive ion mode from 100-1000 Da at an acquisition rate of1 spectrum/0.9 s with a 0.1 s interscan delay. The instrument is tunedfor a resolution of 5000 (FWHM). Every 5^(th) scan is taken from thereference position of the Lockspray source. Leucine enkephalin (556.2771[M+H]⁺) is used as the reference, or lock mass.

Structure Name [M + H]⁺

N-(3,4-dimethoxyphenyl)-6-(3- methylphenyl)imidazo[1,2-a]pyrazin-8-amine 361.2

N-(3,4-dimethoxyphenyl)-6-(3- nitrophenyl)imidazo[1,2-a]pyrazin- 8-amine392.1

N-(3,4-dimethoxyphenyl)-6-{3- [(ethylamino)methyl]phenyl}imidazo[1,2-a]pyrazin-8-amine 404.7

N-(3,4-dimethoxyphenyl)-6-[3- (trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine 415.5

N-(3,4-dimethoxyphenyl)-6-(3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 377.5

N-(3,4-dimethoxyphenyl)-6- (pyridin-4-yl)imidazo[1,2-a]pyrazin- 8-amine348.3

N-(3,4-dimethoxyphenyl)-6- (pyridin-3-yl)imidazo[1,2-a]pyrazin- 8-amine348.2

N-(3,4-dimethoxyphenyl)-6- phenylimidazo[1,2-a]pyrazin-8- amine 347

3-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzonitrile 372

N-(3,4-dimethoxyphenyl)-6-(4- fluorophenyl)imidazo[1,2-a]pyrazin-8-amine 365.2

4-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a] pyrazin-6-yl}benzene-1-sulfonamide 426.2

N-(3,4-dimethoxyphenyl)-6-{4- [(ethylamino)methyl]phenyl}imidazo[1,2-a]pyrazin-8-amine 404.7

6-(4-chlorophenyl)-N-(3,4- dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 381.2

6-(3-chlorophenyl)-N-(4-ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 395.2

N-(3,4-dimethoxyphenyl)-6-(4- methanesulfonylphenyl)imidazo[1,2-a]pyrazin-8-amine 425.2

4-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzonitrile 372.1

N-(3,4-dimethoxyphenyl)-6-(4- methylphenyl)imidazo[1,2-a]pyrazin-8-amine 361.2

N-(4-ethoxy-3-methoxyphenyl)-6- (3-methylphenyl)imidazo[1,2-a]pyrazin-8-amine 375.2

N-(4-ethoxy-3-methoxyphenyl)-6- (3-fluorophenyl)imidazo[1,2-a]pyrazin-8-amine 379.1

6-(3,4-difluorophenyl)-N-(4-ethoxy- 3-methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 397.1

6-(4-chloro-3-methylphenyl)-N-(4- ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 409

3-{8-[(4-ethoxy-3- methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzene-1- sulfonamide 440.1

N-(4-ethoxy-3-methoxyphenyl)-6- (3- methanesulfonylphenyl)imidazo[1,2-a]pyrazin-8-amine 439.3

N-(4-ethoxy-3-methoxyphenyl)-6- (4-fluoro-3- methylphenyl)imidazo[1,2-a]pyrazin-8-amine 393.2

N-(4-ethoxy-3-methoxyphenyl)-6- (3-fluoro-4- methylphenyl)imidazo[1,2-a]pyrazin-8-amine 393.2

6-(3-chloro-4-methylphenyl)-N-(4- ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 409.2

N-(4-ethoxy-3-methoxyphenyl)-6- (2-fluoropyridin-4-yl)imidazo[1,2-a]pyrazin-8-amine 380.3

N-(4-ethoxy-3-methoxyphenyl)-6- (5-methylpyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine 376.5

6-(5-chloropyridin-3-yl)-N-(4- ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 396.2

N-(4-ethoxy-3-methoxyphenyl)-6- (pyrimidin-5-yl)imidazo[1,2-a]pyrazin-8-amine 363.5

1-{4-[(4-{8-[(4-ethoxy-3- methoxyphenyl)amino]imidazo[1,2- a]pyrazin-6-yl}phenyl)methyl]piperazin-1- yl}ethan-1-one 487.5

1-{4-[(3-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a] pyrazin-6-yl}phenyl)methyl]piperazin-1- yl}ethan-1-one 487.1

N-(3,4-dimethoxyphenyl)-6-[3- (piperazin-1- ylmethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine 445.3

N-(3,4-dimethoxyphenyl)-6-[4- (piperazin-1- ylmethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine 445.3

6-(2,3-dihydro-1,4-benzodioxin-6- yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2- a]pyrazin-8-amine 404.42

N-(3-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}phenyl)acetamide 404.9

6-(3-aminophenyl)-N-(3,4- dimethoxyphenyl)imidazo[1,2- a]pyrazin-8-amine362.8

N-(4-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}phenyl)acetamide 404.6

N-(3,4-dimethoxyphenyl)-6- (thiophen-3-yl)imidazo[1,2- a]pyrazin-8-amine353.5

N-(3,4-dimethoxyphenyl)-6-(1H- indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 387.2

N-(3,4-dimethoxyphenyl)-6-[4-(1H- imidazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 413.3

N-(3,4-dimethoxyphenyl)-6- (quinolin-6-yl)imidazo[1,2-a]pyrazine-8-amine 398

N-(3,4-dimethoxyphenyl)-6-(1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 387.4

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-3,4-dihydro-2H- 1,4-benzoxazin-3-one 418.6

6-(1,3-benzothiazol-5-yl)-N-(3,4- dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 404.6

6-(1,3-benzothiazol-6-yl)-N-(3,4- dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 404.9

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinazolin-2- amine 414.4

N-(3,4-dimethoxyphenyl)-6- (thiophen-2-yl)imidazo[1,2- a]pyrazin-8-amine353.4

3-amino-5-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1-methyl-1,2- dihydropyridin-2-one 393.3

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinolin-2-amine 413.3

6-(4-aminophenyl)-N-(3,4- dimethoxyphenyl)imidazo[1,2- a]pyrazin-8-amine362.6

6-(1H-1,3-benzodiazol-5-yl)-N- (3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 387.1

N-(3,4-dimethoxyphenyl)-6-[3-(1H- imidazol-5-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 413.3

7-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-3,4-dihydro-2H- 1,4-benzoxazin-3-one 418.7

N-(4-ethoxy-3-methoxyphenyl)-6- (1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 401.2

N-(3,4-dimethoxyphenyl)-6-[4-(1H- imidazol-5-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 413.4

N-(4-ethoxy-3-methoxyphenyl)-6- (1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 401.1

6-(1,3-benzothiazol-6-yl)-N-(4- ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 418.7

N-(3,4-dimethoxyphenyl)-6-[3-(1,3- thiazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 430.5

N-(3,4-dimethoxyphenyl)-6-(1- methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 401.3

5-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1, 2-a]pyrazin-6-yl}-1,2-dihydropyridin-2-one 364.5

6-(1,3-benzothiazol-5-yl)-N-(4- ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 418.7

N-(3,4-dimethoxyphenyl)-6-[4-(1,3- oxazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 414.1

(3-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)methanol 357

5-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}pyridin-2-amine 363.2

N-(3,4-dimethoxyphenyl)-6-[3-(1,3- oxazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 414.3

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6-amine 384

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol 371.1

N-(3,4-dimethoxyphenyl)-6-[4-(1,3- thiazol-2-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 430.5

(5-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-methoxyphenyl)methanol 387.2

N-(3,4-dimethoxyphenyl)-6-(1H- indol-6-yl)imidazo[1,2-a]pyrazin-8- amine386.3

N-(3,4-dimethoxyphenyl)-6-(1- methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 401.2

N-(4-ethoxy-3-methoxyphenyl)-6- (1-methyl-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 415.6

N-(4-ethoxy-3-methoxyphenyl)-6- (1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 415.5

N-(3,4-dimethoxyphenyl)-6-(1- methyl-1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 401.3

6-(1H-1,2,3-benzotriazol-6-yl)-N- (3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 388.2

N-(3,4-dimethoxyphenyl)-6-{1H- imidazo[4,5-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine 388.3

6-(1,3-benzoxazol-5-yl)-N-(3,4- dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 388.7

6-(1,3-benzoxazol-6-yl)-N-(3,4- dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 388.3

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-4-methyl-3,4- dihydro-2H-1,4-benzoxazin-3-one 432.4

N-(3,4-dimethoxyphenyl)-6-(1- methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 400.3

N-(3,4-dimethoxyphenyl)-6-(1H- indol-5-yl)imidazo[1,2-a]pyrazin-8- amine386.4

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinolin-3-amine 413.7

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 385.1

5-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3- amine 402.1

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1, 2-a]pyrazin-6-yl}-1H-1,3-benzodiazol-2-amine 402.3

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1, 2-a]pyrazin-6-yl}-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one 419.5

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2-methyl-3,4- dihydro-2H-1,4-benzoxazin-3-one 432.5

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2,2-dimethyl-3,4- dihydro-2H-1,4-benzoxazin-3-one446.4

7-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinolin-2-ol 414.3

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 1-ol 399.3

6-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3- amine 400.2

(4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-methoxyphenyl)methanol 385.3

6-(2,3-dihydro-1H-indol-6-yl)-N- (3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 388.8

N-[6-(3-amino-1H-indazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6- amine 399.2

N-{4-[3-(dimethylamino)propoxy]- 3-methoxyphenyl}-6-{1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 458.7

3-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenoxy)propan-1-ol 431.6

6-(1H-indazol-6-yl)-N-[4-methoxy- 3-(pyrrolidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.3

5-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2,3-dihydro-1H-indol-2-one 382.3

7-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}quinoxalin-2-ol 413.5

7-{8-[(3,4- dimethoxyphenyl)amino]imidazo[1, 2-a]pyrazin-6-yl}-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one 419.5

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7- amine 398.3

N-(2-fluoro-4-methoxyphenyl)-6- (1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 375.3

6-(1H-indazol-6-yl)-N-[3-methoxy- 4-(pyrrolidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 425.5

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-amine 398.5

1-(4-{[6-(3-amino-1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol 386.4

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2- a]pyrazin-8-amine 404.5

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6- amine 396.3

6-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2,3-dihydro-1H-indol-2-one 382.3

N-(3,4-dimethoxyphenyl)-6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine 387.6

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-7-amine 384.3

6-{8-[(4-ethoxy-3- methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3-amine 416.8

N-[6-(2-aminoquinazolin-6- yl)imidazo[1,2-a]pyrazin-8-yl]-4-methyl-3,4-dihydro-2H-1,4- benzoxazin-6-amine 425.2

2-methyl-2-(4-{[6-(1-methyl-1H- 1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)propan-1-ol 413.7

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-(4-ethoxy-3-methoxyphenyl)imidazo[1,2- a]pyrazin-8-amine 418.4

N-[6-(2,3-dihydro-1H-indol-6- yl)imidazo[1,2-a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6- amine 385.3

(2-methoxy-5-{[6-(1-methyl-1H-1,3- benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)methanol 401.2

6-(1H-indazol-6-yl)-N-{4-[2-methyl- 1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8- amine 468.6

N-[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-3,4-dihydro-2H-1,4-benzoxazin-6-amine 383.4

7-{8-[(4-methyl-3,4-dihydro-2H-1,4- benzoxazin-7-yl)amino]imidazo[1,2-a]pyrazin-6- yl}quinoxalin-2-ol 426.2

1-(4-{[6-(1,3-benzothiazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol 388.7

6-(1H-1,2,3-benzotriazol-6-yl)-N- [3-methoxy-4-(propan-2-yloxy)phenyl]imidazo[1,2- a]pyrazin-8-amine 416.6

5-(8-{[3-methoxy-4-(pyrrolidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine 441.4

2-(4-{[6-(2-aminoquinazolin-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 412.4

6-(1H-indazol-6-yl)-N-[3-methoxy- 4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 442.5

2-(4-{[6-(1,3-benzothiazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 402.3

6-(8-{[4-(2-hydroxypropan-2- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 416.7

6-(1H-indazol-6-yl)-N-(3- methoxyphenyl)imidazo[1,2- a]pyrazin-8-amine357.3

6-(1H-indazol-6-yl)-N-(4- methoxyphenyl)imidazo[1,2- a]pyrazin-8-amine357.3

2-(4-{[6-(1-methyl-1H-1,3- benzodiazol-5-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)propan-2-ol 399.1

2-(4-{[6-(1-methyl-1H-1,3- benzodiazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)propan-2-ol 399.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)piperidin-4-ol 456.5

6-(1H-indazol-6-yl)-N-[4-(pyrrolidin- 1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 396.1

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol 412.3

2-(4-{[6-(4-methyl-3,4-dihydro-2H- 1,4-benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)propan-2-ol 416.5

2-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)propan-2-ol 402.5

2-(4-{[6-(1,4-dimethyl-1,2,3,4- tetrahydroquinoxalin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)propan-2-ol 429.4

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)azetidin-3-ol 428.3

2-(4-{[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)propan-2-ol 384.2

2-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)propan-2-ol 402.5

2-(4-{[6-(4-methyl-3,4-dihydro-2H- 1,4-benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)propan-2-ol 416.7

2-(4-{[6-(2,3-dimethyl-2H-indazol- 5-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 413.4

2-(4-{[6-(3-methyl-1H-indazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 399.2

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2- a]pyrazin-8-amine 456.3

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)quinazolin-2-amine 469.4

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 398.3

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol 442.5

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 459.7

6-(1H-indazol-6-yl)-N-[4-(2- methoxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 399.4

N-(4-ethoxy-3-methoxyphenyl)-6- (1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-amine 400.1

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2- a]pyrazin-8-amine 456.4

N-[4-(4-ethylpiperazin-1-yl)-3- methoxyphenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 469.7

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)-3-methylpiperidin-3-ol 440.5

N-[4-(4-ethylpiperazin-1-yl)phenyl]- 6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 439.4

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine 457.6

5-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine 457.5

6-(8-{[4-(2-hydroxypropan-2- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 399.45

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4-ol 426.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-2- methylpropan-2-ol 443.6

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-4- methylpiperidin-4-ol 470.9

2-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)(methyl)amino] ethan-1-ol 430.5

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)-4-methylpiperidin-4-ol 440.4

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenol 343.2

2-(4-{[6-(2,3-dihydro-1H-indol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 386.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)-3-methylpyrrolidin-3-ol 426.2

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(2-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2- a]pyrazin-8-amine 456.3

N-(4-ethoxy-3-methoxyphenyl)-6- (1-methyl-1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 415.6

(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol 412.2

(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol 442.7

(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)pyrrolidin-3-ol 442.7

[4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2- yl]methanol 442.7

N-(4-ethoxy-3-methoxyphenyl)-6- (1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 415.4

6-(5-fluoro-1H-indazol-6-yl)-N-[3- methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 460.6

2-[1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4- yl]propan-2-ol 468.5

(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol 412.1

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(3-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 456.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3- methylpyrrolidin-3-ol 456.2

6-(1H-1,3-benzodiazol-6-yl)-N-(4- ethoxy-3- methoxyphenyl)imidazo[1,2-a]pyrazin-8-amine 401.2

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 457.7

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3- dihydro-1H-indol-2-one 485.7

N-(4-ethoxy-3-methoxyphenyl)-6- {1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine 401.2

4-N-[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]-2-methoxy-1-N-(2-methoxyethyl)-1- N-methylbenzene-1,4-diamine 444.3

4-methyl-1-(4-{[6-(1-methyl-1H- 1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-4-ol 454.1

6-(3,4-dihydro-2H-1,4-benzoxazin- 7-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 459.4

6-(8-{[4-(1-hydroxy-2- methylpropan-2- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 430.2

1-(4-{[6-(1H-1,3-benzodiazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 2-ol 397.2

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-amine 442.7

2-(4-{[6-(1H-1,3-benzodiazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-1,1,1,3,3,3- hexafluoropropan-2-ol 493.5

2-methyl-2-(4-{[6-(1-methyl-1H- 1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)propan-1-ol 413.4

2-methyl-2-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}propan-1-ol 399.2

2,2,2-trifluoro-1-(4-{[6-(1H-indazol- 6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)ethan-1-ol 425.3

2-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2- methylpropan-1-ol 416.8

6-(8-{[4-(4-hydroxy-4- methylpiperidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 471.7

4-methyl-1-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}piperidin-4-ol 440.5

1-(4-{[6-(1H-1,3-benzodiazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4- methylpiperidin-4-ol 438.2

6-(1H-indazol-6-yl)-N-[4-(1- methoxy-2-methylpropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 413.3

4-methyl-1-(4-{[6-(1-methyl-1H- 1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-4-ol 454.1

6-(1H-1,3-benzodiazol-6-yl)-N-[3- methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 442.8

1,1,1-trifluoro-2-(4-{[6-(1H-indazol- 6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-2-ol 437.4

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 2-ol 399.3

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)cyclobutan-1-ol 397.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3- methylpiperidin-3-ol 470.9

4-N-[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]-1-N-(2-methoxyethyl)-1-N- methylbenzene-1,4-diamine 414.5

6-{8-[(4-ethoxy-3- methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazole-3- carboxamide 444.8

2-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(methyl)amino] ethan-1-ol 400.2

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4- methylpiperidin-4-ol 457.6

6-(1H-indazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 412.4

N-[4-(morpholin-4-yl)phenyl]-6- {1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-amine 412.5

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pipendin-3-ol 426.2

6-(1H-indol-6-yl)-N-[4-(morpholin- 4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 411.2

2-(4-{[6-(1H-1,3-benzodiazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 1-ol 399.1

6-(8-{[4-(1-hydroxy-2- methylpropan-2- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 414.5

2-(4-{[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)-2-methylpropan-1-ol 398.2

6-{8-[(4-ethoxy-3- methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-2,3-dihydro-1H- indol-2-one 416.7

2-(4-{[6-(3-amino-1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 1-ol 414.4

5-{8-[(4-ethoxy-3- methoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-1H-indazol-3-amine 416.7

2-(4-{[6-(3-amino-1H-indazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 1-ol 414.6

(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3- methylpyrrolidin-3-ol 456.1

(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3- methylpyrrolidin-3-ol 456.2

7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)-1,2-dihydroquinoxalin-2-one 440.5

N,N-dimethyl-6-(8-{[4-(morpholin- 4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazole-3- carboxamide 483.4

5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 428.3

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2- methylpropan-2-ol 416.8

N-methyl-2-(4-{[6-(2-oxo-2,3- dihydro-1H-indol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenoxy)acetamide 429.4

N-[3-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)phenyl]methanesulfonamide 465.4

N-[4-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)phenyl]methanesulfonamide 465.4

[(2S)-4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2- yl]methanol 442.3

[(2R)-4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-2- yl]methanol 442.3

6-(8-{[4-(2-hydroxy-2- methylpropyl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro- 2H-1,4-benzoxazin-3-one 430.4

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)-4-methylpiperidin- 4-ol 487.5

N-(2-hydroxyethyl)-N-methyl-6-(8- {[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)-1H-indole-3- carboxamide512.7

6′-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1′,2′- dihydrospiro[cyclopropane-1,3′- indole]-2′-one453.1

3-methyl-1-(4-{[6-(1-methyl-1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 426.3

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-methoxyphenol 373.2

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(6-methoxypyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine 433.5

6-(1H-1,2,3-benzotriazol-6-yl)-N- [4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 413.5

N,N-dimethyl-6-(8-{[4-(morpholin- 4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indole-3- carboxamide 482.4

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(5-methoxypyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine 433.4

6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine 427.4

7-[8-({4-[(3S)-3-hydroxypyrrolidin- 1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-2-one 444.8

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-N-methyl-N-(oxan-4-yl)benzamide 468.2

6-(3-ethyl-1H-indazol-6-yl)-N-{4-[2- methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8- amine 496.9

2,2-difluoro-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 479.1

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)-3-methylazetidin- 3-ol 459.3

6-(1H-indol-2-yl)-N-[4-(morpholin- 4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 411.3

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)pyrrolidin-3-ol 459.6

1-(4-{[6-(4-fluoro-1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-ol 430.2

6-(1H-indazol-6-yl)-N-[4-(2H- 1,2,3,4-tetrazol-5-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 395.1

7-(8-{[4-(3-hydroxy-3- methylazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-2-one 444.2

6-(1H-indazol-6-yl)-N-[3-methoxy- 4-(2-methoxyethoxy)phenyl]imidazo[1,2- a]pyrazin-8-amine 431.5

6-(2-ethyl-1,2,3,4- tetrahydroisoquinolin-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 455.4

4-{[6-(3,3-dimethyl-2-oxo-2,3- dihydro-1H-indol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N- propylbenzamide 455.3

6-(8-{[3-ethoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3- dihydro-1H-indol-2-one 499.7

6-(1H-indol-3-yl)-N-[4-(morpholin- 4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 411.2

6-(1,3-benzothiazol-5-yl)-N-{4-[2- methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8- amine 485.7

(3E)-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3-(1,3-thiazol-4- ylmethylidene)-2,3-dihydro-1H-indol-2-one 522.6

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-N-(oxan-4-yl)benzamide 454

6-(2-methyl-1,3-benzothiazol-5-yl)- N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2- a]pyrazin-8-amine 499.5

6-(2,3-dihydro-1,4-benzodioxin-6- yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 460.6

6-(1H-indazol-6-yl)-N-[4-(2- methoxyethoxy)phenyl]imidazo[1,2-a]pyrazin-8-amine 401.1

6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)quinazolin-2-amine 439.7

6-(8-{[4-(4-hydroxy-4- methylpiperidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3- dihydro-1H-indol-2-one 483.5

6-(1H-indazol-6-yl)-N-{4-[(2S)- oxolan-2- ylmethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine 427.1

6-(3-ethyl-1H-indazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 440.5

N-(2,3-dihydro-1,4-benzodioxin-6- yl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 385.3

N-(2H-1,3-benzodioxol-5-yl)-6-(1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 371.2

1-(2-ethoxy-4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4- methylpiperidin-4-ol 484.7

6-[8-({4-[(3S)-3-hydroxypyrrolidin- 1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,3-dimethyl-2,3- dihydro-1H-indol-2-one 455.2

6-(8-{[4-(3-hydroxy-3- methylazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,3-dimethyl-2,3- dihydro-1H-indol-2-one 455.3

6-(2H-1,3-benzodioxol-5-yl)-N-[3- methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 446.3

6-(1H-indol-6-yl)-N-{4-[2-methyl-1- (morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-a]pyrazin-8- amine 467.4

6-(1H-indazol-6-yl)-N-[4-(pyridin-4- yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine 420.3

(3E)-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3-(pyridin-4- ylmethylidene)-2,3-dihydro-1H- indol-2-one516.4

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-N-(oxetan-3-yl)benzamide 426.1

6-{3-[(diethylamino)methyl]-1H- indazol-6-yl}-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 497.3

1-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]-3- methylazetidin-3-ol 440.2

[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3- yl]methanol 442.3

N-[4-(morpholin-4-yl)phenyl]-6- (1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-amine 362.6

6-(4-fluoro-1H-indazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 430.3

N-[4-(morpholin-4-yl)phenyl]-6- {1H,2H,3H-pyrido[2,3-b][1,4]oxazin-6-yl}imidazo[1,2- a]pyrazin-8-amine 430.3

N-[4-(morpholin-4-yl)phenyl]-6- (1,3-thiazol-5-yl)imidazo[1,2-a]pyrazin-8-amine 379.2

{4-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl] morpholin-2-yl}methanol 470.8

1-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]piperidin- 4-ol 454.1

N-ethyl-N-(2-hydroxyethyl)-4-{[6- (1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}benzamide 440.2

2-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenoxy)-N- methylacetamide 461.4

7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2-dihydroquinolin- 2-one 439.5

6-(2-ethyl-1,2,3,4- tetrahydroisoquinolin-7-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 455.4

1-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]-4- methylpiperidin-4-ol 468.4

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-methoxybenzoic acid 401.1

6-(1H-indazol-6-yl)-N-{4-[(4- methylpiperazin-1-yl)carbonyl]phenyl}imidazo[1,2- a]pyrazin-8-amine 453.1

1-[(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)carbonyl]azetidin- 3-ol 426.3

3,3-dimethyl-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 455.4

6-(1H-indazol-6-yl)-N-[4-(1- methylpiperidin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 424.2

2-(4-{[6-(4-fluoro-1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2-methylpropan- 1-ol 417.7

2-[ethyl(4-{[6-(4-fluoro-1H-indazol- 6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)amino]ethan-1-ol 431.47

6-(1H-indazol-7-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 412.2

6-[8-({4-[ethyl(2- hydroxyethyl)amino]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,3- dimethyl-2,3-dihydro-1H-indol-2- one457.6

N-{4-[2- (dimethylamino)ethoxy]phenyl}-6- (1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 414.6

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-{4-[2-(dimethylamino)ethoxy]phenyl} imidazo[1,2-a]pyrazin-8-amine 431.4

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylazetidin-3-ol 429.3

2-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2H-indazol-2- yl]ethan-1-ol 456.3

3-(2-ethoxy-4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2,2- dimethylpropan-1-ol 473.4

3-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2,2- dimethylpropan-1-ol 429.5

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-N- methylacetamide 444.8

2-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-N- methylacetamide 431.4

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenoxy)-N-methylacetamide 414.4

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)acetic acid 401.1

N-(2-hydroxyethyl)-4-{[6-(1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxybenzamide 442.1

6-(1,3-benzothiazol-5-yl)-N-[3- ethoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 473.2

6-(1H-indazol-6-yl)-N-{3-methoxy- 4-[(2R)-oxolan-2-ylmethoxy]phenyl}imidazo[1,2- a]pyrazin-8-amine 457.4

6-(1H-indazol-6-yl)-N-{4-[(2R)- oxolan-2- ylmethoxy]phenyl}imidazo[1,2-a]pyrazin-8-amine 427

6-(8-{[4-(3-hydroxy-3- methylazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 443.2

6-(1H-indazol-6-yl)-N-[4- (morpholin-4- ylcarbonyl)phenyl]imidazo[1,2-a]pyrazin-8-amine 440.3

N-(2-hydroxyethyl)-4-{[6-(1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N-methylbenzamide 428.2

2-[(2-ethoxy-4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(methyl)amino] ethan-1-ol 444.6

N-[2-(dimethylamino)ethyl]-4-{[6- (1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-N- methylbenzamide 455.3

1-(2-fluoro-4-{[6-(1H-inazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-ol 430.4

(3S)-1-(4-{[6-(4-fluoro-1H-indazol- 6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol 430.4

2-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-1- yl]ethan-1-ol 456.3

6-(8-{[4-(3-hydroxy-3- methylazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 427.2

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-amine 396.1

N-[3-ethoxy-4-(morpholin-4- yl)phenyl]-6-(4-fluoro-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 474.2

1-(2-ethoxy-4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2- methylpropan-2-ol 459.4

(3R)-3-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-1,4- dimethylpiperazin-2-one 453.4

N-(2-hydroxyethyl)-4-{[6-(1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}benzamide 414.5

6-(8-{[3-ethoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 471.7

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-[3-ethoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 473.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-N,N- dimethylpiperidin-4-amine 453.1

1-(4-{[6-(1,3-benzothiazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2- methylpropan-2-ol 432.4

(3R)-1-(2-ethoxy-4-{[6-(1H-indazol- 6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol 456.4

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)ethan-1-ol 387.3

1-(2-ethoxy-4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-ol 456.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3- methylazetidin-3-ol 442.2

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}benzoic acid371

N-[3-ethoxy-4-(4-ethylpiperazin-1- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 483.3

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-N-propylbenzamide 412.1

1-(4-{[6-(4-fluoro-1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4- methylpiperidin-4-ol 458.6

3-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenoxy)-2,2- dimethylpropan-1-ol 459.5

6-(4-fluoro-1H-indazol-6-yl)-N-[4- (1,4-oxazepan-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 444.7

6-(8-{[3-ethoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 487.5

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-2- methylpropan-2-ol 432.4

2-methyl-1-(4-{[6-(1-methyl-1H- 1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenoxy)propan-2-ol 429.3

6-(8-{[4-(2-hydroxy-2- methylpropoxy)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro- 1H-indol-2-one 430.2

N-[3-fluoro-4-(morpholin-4- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 430.4

1-(4-{[6-(1,3-benzothiazol-5- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-ol 429.1

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-1,2,3,4-tetrahydroisoquinolin-6-amine 382.2

N-[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]-2,3-dihydro-1H-indol-6-amine 368.2

1-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4- tetrahydroisoquinolin-2-yl]ethan-1- one 469.6

1-[7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4- tetrahydroisoquinolin-2-yl]ethan-1- one 469.7

N-[4-(morpholin-4-yl)phenyl]-6- {1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl}imidazo[1,2- a]pyrazin-8-amine 430.4

6-(1-methyl-1H-indazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.1

N-[4-(morpholin-4-yl)phenyl]-6- {2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}imidazo[1,2- a]pyrazin-8-amine 430.4

6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-2-one 444.2

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpipendin-3-ol 457.2

5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 427

1-methyl-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 441.4

6-(8-{[4-(2-hydroxy-2- methylpropoxy)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro- 2H-1,4-benzoxazin-3-one 446.3

2-[4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperazin-1- yl]ethan-1-ol 455.2

6-(1H-indazol-4-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 412.2

N-[3-ethoxy-4-(morpholin-4- yl)phenyl]-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2- a]pyrazin-8-amine 470.2

6-(1H-indazol-6-yl)-N-[4-(piperazin- 1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 411.2

N-[4-(morpholin-4-yl)phenyl]-6- (1,2,3,4-tetrahydroisoquinolin-7-yl)imidazo[1,2-a]pyrazin-8-amine 427.1

N-[4-(morpholin-4-yl)phenyl]-6- (1,2,3,4-tetrahydroisoquinolin-6-yl)imidazo[1,2-a]pyrazin-8-amine 427

7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H,2H,3H- pyrido[2,3-b][1,4]oxazin-2-one 444.8

6-{1-methyl-1H-pyrrolo[3,2- b]pyridin-6-yl}-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.2

6-(1-methyl-1H-indol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 425.3

6-(1,3-benzoxazol-5-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 413.5

6-(4-methyl-3,4-dihydro-2H-1,4- benzoxazin-7-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin- 8-amine 443.6

6-(4-methyl-3,4-dihydro-2H-1,4- benzoxazin-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin- 8-amine 443.9

6-[8-({4-[(3S)-3-hydroxypyrrolidin- 1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-3,4-dihydro-2H-1,4- benzoxazin-3-one 443.7

(3R)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpiperidin-3-ol 457.2

6-[8-({4-[(3S)-3-hydroxy-3- methylpiperidin-1-yl]phenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-3,4-dihydro-2H-1,4-benzoxazin-3-one 471.7

6-[8-({4-[(3R)-3-hydroxy-3- methylpiperidin-1-yl]phenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-3,4-dihydro-2H-1,4-benzoxazin-3-one 471.6

6-[8-({4-[(3S)-3-hydroxy-3- methylpiperidin-1-yl]phenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-2,3-dihydro-1H- indol-2-one455.4

6-[8-({4-[(3R)-3-hydroxy-3- methylpiperidin-1-yl]phenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-2,3-dihydro-1H- indol-2-one455.2

(3R)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpiperidin-3-ol 457.2

(3S)-3-methyl-1-(4-{[6-(1-methyl- 1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-3-ol 454.6

(3R)-3-methyl-1-(4-{[6-(1-methyl- 1H-1,3-benzodiazol-5-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-3-ol 454.2

(3R)-3-methyl-1-(4-{[6-(1-methyl- 1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-3-ol 454.1

6-(8-{[4-(4-ethylpiperazin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 470.8

6-(1,3-benzothiazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 429.3

6-(1,3-benzothiazol-5-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 429.4

6-(1,3-benzoxazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 413.5

6-(1H-indazol-5-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 412.3

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpiperidin-3-ol 457.6

(3S)-3-methyl-1-(4-{[6-(1-methyl- 1H-1,3-benzodiazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-3-ol 450.4

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-ol 412.3

N-{4-[(4-ethylpiperazin-1- yl)methyl]phenyl}-6-(1-methyl-1H-1,3-benzodiazol-6-yl)imidazo[1,2- a]pyrazin-8-amine 467.5

2-[ethyl(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)amino]ethan-1-ol 414.4

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 415.2

7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2H,3H,4H- pyrido[3,2-b][1,4]oxazin-3-one 444.8

6-(1-methyl-1H-indazol-5-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.1

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenoxy)-2-methylpropan-2-ol 415.4

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 429.3

4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperazin-2-one 425.1

6-(1-methyl-1H-1,3-benzodiazol-6- yl)-N-[4-(morpholin-4-ylmethyl)phenyl]imidazo[1,2- a]pyrazin-8-amine 440.4

6-(1H-1,3-benzodiazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 412.2

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 415.4

6-(1H-indazol-6-yl)-N-[4-(1,4- oxazepan-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 426.1

(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpiperidin-3-ol 440.3

(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpiperidin-3-ol 440.3

(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpyrrolidin-3-ol 426.1

(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3- methylpyrrolidin-3-ol 426.2

6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 443.7

6-(8-{[4-(3-hydroxyazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 413.4

6-(8-{[4-(3-hydroxy-3- methylpyrrolidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 457.6

6-(1-methyl-1H-1,3-benzodiazol-6- yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.2

6-(3,4-dihydro-2H-1,4-benzoxazin- 7-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 429.2

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4- methylpiperidin-4-ol 457.2

1-(4-{[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)-4-methylpiperidin-4-ol 439.7

1-(4-{[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 397.1

1-(4-{[6-(1-methyl-1H-1,3- benzodiazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 412.3

1-(4-{[6-(1-methyl-1H-1,3- benzodiazol-5-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 412.2

6-(1-methyl-1H-1,3-benzodiazol-5- yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.1

6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 427.1

6-(8-{[4-(3-hydroxyazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 429.3

5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1,3- benzoxazol-2-one 429.3

4-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-N,N-dimethylbenzene-1-sulfonamide 434.3

6-(1H-indazol-6-yl)-N-{4-[4- (propan-2-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8- amine 453.9

2-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-7-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-2- methylpropan-1-ol 416.8

4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)thiomorpholine- 1,1-dione 460.4

6-(1H-indazol-6-yl)-N-[4-(2- methylmorpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.1

N-(4-ethoxy-3-methoxyphenyl)-6- (1H-indazol-6-yl)-5-methylimidazo[1,2-a]pyrazin-8- amine 415.3

1-(4-{[6-(1H-indazol-6-yl)-5- methylimidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-4- methylpiperidin-4-ol 454.2

N,6-bis[4-(morpholin-4- yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 457.3

2-[1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-4- yl]ethan-1-ol 454.1

6-[3-(morpholin-4-yl)phenyl]-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 457.6

2-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indol-3-yl]ethan- 1-ol 455.2

[1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pipendin-4- yl]methanol 440.4

1-[4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperazin-1- yl]ethan-1-one 453

6-(5-chloro-8-{[3-methoxy-4- (morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 491.3

5-chloro-N-[3-methoxy-4- (morpholin-4-yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6- yl}imidazo[1,2-a]pyrazin-8-amine 476.4

N-methyl-5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3-amine 402.3

6-(1H-indazol-6-yl)-N-(4-{7-oxa-2- azaspiro[3.5]nonan-2-yl}phenyl)imidazo[1,2-a]pyrazin-8- amine 452.3

6-(2-methyl-1H-1,3-benzodiazol-6- yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.2

5-(8-{[4-(3-hydroxy-3- methylazetidin-1- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3- dihydro-1H-1,3-benzodiazol-2-one 442.7

N-{4-[(2R,6S)-2,6- dimethylmorpholin-4-yl]phenyl}-6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-amine 440.3

N-[6-(1H-indazol-6-yl)-5- methylimidazo[1,2-a]pyridin-8-yl]-5-(morpholin-4-yl)pyridin-2-amine 426.2

[(2R)-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-2-yl]methanol 459.3

6-(1H-indazol-6-yl)-N-[3- (methoxymethyl)-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 456.3

7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4- tetrahydroquinoxalin-2-one 442.4

5-chloro-6-(1H-indazol-6-yl)-N-[3- methoxy-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 476.1

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-amine 411.3

[(2S)-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-2-yl]methanol 459.3

7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4- tetrahydroquinolin-2-one 441.5

5-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-(morpholin-4-yl)benzonitrile 437.1

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-3-methyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 443.9

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-3-methyl-6-{1H-pyrrolo[3,2-b]pyridin-6- yl}imidazo[1,2-a]pyrazin-8-amine 456.4

5-methyl-6-(2-methyl-1H-1,3- benzodiazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin- 8-amine 440.2

5-ethyl-6-(1H-indazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 440.4

1-methyl-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 442.7

6-(3-methyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 441.3

1,3-dimethyl-5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 456.2

2-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3- yl]propan-2-ol 470.8

6-{4-fluoro-1H-indol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 429.3

5-{[6-(1H-indazol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-(morpholin-4-yl)benzamide 455.2

5-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}-5-methylimidazo[1,2-a]pyrazin-6-yl)- 2,3-dihydro-1H-1,3-benzodiazol-2- one472.4

5-(5-methyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 442.4

[2-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]methanol 402.2

1-methyl-5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 442.7

2-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-4-yl]ethan-1-ol 473.2

(3R)-2,2-dimethyl-6-(8-{[4- (morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-3-ol 457.6

6-(1H-indazol-6-yl)-N-{3-methoxy- 4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8- amine 499.6

2-(4-{2-methoxy-4-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}piperazin-1- yl)ethan-1-ol485.7

1-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3- yl]ethan-1-ol 456.5

2-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3- yl]ethan-1-ol 456.5

2-{[5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3- yl]amino}ethan-1-ol 432.6

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-5-methyl-6-{1H-pyrrolo[3,2-b]pyridin-6- yl}imidazo[1,2-a]pyrazin-8-amine 456.2

(3S)-2,2-dimethyl-6-(8-{[4- (morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-3-ol 457.8

N-{4-[4-(3-fluoropropyl)piperazin-1- yl]phenyl}-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 471.4

6-(1H-indazol-6-yl)-N-[4-(oxan-4- yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 411.3

N-[4-(4-fluoropiperidin-1-yl)phenyl]- 6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 428.2

6-(1H-indazol-6-yl)-N-[3-(2- methoxyethoxy)-4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 486.6

6-(1H-indazol-6-yl)-N-[4-(4H-1,2,4- triazol-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 394.3

N-[4-(3,3-difluoropyrrolidin-1- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 432.3

6-(1H-indazol-6-yl)-N-[3-methoxy- 4-(morpholin-4-yl)phenyl]-5-methylimidazo[1,2-a]pyrazin-8- amine 456.3

2,2-dimethyl-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-3-one 455.3

6-(1H-indazol-6-yl)-N-[3-methoxy- 4- (methoxymethyl)phenyl]imidazo[1,2-a]pyrazin-8-amine 401.2

1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-methoxyphenyl)-2- methylpropan-2-ol 429.4

[(2S)-4-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)morpholin-2- yl]methanol 459.3

N-[4-(4,4-difluoropipendin-1- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 446.3

6-(1H-indazol-6-yl)-N-{3-methoxy- 4-[(2- methoxyethoxy)methyl]phenyl}imidazo[1,2-a]pyrazin-8-amine 445.5

2-[2-(morpholin-4-yl)-5-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenoxy]ethan-1-ol 472.4

6-(1H-indazol-6-yl)-N-[4-(3- methoxy-3-methylazetidin-1-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.2

5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3-amine 388.8

N-[4-(morpholin-4-yl)phenyl]-6- (1,5-naphthyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine 424.2

3-ethyl-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)azetidin-3-ol 426

N-[4-(3-fluoro-3-methylazetidin-1- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 414.5

N-[4-(3,3-difluoropiperidin-1- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 446.2

[(2R)-4-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)morpholin-2- yl]methanol 459.4

N-[4-(3,3-difluoroazetidin-1- yl)phenyl]-6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 418.6

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)pyrrolidin-3-ol 459.5

(3R)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)pyrrolidin-3-ol 459.5

N-[4-(3-fluoroazetidin-1-yl)phenyl]- 6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 400.2

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-N-[3-methoxy-4-(morpholin-4-yl)phenyl]-5-methylimidazo[1,2- a]pyrazin-8-amine 473.2

N,N-diethyl-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine 483.6

(3S)-3-hydroxy-3-methyl-6-(8-{[4- (morpholin-4-yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one457.6

N-[4-(morpholin-4-yl)phenyl]-6- (quinoxalin-6-yl)imidazo[1,2-a]pyrazin-8-amine 424.3

(3R)-3-hydroxy-3-methyl-6-(8-{[4- (morpholin-4-yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one457.6

6-(1H-indazol-6-yl)-N-{3-methoxy- 4-[(2S)-oxolan-2-ylmethoxy]phenyl}imidazo[1,2- a]pyrazin-8-amine 457.5

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}-5-methylimidazo[1,2-a]pyrazin-6-yl)- 2,3-dihydro-1H-indol-2-one 471.7

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}-5-methylimidazo[1,2-a]pyrazin-6-yl)- 3,4-dihydro-2H-1,4-benzoxazin-3- one487.5

(3S)-1-{4-[(6-{1H,2H,3H- pyrido[2,3-b][1,4]oxazin-7-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}pyrrolidin-3-ol 430.4

(3R)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)pyrrolidin-3-ol 429.4

6-[8-({4-[(3R)-3-hydroxypyrrolidin- 1-yl]-3-methoxyphenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one 457.3

N-[4-(1H-imidazol-1-yl)phenyl]-6- (1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 393.3

6-(1H-indazol-6-yl)-N-[4-(1H- pyrazol-1-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine 393.2

6-[8-({4-[(3R)-3-hydroxypyrrolidin- 1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H- indol-2-one 427.1

6-[8-({4-[(3S)-3-hydroxypyrrolidin- 1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1H- indol-2-one 427

1-(4-{[6-(1H-indazol-6-yl)-5- methylimidazo[1,2-a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin- 3-ol 426.2

(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)piperidin-3-ol 426.2

(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pipendin-3-ol 426.2

2-[3-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]propan-2-ol 430.2

6-(5-methyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 457.2

N-ethyl-6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3-amine 455.2

2-[4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)piperazin-1- yl]ethan-1-ol 485.6

6-[8-({4-[(3S)-3-hydroxypyrrolidin- 1-yl]-3-methoxyphenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-2,3-dihydro-1H-indol-2-one 457.6

2-(5-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2-(morpholin-4- yl)phenoxy)ethan-1-ol 472.4

(3S)-1-(4-{[6-(1-methyl-1H-indazol- 6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3-ol 426.2

6-(5-methyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 441.3

2-methyl-1-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2H-indazol-2- yl]propan-2-ol 484.6

2-methyl-1-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}propan-2-ol 399.2

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)pyrrolidin-3-ol 429.4

2-[4-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)phenyl]propan-2-ol 430.2

6-(1H-indazol-6-yl)-3-methyl-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 426.2

N-(2-hydroxyethyl)-N-methyl-6-(8- {[4-(morpholin-4-yl)phenyl]amino}imidazo[1,2- a]pyrazin-6-yl)-1H-indazole-3- carboxamide513.6

5-chloro-6-(1H-indazol-6-yl)-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 446.4

N-(2-hydroxyethyl)-2-(4-{[6-(1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)acetamide 444.8

1-(4-{[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}-2-methoxyphenyl)-3-methylazetidin- 3-ol 441.4

1-(4-{[6-(1H-indol-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)-3-methylazetidin-3-ol 411.4

2-methyl-1-[6-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-1- yl]propan-2-ol 484.7

6-(1H-indazol-6-yl)-N-[3-methoxy- 4-(oxan-4- yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine 457.6

N-[3-methoxy-4-(morpholin-4- yl)phenyl]-6-(1-methyl-1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-amine 456.2

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-5-methyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 443.3

2-methyl-2-(4-{[6-(1-methyl-1H- indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)propan-1-ol 413.5

1-(3-hydroxy-3-methylazetidin-1- yl)-2-(4-{[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenoxy)ethan-1-one 470.7

1-[6-(1,3-benzothiazol-5- yl)imidazo[1,2-a]pyridin-8-yl]-3- methylurea324.2

1-[6-(1,3-benzothiazol-5- yl)imidazo[1,2-a]pyridin-8-yl]-3- ethylurea338.3

1-{2-ethoxy-4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}-3- methylazetidin-3-ol 456.4

1-{2-methoxy-4-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}-3-methylazetidin- 3-ol442.4

6-(1H-indol-6-yl)-N-[3-methoxy-4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 441.5

6-(1H-indazol-6-yl)-N-[4-(oxan-4- yloxy)phenyl]imidazo[1,2-a]pyrazin-8-amine 427

6-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-3,4-dihydro-2H-1,4- benzoxazin-3-one 473.2

6-(1H-indazol-6-yl)-N-[3- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 412.5

2-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)-N,N- dimethylacetamide 428.3

3-methyl-1-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}azetidin-3-ol 412.3

1-methyl-5-(5-methyl-8-{[4- (morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 456.5

1-ethyl-5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H-1,3- benzodiazol-2-one 456.5

6-(3,4-dihydro-2H-1,4-benzoxazin- 6-yl)-5-ethyl-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 457.6

6-(5-ethyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 455.1

(3S)-1-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-yl)amino]phenyl}piperidin-3-ol 426.2

(3S)-1-{2-methoxy-4-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}piperidin-3-ol 456.2

2-(1-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-yl)amino]phenyl}pipendin-4- yl)ethan-1-ol 454.2

2-[6-(5-methyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3- yl]ethan-1-ol 470.6

1-[4-({6-[3-(2-hydroxyethyl)-1H- indazol-6-yl]imidazo[1,2-a]pyrazin-8-yl}amino)phenyl]-3- methylazetidin-3-ol 456.4

6-[8-({4-[(2R)-2- (hydroxymethyl)morpholin-4-yl]phenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-2,3-dihydro-1H- indol-2-one457.5

6-[8-({4-[(2S)-2- (hydroxymethyl)morpholin-4-yl]phenyl}amino)imidazo[1,2- a]pyrazin-6-yl]-2,3-dihydro-1H- indol-2-one457.6

5-(5-ethyl-8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3- dihydro-1H-1,3-benzodiazol-2-one 470.7

5-ethyl-N-[4-(morpholin-4- yl)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-amine 440.4

(3R)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)piperidin-3-ol 473.3

N-[4-(morpholin-4-yl)phenyl]-6- (1,2,3,5-tetrahydro-4,1-benzoxazepin-8-yl)imidazo[1,2- a]pyrazin-8-amine 443.4

[(3R)-4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-3- yl]methanol 442.3

[(3S)-4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)morpholin-3- yl]methanol 442.2

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)piperidin-3-ol 473.2

(1-{4-(6-{1H-pyrrolo[3,2-b]pyridin- 6-yl}imidazo[1,2-a]pyrazin-8-yl)amino]phenyl}piperidin-4- yl)methanol 440.3

[(2R)-4-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)morpholin-2- yl]methanol 489.4

[(2S)-4-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino}-2- methoxyphenyl)morpholin-2- yl]methanol 489.4

4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenoxy)cyclohexan-1-ol 441.5

6-(1H-indazol-6-yl)-N-(4-{2-oxa-6- azaspiro[3.3]heptan-6-yl}phenyl)imidazo[1,2-a]pyrazin-8- amine 424.2

2-[6-(8-{[3-methoxy-4-(morpholin- 4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-3- yl]ethan-1-ol 486.6

[(2S)-4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)morpholin-2- yl]methanol 472.4

[(2R)-4-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8- yl]amino}-2-methoxyphenyl)morpholin-2- yl]methanol 472.4

2-[1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-4- yl]ethan-1-ol 471.8

6-(1H-indazol-6-yl)-N-(4-{8-oxa-3- azabicyclo[3.2.1]octan-3-yl}phenyl)imidazo[1,2-a]pyrazin-8- amine 438.3

[(3R)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3- yl]methanol 426.2

[(3S)-1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3- yl]methanol 426.2

5-chloro-6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)-N-[3-methoxy-4-(morpholin-4- yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 493.5

2-[6-(8-{[3-methoxy-4-(morpholin- 4-yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1H-indol-3-yl]ethan- 1-ol 485.6

(3R)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)piperidin-3-ol 443.8

[1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2- a]pyrazin-8-yl]amino}phenyl)piperidin-4- yl]methanol 457.5

(3S)-1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)imidazo[1,2-a]pyrazin-8- yl]amino}phenyl)pipericlin-3-ol 443.3

[(2S)-4-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-yl)amino]phenyl}morpholin-2- yl]methanol 442.7

[(2R)-4-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-yl)amino]phenyl}morpholin-2- yl]methanol 442.5

2-[1-(4-{[6-(1H-indazol-6- yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)pyrrolidin-3- yl]ethan-1-ol 440.3

6-(1H-indazol-6-yl)-N-[4-(oxan-4- ylmethoxy)phenyl]imidazo[1,2-a]pyrazin-8-amine 441.4

N-[5-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)pyridin-3- yl]acetamide 430.4

6-(8-{[3-methoxy-4-(oxan-4- yloxy)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-2,3-dihydro-1H- indol-2-one 472.4

6-(1H-indol-6-yl)-N-[3-methoxy-4- (morpholin-4-yl)phenyl]-5-methylimidazo[1,2-a]pyrazin-8- amine 455.2

6-(1H-indol-6-yl)-5-methyl-N-[4- (morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8- amine 425.2

1-(4-{[6-(3,4-dihydro-2H-1,4- benzoxazin-6-yl)-5-methylimidazo[1,2-a]pyrazin-8- yl]amino}phenyl)-4- methylpiperidin-4-ol471.8

N-[3-methoxy-4-(oxan-4- yloxy)phenyl]-6-{1H-pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-amine 457.4

6-(1H-indazol-6-yl)-N-(4-{2-oxa-7- azaspiro[3.5]nonan-7-yl}phenyl)imidazo[1,2-a]pyrazin-8- amine 452.2

6-(1H-indazol-6-yl)-N-[3-methoxy- 4-(oxan-4-ylmethoxy)phenyl]imidazo[1,2- a]pyrazin-8-amine 471.8

1-(4-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-yl)amino]phenyl}piperazin-1- yl)ethan-1-one 453.1

5-(8-{[3-(2-hydroxyethoxy)-4- (morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3- dihydro-1H-1,3-benzodiazol-2-one 502.2

[(3S)-1-{2-methoxy-4-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}pyrrolidin-3- yl]methanol456.5

5-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-N-methylpyridin-3- amine 432.5

5-(8-{[3-methoxy-4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1-methyl-2,3- dihydro-1H-1,3-benzodiazol-2-one 472.3

5-[8-({4-[(3R)-3-hydroxypiperidin-1- yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]-1-methyl-2,3- dihydro-1H-1,3-benzodiazol-2-one 456.2

(3R)-1-{2-methoxy-4-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}piperidin-3-ol 456.4

4-methyl-7-(8-{[4-(morpholin-4- yl)phenyl]amino}imidazo[1,2-a]pyrazin-6-yl)-1,2,3,4- tetrahydroquinoxalin-2-one 456.5

[(2R)-4-{2-methoxy-4-[(6-{1H- pyrrolo[3,2-b]pyridin-6-yl}imidazo[1,2-a]pyrazin-8- yl)amino]phenyl}morpholin-2- yl]methanol472.5

(3R)-1-{4-[(6-{1H-pyrrolo[3,2- b]pyridin-6-yl}imidazo[1,2- a]pyrazin-8-yl)amino]phenyl}piperidin-3-ol 426

Example 3 Biochemical Syk Assay

A generalized procedure for one standard biochemical Syk Kinase Assaythat can be used to test compounds disclosed in this application is asfollows.

A master mix minus Syk enzyme is prepared containing 1× Cell Signalingkinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mMdithiothreitol, 0.1 mM Na₃VO₄, 10 mM MgCl₂), 0.5 μM Promega PTKBiotinylated peptide substrate 1, 0.01% casein, 0.01% Triton-X100, and0.25% glycerol. A master mix plus Syk enzyme is prepared containing 1×Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate1, 0.01% casein, 0.01% Triton-X100, 0.25% glycerol and 0.4 ng/well Sykenzyme. Syk enzyme is purchased from Cell Signaling Technologies,expressed in baculovirus and is an N-terminally GST-tagged full lengthhuman wildtype Syk (accession number NM-00377). The Syk protein waspurified in one step using glutathione-agarose. The purity of the finalprotein preparation was assessed by SDS-PAGE and Coomassie staining. Asolution of 200 μM ATP is prepared in water and adjusted to pH7.4 with1N NaOH. A quantity of 1.25 μL of compounds in 5% DMSO is transferred toa 96-well ½ area Costar polystyrene plate Compounds are tested singlyand with an 11-point dose-responsive curve (starting concentration is10-1 μM; 1:2 dilution). A quantity of 18.75 μL of master mix minusenzyme (as a negative control) and master mix plus enzyme is transferredto appropriate wells in 96-well ½ area costar polystyrene plate. 5 μL of200 μM ATP is added to that mixture in the 96-well ½ area Costarpolystyrene plate for final ATP concentration of 40 μM. The reaction isallowed to incubate for 1 hour at room temperature. The reaction isstopped with Perkin Elmer 1× detection buffer containing 30 mM EDTA, 80nM SA-APC, and 4 nM PT66 Ab. The plate is read using time-resolvedfluorescence with a Perkin Elmer Envision using excitation filter 330nm, emission filter 665 nm, and 2^(nd) emission filter 615 nm. IC₅₀values are subsequently calculated using a linear regression algorithm.

Example 4 Ramos Cell pBLNK(Y96) Assay

Another generalized procedure for a standard cellular Syk Kinase Assaythat can be used to test compounds disclosed in this application is asfollows.

Ramos cells are serum starved at 2×10⁶ cells/ml in serum-free RPMI for 1hour in an upright T175 Falcon TC flask. Cells are centrifuged (1100rpm×5 min) and incubated at a density of 0.5×10⁷ cells/ml in thepresence of test compound or DMSO controls for 1 hr at 37° C. Cells arethen stimulated by incubating with 10 μg/ml anti-human IgM F(ab)₂ for 5minutes at 37° C. Cells are pelleted, lysed in 40 ul cell lysis buffer,and mixed with Invitrogen SDS-PAGE loading buffer. 20 ul of cell lysatefor each sample are subject to SDS-PAGE and western blotting withanti-phosphoBLNK(Tyr96) antibody (Cell Signaling Technology #3601) toassess Syk activity and anti-Syk antibody (BD Transduction Labs #611116)to control for total protein load in each lysate. The images aredetected using fluorescent secondary detection systems and the LiCorOdyssey software.

Example 5 B-Cell Proliferation Assay

A generalized procedure for a standard cellular B-cell proliferationassay that can be used to test compounds disclosed in this applicationis as follows.

B-cells are purified from spleens of 8-16 week old Balb/c mice using aB-cell isolation kit (Miltenyi Biotech, Cat #130-090-862). Testcompounds are diluted in 0.25% DMSO and incubated with 2.5×10⁵ purifiedmouse splenic B-cells for 30 min prior to addition of 10 μg/ml of ananti-mouse IgM antibody (Southern Biotechnology Associates Cat #1022-01)in a final volume of 100 μl. Following 24 hr incubation, 1 μCi³H-thymidine is added and plates are incubated an additional 36 hr priorto harvest using the manufacturer's protocol for SPA[³H] thymidineuptake assay system (Amersham Biosciences # RPNQ 0130). SPA-bead basedfluorescence is counted in a microbeta counter (Wallace Triplex 1450,Perkin Elmer).

Example 6 T Cell Proliferation Assay

A generalized procedure for a standard T cell proliferation assay thatcan be used to test compounds disclosed in this application is asfollows.

T cells are purified from spleens of 8-16 week old Balb/c mice using aPan T cell isolation kit (Miltenyi Biotech, Cat #130-090-861). Testcompounds are diluted in 0.25% DMSO and incubated with 2.5×10⁵ purifiedmouse splenic T cells in a final volume of 100 μl in flat clear bottomplates precoated for 90 min at 37° C. with 10 μg/ml each of anti-CD3 (BD#553057) and anti-CD28 (BD #553294) antibodies. Following 24 hrincubation, 1 μCi ³H-thymidine is added and plates incubated anadditional 36 hr prior to harvest using the manufacturer's protocol forSPA[³H] thymidine uptake assay system (Amersham Biosciences # RPNQ0130). SPA-bead based fluorescence was counted in a microbeta counter(Wallace Triplex 1450, Perkin Elmer).

Example 7 CD69 Inhibition Assay

A generalized procedure for a standard assay for the inhibition of Bcell activity that can be used to test compounds disclosed in thisapplication is as follows.

Total mouse splenocytes are purified from spleens of 8-16 week oldBalb/c mice by red blood cell lysis (BD Pharmingen #555899). Testingcompounds are diluted to 0.5% DMSO and incubated with 1.25×10⁶splenocytes in a final volume of 200 μl in flat clear bottom plates(Falcon 353072) for 60 min at 37° C. Cells are then stimulated with theaddition of 15 μg/ml IgM (Jackson ImmunoResearch 115-006-020), andincubated for 16 hr at 37° C., 5% CO₂. Following the 16 hr incubation,cells are transferred to conical bottom clear 96-well plates andpelleted by centrifugation at 1200×g×5 min. Cells are preblocked byCD16/CD32 (BD Pharmingen #553142), followed by triple staining withCD19-FITC (BD Pharmingen #553785), CD69-PE (BD Pharmingen #553237), and7AAD (BD Pharmingen #51-68981E). Cells are sorted on a BD FACSCaliburand gated on the CD19⁺/7AAD⁻ population. The levels of CD69 surfaceexpression on the gated population is measured versus test compoundconcentration.

Example 8 BMMC Degranulation

A generalized procedure for a standard assay for bone-marrow derivedmouse mast cell (BMMC) degranulation that can be used to test compoundsdisclosed in this application is as follows.

Bone-marrow derived mast cells were cultured for >4 weeks with IL-3 (10ng/ml) and SCF (10 ng/ml). The cells were determined to be >90%cKit⁺/FceR1⁺ by FACS analysis at the time of use. Cells (6×10⁷ cells/50ml) were serum-starved in a T150 tissue culture flask for 16 h in theabsence of IL-3 and SCF containing IgEα-DNP at 1 ug/ml. Overnightsensitized cells are washed twice in Tyrodes buffer and resuspended to5×10⁶ cells/ml. 5×10⁵ cells (100 ul) are plated in a 96 well microtiterplate (Falcon 353072) and test compounds are serially diluted to a finalconcentration 0.25% DMSO in the plate for 1 hr at 37° C., 5% CO₂. Wellsare treated with a DNP-BSA antigen challenge (50 ng/ml) and incubatedfor and additional 30 min at 37° C. Supernatants are assayed forhexosamimidase release versus control wells. Cell pellets aresimultaneously lysed and assed for total hexosamimidase release tocalculate specific release. Dose-response curves are generated using4-parameter logistical fit and IC50s calculated.

Example 9 Passive Cutaneous Anaphylaxis (PCA)

The following is a procedure for a standard PCA model used for measuringin vivo IgE anti-DNP Ab sensitization and DNP-BSA antigen for triggeringmast cell degranulation and release of immune regulators that causeacute vessel permeability monitored by Evan's blue dye into the inflamedarea in the mouse ear.

Reagents: Anti-DNP IgE: is supplied as 1.2 mg/ml in a phosphate bufferedsolution with BSA for additional protein and azide for sterility. Thisis diluted 1:100 in sterile PBS as a 12 ug/ml working stock that can befurther diluted in PBS to the appropriate concentration for injection. Afurther 1:5 dilution give a final 1:500 solution at 2.4 ng/ul. (10ul/ear=24 ng). Sterile PBS alone will be used as a negativecontrol.—DNP-BSA: will be made up at 4 mg/ml in sterile ddH₂O and storedat 40° C. solution. It is further diluted 1:1 with sterile saline priorto use. This solution or a further dilution in saline is diluted 1:1with 2% Evan's Blue in sterile saline that has been filtered though 0.02um filter and refiltered prior to injection. For these experiments afinal solution of 0.5 mg/ml of DNP-BSA in 1% Evans blue can be used.Tail vein injections will be held constant at 200 ul=100 ug in 1% Evan'sBlue.—Evan's blue dye: A 2% stock in saline will be sterile filtered anddiluted 1:1 with DNP-BSA saline solution for final concentration of 1%for injection.

General PCA Protocol Using Intradermal Ear Sensitization

1) On d0, animals, anesthetized with isofluorine, are passivelysensitized by intradermal injections of IgE anti-DNP using a 29-gaugeinsulin syringe. By convention, the right ear receives 10 ul intradermalinjection of anti-DNP IgE while the left ear receives PBS. 2) 20 hr postsensitization, antigen challenge is administered by tail i.v. injectionof DNP-BSA in 200 ul of 1% Evan's blue dye solution in saline. Tails areimmersed in warm water prior to iv injection to improve success. 3) 30minutes to 2 hr prior to this antigen challenge, drug is delivered sc orpo in 10% EtOH/20% cremaphor/70% saline. 4) Animals are sacrifice by CO₂inhalation 30-60 min post antigen challenge and ears are removed forextraction of Evan's blue dye in 500 ul of formamide overnight at 65° C.5) Blood is obtained by cardiac puncture just prior to final cervicaldislocation and processed for plasma to provide PK analysis. 6) Evan'sblue dye is quantified by reading absorbency of 200 ul of extractedsolution in microtiter plates at 620 nm.

Study Design of Experiment

Each animal has one anti-DNP IgE sensitized ear (right ear byconvention) and one PBS control ear (left ear by convention). Groups1-8: represent the vehicle and compound testing arms; Group 9:represents the non-antigen negative control; Group 10: represents thenon-sensitized challenged negative control; Group 11: represents thenon-antigen challenged, non-sensitized negative control group (Groups9-11 represent negative controls for background levels only and requireonly minimal number of animals per group.)

The compounds disclosed in the examples above were tested in the Sykbiochemical assay described herein (Example 3) and certain of thosecompounds exhibited an IC₅₀ value less than or equal to 1 micromolar.Certain of those compounds exhibited an IC₅₀ value less than or equal to100 nM. Certain of those compounds exhibited an IC₅₀ value less than orequal to 10 nM. Certain of those compounds exhibited an IC₅₀ value lessthan or equal to 1 nM.

Some of the compounds disclosed in Example 2 were tested in the B-cellproliferation assay (as described in Example 5) and exhibited an IC₅₀value less than or equal to 10 micromolar. Certain of those compoundsexhibited an IC₅₀ value less than or equal to 1 micromolar.

Certain of those compounds did not inhibit T-cell proliferation and hadIC₅₀ values greater than or equal to 5 micromolar when assayed underconditions described herein (as described in Example 6).

Certain compounds described herein exhibited IC₅₀ values for inhibitionof T-cell proliferation that were at least 3-fold, and in some instances5-fold, greater than the IC₅₀ values of those compounds for inhibitionof B-cell proliferation.

Some of the compounds described herein were tested in an assay forinhibition of B cell activity (under the conditions described in example7), and exhibited an IC₅₀ value less than or equal to 10 micromolar.Certain of those compounds exhibited an IC₅₀ value less than or equal to1 micromolar.

Some of the compounds disclosed in described herein exhibited bothbiochemical and cell-based activity. For example, some of the compoundsdescribed herein exhibited an IC₅₀ value less than or equal to 10micromolar in the Syk biochemical assay described herein (Example 3) andan IC₅₀ value less than or equal to 10 micromolar in at least one of thecell-based assays (other than the T-cell assay) described herein(Examples 4, 5, 7 or 8). Certain of those compounds exhibited an IC₅₀value less than or equal to 1 micromolar in the Syk biochemical assaydescribed herein (Example 4) and an IC₅₀ value less than or equal to 10micromolar in at least one of the cell-based assays (other than theT-cell assay) described herein (Examples 4, 5, 7 or 8). Certain of thosecompounds exhibited an IC₅₀ value less than or equal to 0.1 micromolarand an IC₅₀ value less than or equal to 10 micromolar in at least one ofthe cell-based assays (other than the T-cell assay) described herein(Examples 4, 5, 7 or 8).

While some embodiments have been shown and described, variousmodifications and substitutions may be made thereto without departingfrom the spirit and scope of the invention. For example, for claimconstruction purposes, it is not intended that the claims set forthhereinafter be construed in any way narrower than the literal languagethereof, and it is thus not intended that exemplary embodiments from thespecification be read into the claims. Accordingly, it is to beunderstood that the present invention has been described by way ofillustration and not limitations on the scope of the claims.

1. At least one chemical entity chosen from compounds of Formula I:

and pharmaceutically acceptable salts thereof, wherein R₁ is phenylsubstituted with one or two groups chosen from halo, hydroxy, carboxy,cyano, cycloalkyl optionally substituted with one or two groups chosenfrom hydroxy, lower alkoxy, and lower alkyl, cycloalkyloxy optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,and lower alkyl, heterocycloalkyl optionally substituted with one or twogroups chosen from acyl, halo, optionally substituted amino, hydroxy,lower alkoxy, lower alkyl, lower alkyl substituted with hydroxy, loweralkyl substituted with lower alkoxy, lower alkyl substituted with one,two, or three halo groups, optionally substituted amino, optionallysubstituted heterocycloalkyl, and oxo, heterocycloalkyloxy optionallysubstituted with one or two groups chosen from halo, optionallysubstituted amino, hydroxy, lower alkoxy, lower alkyl, lower alkylsubstituted with hydroxy, lower alkyl substituted with lower alkoxy,lower alkyl substituted with one, two, or three halo groups, optionallysubstituted amino, optionally substituted heterocycloalkyl, and oxo,heteroaryl, amino optionally substituted with one or two groups chosenfrom lower alkyl, lower alkyl substituted with halo, lower alkylsubstituted with hydroxy, and lower alkyl substituted with lower alkoxy,—C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from hydrogen,lower alkyl, lower alkyl substituted with hydroxy, lower alkylsubstituted with optionally substituted amino, cycloalkyl, aryl,heteroaryl, and heterocycloalkyl, or R₆ and R₇ together with thenitrogen to which they are bound form a 3- to 7-memberedheterocycloalkyl ring optionally substituted with one or two groupschosen from hydroxy, lower alkyl, and lower alkyl substituted withhydroxy, —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected fromhydrogen, lower alkyl, lower alkyl substituted with hydroxy, lower alkylsubstituted optionally substituted amino, cycloalkyl, aryl, heteroaryl,and heterocycloalkyl, or R₆ and R₇ together with the nitrogen to whichthey are bound form a 3- to 7-membered heterocycloalkyl ring optionallysubstituted with one or two groups chosen from hydroxy, lower alkyl, andlower alkyl substituted with hydroxy, provided that at least one of R₆and R₇ is not hydrogen, lower alkoxy optionally substituted with one ortwo groups chosen from hydroxy, lower alkoxy, optionally substitutedaminocarbonyl, optionally substituted amino, carboxy, aminocarbonyl, andheterocycloalkyl, heteroaryloxy, and lower alkyl optionally substitutedwith one or two groups chosen from hydroxy, lower alkoxy, halo,trifluoromethyl, optionally substituted amino, and heterocycloalkyloptionally substituted with lower alkyl; or R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted; R₂ is chosen from optionally substituted aryland optionally substituted heteroaryl; R₃ is chosen from hydrogen, loweralkyl, and halo; R₄ is chosen from hydrogen and lower alkyl; and R₅ ishydrogen, provided that if R₃ and R₄ are hydrogen and R₁ is3-methoxy-4-(morpholin-4-ylcarbonyl)phenyl, 4-(morpholin-4-yl)phenyl,3,4-diethoxyphenyl, 3-fluoro-4-methoxyphenyl,4-(4-ethylpiperazin-1-1)phenyl, 4-(3-oxopiperazin-1-yl)phenyl,4-(morpholin-4-yl)phenyl, 3-methoxy-4-(morpholin-4-yl)phenyl,3-methoxy-4-methylphenyl, 4-methoxy-3-methylphenyl,2-(dimethylamino)ethoxy-3-methoxyphenyl, 3-ethoxy-4-methoxyphenyl, or4-ethoxy-3-methoxyphenyl, then R₂ is not phenyl substituted with—(CO)NHR₆ where R₆ is optionally substituted aryl; if R₃ and R₄ arehydrogen and R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenylsubstituted with —(CO)NR₈R₉ where R₈ and R₉ taken together form anheterocycloalkyl or optionally substituted heteroaryl or where R₈ ishydrogen, methyl or ethyl and R₉ is hydrogen, optionally substitutedaryl, optionally substituted cycloalkyl, optionally substitutedheterocycloalkyl, optionally substituted alkyl, or optionallysubstituted heteroaryl wherein said phenyl is further optionallysubstituted with a group chosen from methyl, methoxy, and halo, or—(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl; if R₃ and R₄ arehydrogen and R₁ is 4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl,2-fluorophenyl, benzo[d][1,3]dioxolyl, 2-methoxyphenyl,2,6-dimethoxyphenyl, 3-acetamidophenyl, 3-carboxyphenyl,2-(hydroxymethyl)phenyl, furanyl, or 3-(hydroxyethylcarbamoyl)phenyl; ifR₃ and R₄ are hydrogen and R₁ is chlorophenyl, then R₂ is not phenylsubstituted with piperidin-1-yl-carbonyl or NH(CO)NHR₁₂ where R₁₂ isphenyl substituted with trifluoromethyl or one or more halogens; if R₃and R₄ are hydrogen and R₁ is phenyl substituted with optionallysubstituted piperazinyl then R₂ is not 3-aminophenyl; if R₃ and R₄ arehydrogen and R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and if R₃ and R₄ are hydrogenand R₁ is 4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then R₂is not 2-methoxyphenyl or 2-fluorophenyl; if R₃ and R₄ are hydrogen andR₁ is 4-[(4-ethylpiperazin-1-yl)methyl]phenyl or4-(2-hydroxypropan-2-yl)phenyl, then R₂ is not phenyl substituted with—(CO)NR₈R₉ where R₈ is hydrogen and R₉ is hydrogen, methyl or optionallysubstituted aryl wherein said phenyl is optionally further substitutedwith a group chosen from methyl; if R₃ and R₄ are hydrogen and R₂ is4-carbamoylphenyl, then R₁ is not 4-(hydroxymethyl)phenyl,3-(1-hydroxyethyl)phenyl, 4-(1H-imidazol-2-yl)-3-methylphenyl,3-methoxy-4-(piperidin-4-yloxy)phenyl,3-methoxy-4-(2-methoxyethoxy)phenyl,4[2-(dimethylamino)ethoxy]-3-methoxyphenyl,4-(2-hydroxyethoxy)-3-methoxyphenyl, 3-methoxy-4-(propan-2-yloxy)phenyl,3-methoxy-4-propoxyphenyl, 4-(propylcarbamoyl)phenyl,4-ethoxy-3-methoxyphenyl, 4-(1H-imidazol-2-yl)phenyl,3-methoxy-4-(1H-pyrazol-5-yl)phenyl, if R₃ and R₄ are hydrogen and R₂ ispyridin-3-yl substituted with carbamoyl, then R₁ is not3,4-dimethoxyphenyl, if R₃ and R₄ are hydrogen and R₁ is4-ethoxy-3-methoxyphenyl, then R₂ is not phenyl substituted with methyland further substituted with —(CO)NR₈R₉ where R₈ is hydrogen and R₉ is4-(methylcarbamoyl)phenyl, and further provided that R₂ is not phenylsubstituted with —NHC(O)R₁₁ where R₁₁ is optionally substituted aryl. 2.At least one chemical entity of claim 1, wherein R₃ is chosen fromhydrogen, methyl, ethyl, and chloro.
 3. At least one chemical entity ofclaim 2, wherein R₃ is hydrogen.
 4. At least one chemical entity ofclaim 1 wherein R₄ is chosen from hydrogen and methyl.
 5. At least onechemical entity of claim 4, wherein R₄ is hydrogen
 6. At least onechemical entity of claim 1 wherein R₁ is phenyl substituted with one ortwo groups chosen from halo, hydroxy, carboxy, cycloalkyl optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,and lower alkyl, heterocycloalkyl optionally substituted with one or twogroups chosen from hydroxy, lower alkoxy, lower alkyl, lower alkylsubstituted with hydroxy, optionally substituted amino, and oxo,heteroaryl, amino optionally substituted with one or two groups chosenfrom lower alkyl, lower alkyl substituted with halo, lower alkylsubstituted with hydroxy, and lower alkyl substituted with lower alkoxy,—C(O)NR₆R₇ wherein R₆ and R₇ are independently selected from hydrogen,lower alkyl, lower alkyl substituted with hydroxy, lower alkylsubstituted with optionally substituted amino, cycloalkyl, aryl,heteroaryl, and heterocycloalkyl, or R₆ and R₇ together with thenitrogen to which they are bound form a 3- to 7-memberedheterocycloalkyl ring optionally substituted with one or two groupschosen from hydroxy, lower alkyl, and lower alkyl substituted withhydroxy, —S(O)₂NR₆R₇ wherein R₆ and R₇ are independently selected fromhydrogen, lower alkyl, lower alkyl substituted with hydroxy, lower alkylsubstituted with optionally substituted amino, cycloalkyl, aryl,heteroaryl, and heterocycloalkyl, or R₆ and R₇ together with thenitrogen to which they are bound form a 3- to 7-memberedheterocycloalkyl ring optionally substituted with one or two groupschosen from hydroxy, lower alkyl, and lower alkyl substituted withhydroxy, provided that at least one of R₆ and R₇ is not hydrogen, loweralkoxy optionally substituted with one or two groups chosen fromhydroxy, lower alkoxy, optionally substituted amino, carboxy,aminocarbonyl, and heterocycloalkyl heteroaryloxy, and lower alkyloptionally substituted with one or two groups chosen from hydroxy, loweralkoxy, halo, trifluoromethyl, optionally substituted amino, andheterocycloalkyl optionally substituted with lower alkyl; or R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted; R₂ is chosen from optionally substituted aryland optionally substituted heteroaryl; R₃ is hydrogen; R₄ is hydrogen;and R₅ is hydrogen, provided that if R₁ is 3-methoxy-4-methylphenyl,4-methoxy-3-methylphenyl, 2-(dimethylamino)ethoxy-3-methoxyphenyl,3-ethoxy-4-methoxyphenyl, or 4-ethoxy-3-methoxyphenyl, then R₂ is notphenyl substituted with —(CO)NHR₆ where R₆ is optionally substitutedaryl; if R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenyl substitutedwith —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionallysubstituted heterocycloalkyl or optionally substituted heteroaryl orwhere R₈ is hydrogen and R₉ is optionally substituted aryl, optionallysubstituted cycloalkyl, optionally substituted heterocycloalkyl,optionally substituted alkyl, or optionally substituted heteroaryl, or—(SO₂)NHR₁₀ where R₁₀ is optionally substituted phenyl; if R₁ is4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl, 2-fluorophenyl,benzo[d][1,3]dioxolyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl,3-acetamidophenyl, 3-carboxyphenyl, 2-(hydroxymethyl)phenyl, furanyl, or3-(hyroxyethylcarbamoyl)phenyl; if R₁ is chlorophenyl, then R₂ is notphenyl substituted with piperidin-1-yl-carbonyl or NH(CO)NR₁₂ where R₁₂is phenyl substituted with trifluoromethyl or one or more halogens; ifR₁ is optionally substituted piperazinyl then R₂ is not 3-aminophenyl;if R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and if R₁ is4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then R₂ is not2-methoxyphenyl or 2-fluorophenyl; and further provided that R₂ is notphenyl substituted with —NHC(0)R₁₁ where R₁₁ is optionally substitutedaryl.
 7. At least one chemical entity of claim 1, wherein R₁ is phenylsubstituted with one or two groups chosen from halo, hydroxy, carboxy,cycloalkyl optionally substituted with one or two groups chosen fromhydroxy, lower alkoxy, and lower alkyl, heterocycloalkyl optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,lower alkyl, lower alkyl substituted with hydroxy, optionallysubstituted amino, and oxo, heteroaryl, amino optionally substitutedwith one or two groups chosen from lower alkyl, lower alkyl substitutedwith halo, lower alkyl substituted with hydroxy, and lower alkylsubstituted with lower alkoxy, —C(O)NR₆R₇ wherein R₆ and R₇ areindependently selected from hydrogen, lower alkyl, lower alkylsubstituted with hydroxy, lower alkyl substituted with optionallysubstituted amino, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl,or R₆ and R₇ together with the nitrogen to which they are bound form a3- to 7-membered heterocycloalkyl ring optionally substituted with oneor two groups chosen from hydroxy, lower alkyl, and lower alkylsubstituted with hydroxy, —S(O)₂NR₆R₇ wherein R₆ and R₇ areindependently selected from hydrogen, lower alkyl, lower alkylsubstituted with hydroxy, lower alkyl substituted with optionallysubstituted amino, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl,or R₆ and R₇ together with the nitrogen to which they are bound form a3- to 7-membered heterocycloalkyl ring optionally substituted with oneor two groups chosen from hydroxy, lower alkyl, and lower alkylsubstituted with hydroxy, provided that at least one of R₆ and R₇ is nothydrogen, lower alkoxy optionally substituted with one or two groupschosen from hydroxy, lower alkoxy, optionally substituted amino,carboxy, aminocarbonyl, and heterocycloalkyl, heteroaryloxy, and loweralkyl optionally substituted with one or two groups chosen from hydroxy,lower alkoxy, halo, trifluoromethyl, optionally substituted amino, andheterocycloalkyl optionally substituted with lower alkyl.
 8. At leastone chemical entity of claim 7, wherein R₁ is phenyl substituted withone or two groups chosen from halo, hydroxy, heterocycloalkyl optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,lower alkyl, and lower alkyl substituted with hydroxy, amino optionallysubstituted with one or two groups chosen from lower alkyl, lower alkylsubstituted with hydroxy, and lower alkyl substituted with lower alkoxy,lower alkoxy optionally substituted with one or two groups chosen fromhydroxy, lower alkoxy, and optionally substituted amino, lower alkyloptionally substituted with one or two groups chosen from hydroxy, loweralkoxy, trifluoromethyl, optionally substituted amino, andheterocycloalkyl, and —C(O)NR₆R₇ wherein R₆ and R₇ are independentlyselected from hydrogen, lower alkyl, lower alkyl substituted withhydroxy, lower alkyl substituted with optionally substituted amino,cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, or R₆ and R₇together with the nitrogen to which they are bound form a 3- to7-membered heterocycloalkyl ring optionally substituted with one or twogroups chosen from hydroxy, lower alkyl, and lower alkyl substitutedwith hydroxy.
 9. At least one chemical entity of claim 8, wherein R₁ isphenyl substituted with one or two groups chosen from hydroxy,heterocycloalkyl optionally substituted with one or two groups chosenfrom hydroxy, lower alkoxy, lower alkyl, and lower alkyl substitutedwith hydroxy, lower alkoxy optionally substituted with one or two groupschosen from hydroxy and lower alkoxy, and lower alkyl substituted withone or two groups chosen from hydroxy, lower alkoxy, trifluoromethyl,optionally substituted amino, and heterocycloalkyl.
 10. At least onechemical entity of claim 1 wherein R₁ is phenyl substituted with one ortwo groups chosen from halo, hydroxy, cycloalkyl optionally substitutedwith one or two groups chosen from hydroxy, lower alkoxy, and loweralkyl, heterocycloalkyl optionally substituted with one or two groupschosen from hydroxy, lower alkoxy, and lower alkyl, amino optionallysubstituted with one or two groups chosen from lower alkyl, lower alkylsubstituted with halo, lower alkyl substituted with hydroxy, and loweralkyl substituted with lower alkoxy, lower alkoxy optionally substitutedwith one or two groups chosen from hydroxy, lower alkoxy, and optionallysubstituted amino, and lower alkyl optionally substituted with one ortwo groups chosen from hydroxy, lower alkoxy, halo, trifluoromethyl, andoptionally substituted amino; or R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted; R₂ is chosen from optionally substituted aryland optionally substituted heteroaryl; R₃ is hydrogen; R₄ is hydrogen;and R₅ is hydrogen, provided that if R₁ is 3-methoxy-4-methylphenyl,4-methoxy-3-methylphenyl, 2-(dimethylamino)ethoxy-3-methoxyphenyl,3-ethoxy-4-methoxyphenyl, or 4-ethoxy-3-methoxyphenyl, then R₂ is notphenyl substituted with —(CO)NHR₆ where R₆ is optionally substitutedaryl; if R₁ is 3,4-dimethoxyphenyl, then R₂ is not phenyl substitutedwith —(CO)NR₈R₉ where R₈ and R₉ taken together form an optionallysubstituted heterocycloalkyl or optionally substituted heteroaryl orwhere R₈ is hydrogen and R₉ is optionally substituted aryl, optionallysubstituted cycloalkyl, optionally substituted heterocycloalkyl,optionally substituted alkyl, or optionally substituted heteroaryl, or—S(O₂)NHR₁₀ where R₁₀ is optionally substituted phenyl; if R₁ is4-(morpholin-4-yl)phenyl, then R₂ is not pyridinyl, 2-fluorophenyl,benzo[d][1,3]dioxolyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl,3-acetamidophenyl, 3-carboxyphenyl, 2-(hydroxymethyl)phenyl, furanyl, or3-(hyroxyethylcarbamoyl)phenyl; if R₁ is chlorophenyl, then R₂ is notphenyl substituted with piperidin-1-yl-carbonyl or NH(CO)NR₁₂ where R₁₂is phenyl substituted with trifluoromethyl or one or more halogens; ifR₁ is optionally substituted piperazinyl then R₂ is not 3-aminophenyl;if R₁ is 4-chlorophenyl, then R₂ is not 4-carboxyphenyl,3-(2-(dimethylamino)ethylcarbamoyl)phenyl, or4-(2-(dimethylamino)ethylcarbamoyl)phenyl; and if R₁ is4-(2-hydroxy-ethyl)phenyl or 4-(hydroxyethyl)phenyl, then R₂ is not2-methoxyphenyl or 2-fluorophenyl; and further provided that R₂ is notphenyl substituted with —NHC(O)R₁₁ where R₁₁ is optionally substitutedaryl.
 11. At least one chemical entity of claim 10 wherein R₁ is phenylsubstituted with one or two groups chosen from halo, hydroxy,heterocycloalkyl optionally substituted with one or two groups chosenfrom hydroxy, lower alkoxy, and lower alkyl, lower alkoxy optionallysubstituted with optionally substituted amino, and lower alkyloptionally substituted with one or two groups chosen from hydroxy, loweralkoxy, and optionally substituted amino; or R₁ is

wherein A is chosen from aryl, cycloalkyl and heterocycloalkyl groups,each of which groups having from 5 to 7 ring atoms including the atomsshared with the 6 membered aromatic ring and each of which groups beingoptionally substituted.
 12. At least one chemical entity of claim 11,wherein R₁ is phenyl substituted with one or two groups chosen fromhydroxy, heterocycloalkyl optionally substituted with one or two groupschosen from hydroxy, lower alkoxy, and lower alkyl, amino optionallysubstituted with one or two groups chosen from lower alkyl, lower alkylsubstituted with hydroxy, and lower alkyl substituted with lower alkoxy,lower alkoxy optionally substituted with one or two groups chosen fromhydroxy and optionally substituted amino, and lower alkyl optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,trifluoromethyl, and optionally substituted amino.
 13. At least onechemical entity of claim 12, wherein R₁ is phenyl substituted with oneor two groups chosen from hydroxy, heterocycloalkyl optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,and lower alkyl, lower alkoxy, and lower alkyl substituted with one ortwo groups chosen from hydroxy, lower alkoxy, trifluoromethyl, andoptionally substituted amino.
 14. At least one chemical entity of claim13, wherein R₁ is chosen from (1-hydroxycyclobutyl)phenyl,(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl,(2,2,2-trifluoro-1-hydroxyethyl)phenyl,(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl,(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl,(2-hydroxyethyl)(methyl)amino)-3-methoxyphenyl,(2-methoxyethyl)(methyl)amino)-3-methoxyphenyl, (1-hydroxyethyl)phenyl,3,4-dimethoxyphenyl, 3-methoxyphenyl, 4-ethoxy-3-methoxyphenyl,4-hydroxymethyl-3-methoxyphenyl, 3-hydroxymethyl-4-methoxyphenyl,2-fluoro-4-methoxyphenyl, 4-(dimethylamino)propoxy-3-methoxyphenyl,4-hydroxypropoxy-3-methoxyphenyl, 4-(2-hydroxy-1,1-dimethylethyl)phenyl,4-(1-hydroxy-1-methylethyl)phenyl, 4-methoxy-3-(pyrrolidin-1-yl)phenyl,3-methoxy-4-(pyrrolidin-1-yl)phenyl, 3-methoxy-4-(propan-2-yloxy)phenyl,3-methoxy-4-(morpholin-4-yl)phenyl,4-(pyrrolidin-1-yl)phenyl,4-(3-hydroxypyrrolidinyl)phenyl,4-(4-hydroxypiperidinyl)-3-methoxyphenyl,4-(3-hydroxyazetidinyl)-3-methoxyphenyl,4-(3-hydroxypyrrolidinyl)-3-methoxyphenyl,4-(2-methoxypropan-2-yl)phenyl,4-(4-ethylpiperazin-1-yl)-3-methoxyphenyl,4-(4-ethylpiperazin-1-yl)phenyl,4-(3-hydroxy-3-methylpiperidinyl)phenyl, and 3-hydroxymethylphenyl. 15.At least one chemical entity of claim 1 wherein R₁ is phenyl substitutedwith one or two groups chosen from hydroxy, heterocycloalkyl optionallysubstituted with one or two groups chosen from hydroxy, lower alkoxy,and lower alkyl, lower alkoxy optionally substituted with optionallysubstituted amino, and lower alkyl optionally substituted with one ortwo groups chosen from hydroxy, lower alkoxy, and optionally substitutedamino.
 16. At least one chemical entity of claim 15, wherein R₁ isphenyl substituted with one or two groups chosen from hydroxy,heterocycloalkyl optionally substituted with one or two groups chosenfrom hydroxy, lower alkoxy, and lower alkyl, lower alkoxy, and loweralkyl substituted with one or two groups chosen from hydroxy, loweralkoxy, and optionally substituted amino.
 17. At least one chemicalentity of claim 16, wherein R₁ is phenyl substituted with one or twogroups chosen from hydroxy, heterocycloalkyl optionally substituted withone or two groups chosen from hydroxy and lower alkyl, lower alkoxy, andlower alkyl substituted with one or two groups chosen from hydroxy andlower alkoxy.
 18. At least one chemical entity of claim 15, wherein R₁is chosen from (1-hydroxyethyl)phenyl, 3,4-dimethoxyphenyl,3-methoxyphenyl, 4-ethoxy-3-methoxyphenyl,4-hydroxymethyl-3-methoxyphenyl, 3-hydroxymethyl-4-methoxyphenyl,2-fluoro-4-methoxyphenyl, 4-(dimethylamino)propoxy-3-methoxyphenyl,4-hydroxypropoxy-3-methoxyphenyl, 4-(2-hydroxy-1,1-dimethylethyl)phenyl,4-(1-hydroxy-1-methylethyl)phenyl, 4-methoxy-3-(pyrrolidin-1-yl)phenyl,3-methoxy-4-(pyrrolidin-1-yl)phenyl, 3-methoxy-4-(propan-2-yloxy)phenyl,3-methoxy-4-(morpholin-4-yl)phenyl, 4-(pyrrolidin-1-yl)phenyl,4-(3-hydroxypyrrolidinyl)phenyl,4-(4-hydroxypiperidinyl)-3-methoxyphenyl,4-(3-hydroxyazetidinyl)-3-methoxyphenyl,4-(3-hydroxypyrrolidinyl)-3-methoxyphenyl,4-(2-methoxypropan-2-yl)phenyl,4-(4-ethylpiperazin-1-yl)-3-methoxyphenyl,4-(4-ethylpiperazin-1-yl)phenyl,4-(3-hydroxy-3-methylpiperidinyl)phenyl, and 3-hydroxymethylphenyl. 19.At least one chemical entity of claim 1, wherein R₁ is


20. At least one chemical entity of claim 19 wherein A is an optionallysubstituted heterocycloalkyl group comprising one or more heteroatomschosen from O and N.
 21. At least one chemical entity of claim 20,wherein the heterocylcloalkyl group is substituted with one or moregroups chosen from lower alkyl and oxo.
 22. At least one chemical entityof claim 20, wherein the heteroatom N is substituted by lower alkyl. 23.At least one chemical entity of claim 19, wherein R₁ is chosen from3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl, 5-methyl2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl,2,3-dihydro-1H-indol-2-one-6-yl, and 2,3-dihydro-1H-indol-2-one-5-yl.24. At least one chemical entity of claim 1, wherein R₂ is chosen fromoptionally substituted heteroaryl; dihydrobenzoxazinyl optionallysubstituted with one or more groups chosen from lower alkyl, halo, andoxo, dihydroquinoxalinyl optionally substituted with one or more groupschosen from lower alkyl and oxo; dihydrobenzodiazolyl optionallysubstituted with oxo; dihydroindolyl optionally substituted with one ormore groups chosen from lower alkyl and oxo, and phenyl substituted withone or more groups chosen from optionally substituted alkyl, cyano,nitro, lower alkoxy, halo, sulfonyl, optionally substituted amino, andoptionally substituted heteroaryl.
 25. At least one chemical entity ofclaim 24, wherein R₂ is chosen from optionally substituted pyridinyl,pyrimidinyl, thiophenyl, quinolinyl optionally substituted with amino,indazolyl optionally substituted with one or two groups chosen fromcarbamoyl, halo, lower alkyl, and amino, indolyl optionally substitutedwith one or two groups chosen from lower alkyl, carbamoyl,benzoimidazolyl optionally substituted with methyl or amino,benzothiozolyl optionally substituted with lower alkyl, benzoxazolyl,benzotriazolyl, quinoxalinyl optionally substituted with amino,quinazolinyl optionally substituted with amino, dihydrobenzoxazinyloptionally substituted with one or more groups chosen from methyl, halo,and oxo, 1H-pyrrolo[3,2-b]pyridinyl, dihydrobenzoxazinyl optionallysubstituted with one or more groups chosen from lower alkyl, halo, andoxo, dihydroindolyl optionally substituted with one or more groupschosen from lower alkyl and oxo, and phenyl substituted with one or moregroups chosen from optionally substituted alkyl, cyano, chloro, fluoro,nitro, methoxy, sulfonyl, heteroaryl, amino, and NHC(O)R₁₂ where R₁₂ islower alkyl.
 26. At least one chemical entity of claim 25, wherein R₂ ischosen from 2,3-dihydro-1,4-benzodioxin-6-yl,4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl, 1,3-benzoxazol-5-yl,2H-1,3-benzodioxol-5-yl, 2,3-dihydro-1H-indol-6-yl,2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl,1-methyl-2,3-dihydro-1H-indol-2-one-6-yl,1,2,3,4-tetrahydroisoquinolin-2-yl-ethan-1-one-6-yl,2-ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl, 2-aminoquinazolin-6-yl,2-hydroxyethyl-2H-indazol-6-yl, 1-hydroxyethyl-2H-indazol-6-yl1H-indazol-7-yl, 1,2,3,4-tetrahydroisoquinolin-6-yl,3-(diethylamino)methyl-1H-indazol-6-yl,1,2-dihydroquinoxalin-2-one-6-yl, 1,2-dihydroquinolin-2-one-6-yl,1H-pyrazol-4-yl, 1,3-thiazol-5-yl, 2-methyl-1,3-benzothiazol-5-yl,1′2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one-6-yl,3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl,3-(1,3-thizaol-4-ylmethylidene)-2,3-dihydro-1H-indole-2-one-6-yl,1-methyl-1H-indazol-6-yl, (N,N-dimethylaminocarbonyl)indol-6-yl,1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl,1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one-6-yl,2,2-difluoro-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,3-ethyl-1H-indazol-6-yl, 1H-indol-2-yl, 1H-indol-3-yl,4-fluoro-1H-indazol-6-yl, 1H-1,2,3-benzotriazol-6-yl,2,3-dihydro-1H-1,3-benzodiazol-2-one-6-yl, 1H-1,3-benzodiazol-6-yl,1H-indol-6-yl, 1H-pyrrolo[3,2-b]pyridin-6-yl,1-methyl-1H-1,3-benzodiazol-5-yl, 1-methyl-1H-1,3-benzodiazol-6-yl,1-methyl-1H-benzo[d]imidazol-5-yl, 2-methyl-1H-benzo[d]imidazol-5-yl,2-oxoindolin-6-yl, 3,3-dimethyl-2-oxoindolin-6-yl,3,4-dihydro-2H-1,4-benzoxazin-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-7-yl,3-amino-1H-indazol-5-yl, 3-amino-1H-indazol-6-yl,3-carbamoyl-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl,3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,4-(1-hydroxy-2-methylpropan-2-yl)phenyl, 5-fluoro-1H-indazol-6-yl, andindolin-6-yl.
 27. At least one chemical entity of claim 1, wherein R₂ ischosen from optionally substituted heteroaryl, dihydrobenzoxazinyloptionally substituted with lower alkyl and oxo, and phenyl substitutedwith one or more groups chosen from optionally substituted alkyl, cyano,nitro, lower alkoxy, halo, sulfonyl, optionally substituted amino, andoptionally substituted heteroaryl.
 28. At least one chemical entity ofclaim 27, wherein R₂ is chosen from optionally substituted pyridinyl,pyrimidinyl, thiophenyl, quinolinyl optionally substituted with amino,indazolyl optionally substituted with halo, carbamoyl, methyl or amino,indolyl, indolinyl optionally substituted with one or two groups chosenfrom lower alkyl and oxo, benzoimidazolyl optionally substituted withmethyl or amino, benzothiozolyl, benzoxazolyl, benzotriazolyl,quinoxalinyl optionally substituted with amino, quinazolinyl optionallysubstituted with amino, dihydrobenzoxazinyl optionally substituted withmethyl and oxo, 1H-pyrrolo[3,2-b]pyridinyl, and phenyl substituted withone or more groups chosen from optionally substituted alkyl, cyano,chloro, fluoro, nitro, methoxy, sulfonyl, heteroaryl, amino, andNHC(O)R₁₂ where R₁₂ is lower alkyl.
 29. At least one chemical entity ofclaim 28, wherein R₂ is chosen from 1H-1,3-benzodiazol-6-yl,1H-indol-6-yl, 1H-pyrrolo[3,2-b]pyridin-6-yl,1-methyl-1H-1,3-benzodiazol-5-yl, 1-methyl-1H-1,3-benzodiazol-6-yl,1-methyl-1H-benzo[d]imidazol-5-yl, 2-methyl-1H-benzo[d]imidazol-5-yl,2-oxoindolin-6-yl, 3,3-dimethyl-2-oxoindolin-6-yl,3,4-dihydro-2H-1,4-benzoxazin-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-7-yl,3-amino-1H-indazol-5-yl, 3-amino-1H-indazol-6-yl,3-carbamoyl-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl,3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl,4-(1-hydroxy-2-methylpropan-2-yl)phenyl, 5-fluoro-1H-indazol-6-yl, andindolin-6-yl.
 30. At least one chemical entity of claim 1, wherein R₂ ischosen from optionally substituted pyridinyl, pyrimidinyl, thiophenyl,quinolinyl optionally substituted with amino, indazolyl optionallysubstituted with methyl or amino, indolyl, benzoimidazolyl optionallysubstituted with methyl or amino, benzothiozolyl, benzoxazolyl,benzotriazolyl, quinoxalinyl optionally substituted with amino,quinazolinyl optionally substituted with amino, dihydrobenzoxazinyloptionally substituted with methyl and oxo, and phenyl substituted withone or more groups chosen from optionally substituted alkyl, cyano,chloro, fluoro, nitro, methoxy, sulfonyl, heteroaryl, amino, andNHC(O)R₁₂ where R₁₂ is lower alkyl.
 31. At least one chemical entity ofclaim 30, wherein R₂ is chosen from 3-methylphenyl, 4-methylphenyl,3-nitrophenyl, 3-[(ethylamino)methyl]phenyl,4-[(ethylamino)methyl]phenyl, 3-(trifluoromethyl)phenyl,3-methoxyphenyl, 4-pyridinyl, 3-pyridinyl, 4-cyanophenyl, 3-cyanophenyl,4-chlorophenyl, 3-chlorophenyl, 4-chloro-3-methylphenyl,3-chloro-4-methylphenyl, 4-fluorophenyl, 3-fluorophenyl,4-fluoro-3-methylphenyl, 3-fluoro-4-methylphenyl, 3,4-difluorophenyl,4-sulfonamidophenyl, 3-sulfonamidophenyl, 4-methanesulfonylphenyl,3-methanesulfonylphenyl, 2-fluoropyridin-4-yl, 5-methylpyridin-3-yl,5-chloropyridin-3-yl, pyrimidin-5-yl,(4-acetylpiperazin-1-yl)methylphenyl,(3-acetylpiperazin-1-yl)methylphenyl, (3-piperazin-1-ylmethyl)phenyl,(4-piperazin-1-ylmethyl)phenyl, 3-acetamidophenyl, 4-acetamidophenyl,4-aminophenyl, 3-aminophenyl, thiophen-3-yl, thiophen-2-yl,1H-indazol-5-yl, 1H-indazol-6-yl, 3-amino-1H-indazol-5-yl,1-methyl-1H-indazol-5-yl, 1-methyl-1H-indazol-6-yl,3-methyl-1H-indazol-5-yl, 2,3-dimethyl-2H-indazol-5-yl,3-amino-1H-indazol-6-yl, 3-amino-1H-indazol-5-yl,4-(1H-imidazol-2-yl)phenyl, 4-(1H-imidazol-5-yl)phenyl,3-(1H-imidazol-5-yl)phenyl, quinolin-6-yl, 2-aminoquinoline-6-yl,3-aminoquinoline-6-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl,2-aminoquinazoline-6-yl, 3-(1,3-thiazol-2-yl)phenyl,4-(1,3-thiazol-2-yl)phenyl, 3-(1,3-thiazol-2-yl)phenyl,1,2-dihydropyridin-2-one-5-yl, 4-(1,3-oxazol-2-yl)phenyl,3-(1,3-oxazol-2-yl)phenyl, 2-aminopyridine-5-yl,1H-1,2,3-benzotriazol-6-yl, 1H-imidazo[4,5-b]pyridin-6-yl,1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1H-indol-6-yl, 1H-indol-5-yl,1-methyl-1H-1,3-benzodiazol-5-yl, 2-amino-1H-1,3-benzodiazol-6-yl,1-methyl-1H-1,3-benzodiazol-6-yl,2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one-6-yl,1H,2H,3H-pyrido[3,2-b][1,4]oxazin-3-one-6-yl,3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,3,4-dihydro-2H-1,4-benzoxazin-3-one-7-yl,4-methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,2-methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl,2-hydroxyquinolin-6-yl, 1-methyl-1,2-dihydropyridin-2-one-5-yl, andquinoxalin-2-ol-7-yl.
 32. A pharmaceutical composition comprising atleast one chemical entity of claim 1, together with at least onepharmaceutically acceptable vehicle chosen from carriers, adjuvants, andexcipients.
 33. A method for treating a patient having a diseaseresponsive to the inhibition of Syk activity, comprising administeringto the patient an effective amount of at least one chemical entityaccording to claim
 1. 34. The method according to claim 33, wherein thepatient is a human.
 35. The method according to claim 33, wherein aneffective amount of said at least one chemical entity is administered bya method chosen from intravenously, intramuscularly, parenterally, andorally.
 36. (canceled)
 37. The method according to claim 33, wherein thedisease responsive to inhibition of Syk activity is cancer.
 38. Themethod according to claim 37, wherein the disease responsive toinhibition of Syk activity is B-cell lymphoma and leukemia.
 39. Themethod according to claim 33, wherein the disease responsive toinhibition of Syk activity is rheumatoid arthritis, allergic rhinitis,chronic obstructive pulmonary disease (COPD), adult respiratory distresssyndrome (ARDs), an allergy-induced inflammatory disease, multiplesclerosis, an autoimmune disease, an inflammatory disease, an acuteinflammatory reaction, an allergic disorder, or polycystic kidneydisease. 40-49. (canceled)
 50. A method for determining the presence ofSyk in a sample, comprising contacting the sample with at least onechemical entity of claim 1 under conditions that permit detection of Sykactivity, detecting a level of Syk activity in the sample, and therefromdetermining the presence or absence of Syk in the sample.
 51. A methodfor inhibiting B-cell activity comprising contacting cells expressingSyk with at least one chemical entity of claim 1, in an amountsufficient to detectably decrease B-cell activity in vitro.
 52. A methodfor inhibiting ATP hydrolysis, the method comprising contacting cellsexpressing Syk with at least one chemical entity of claim 1 in an amountsufficient to detectably decrease the level of ATP hydrolysis in vitro.